Page last updated: 2024-11-08

arachidonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID444899
CHEMBL ID15594
CHEBI ID15843
CHEBI ID137828
SCHEMBL ID16162
MeSH IDM0025459

Synonyms (119)

Synonym
AC-14348
5,8,11,14-icosatetraenoic acid
einecs 208-033-4
ccris 6312
ai3-09613
(5z,8z,11z,14z)-5,8,11,14-eikosatetraensaeure
BRD-K03070961-001-02-8
gtpl2391
c20:4
all-cis-5,8,11,14-eicosatetraenoic acid
(5z,8z,11z,14z)-5,8,11,14-icosatetraenoic acid
arachidonsaeure
CHEBI:15843 ,
cis-delta(5,8,11,14)-eicosatetraenoic acid
[1-14c]arachidonic acid
chembl15594 ,
bdbm22319
BSPBIO_001539
5z,8z,11z,14z-icosatetraenoic acid
LMFA01030001
(all-z)-5,8,11,14-eicosatetraenoic acid
IDI1_034009
SPECTRUM5_001910
(5z,8z,11z,14z)-icosatetraenoic acid
5z,8z,11z,14z-eicosatetraenoic acid
cis-5,8,11,14-eicosatetraenoic acid
arachidonate
C00219
506-32-1
arachidonic acid ,
(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoic acid
5,8,11,14-eicosatetraenoic acid, (all-z)-
icosa-5,8,11,14-tetraenoic acid
5,8,11,14-eicosatetraenoic acid
arachidonic acid, from porcine liver, >=99% (gc), liquid
arachidonic acid, from porcine liver, >=85% (capillary gc), liquid
arachidonic acid, from porcine liver, bioreagent, suitable for cell culture, >=99% (gc)
DB04557
1ADL
1GNJ
1VYG
NCGC00094608-02
NCGC00094608-03
NCGC00094608-01
NCGC00094608-04
NCGC00094608-05
MLS001361328
smr000857374
arachidonic acid, >95.0% (gc)
fa 20:4
CHEBI:137828
HMS1989M21
D18DBC10-379C-4E78-9A50-8B791A2F4E68
A0781
arachidonic acid (20:4 n-6)
BML3-B03
HMS1791M21
HMS1361M21
NCGC00094608-06
(14c)arachidonic acid
5,8,11,14-eicosatetraenoic acid, labeled with carbon-14, (all-z)-
93444-49-6
AKOS015950830
5,8,11,14-all-cis-eicosatetraenoic acid
unii-27yg812j1i
27yg812j1i ,
(5z,8z,11z,14z)-5,8,11,14-eicosatetraenoic acid
immunocytophyte
arachidonic acid, 99%
arachidonic acid [who-dd]
arachidonic acid [inci]
arachidonic acid [mart.]
arachidonic acid [mi]
S6185
CCG-214838
SCHEMBL16162
(14c)-arachidonic acid
(5z,8z,11z,14z)-5,8,11,14-icosatetraenoic acid #
arachidonic acid (in tocrisolvetrade mark100)
AC-33769
HMS3649B05
HMS3402M21
DTXSID4040420 ,
mfcd00004417
arachidonic acid, 1.0 mg/ml in ethanol, certified reference material
arachidonic acid, from non-animal source, >=98.5% (gc)
arachidonic acid, analytical standard
W15452
aa-[d8]
(all-z)-5,8,11,14-eicosatetraenoate
5-cis,8-cis,11-cis,14-cis-eicosatetraenoic acid
5-cis,8-cis,11-cis,14-cis-eicosatetraenoate
5z,8z,11z,14z-eicosatetraenoate
5,8,11,14-all-cis-eicosatetraenoate
5,8,11,14-eicosatetraenoate
cis-d5,8,11,14-eicosatetraenoic acid
all-cis-5,8,11,14-eicosatetraenoate
cis-d5,8,11,14-eicosatetraenoate
arachidonic acid (20:4, n-6)
Q407699
all-cis-eicosa-5,8,11,14-tetraenoic acid
immunocytophyt
SR-01000838311-2
vevodar
sr-01000838311
BRD-K03070961-001-04-4
FS-5880
HY-109590
CS-0032762
arachidonic-acid
A929392
arachidonic acid, >97%
(5z,8z,11z,14z)-icosa-5,8,11,14-tetraenoicacid
fa(20:4(5z,8z,11z,14z))
BP-29803
arachidonic acid (mart.)
fatty acid 20:4 n-6
dtxcid2020420
all-cis-icosa-5,8,11,14-tetraenoic acid

Research Excerpts

Overview

Arachidonic acid (AA) is an essential fatty acid that is released by phospholipids in cell membranes. It is metabolized by cyclooxygenase (COX), cytochrome P450 (CYP) enzymes, and lipid oxygenase (LOX) pathways to regulate complex cardiovascular function under physiological and pathological conditions.

ExcerptReferenceRelevance
"Arachidonic acid (AA) is an important constituent of membrane phospholipids and can be liberated by activation of cellular phospholipases. "( Direct activation of an inwardly rectifying potassium channel by arachidonic acid.
Curran, ME; Heath, L; Krafte, DS; Liu, D; Liu, Y; Meyers, DM; Silvia, CP; Wagoner, PK; Yu, W, 2001
)
1.99
"Arachidonic acid (AA) is an essential fatty acid that is released by phospholipids in cell membranes and metabolized by cyclooxygenase (COX), cytochrome P450 (CYP) enzymes, and lipid oxygenase (LOX) pathways to regulate complex cardiovascular function under physiological and pathological conditions. "( Effects of Arachidonic Acid Metabolites on Cardiovascular Health and Disease.
Cheang, WS; Khan, H; Xiao, J; Zhou, Y, 2021
)
2.45
"Arachidonic acid (AA) is an important fatty acid that is metabolized to several bioactive compounds by cyclooxygenases, lipoxygenases, and the more recently discovered, cytochrome P450 (P450) enzymes."( The multifaceted role of cytochrome P450-Derived arachidonic acid metabolites in diabetes and diabetic cardiomyopathy.
El-Kadi, AOS; El-Sherbeni, AA; Isse, FA, 2022
)
1.7
"Arachidonic acid (AA) is a polyunsaturated fatty acid."( Arachidonic Acid in Follicular Fluid of PCOS Induces Oxidative Stress in a Human Ovarian Granulosa Tumor Cell Line (KGN) and Upregulates GDF15 Expression as a Response.
Gao, Y; Ma, Y; Wang, Y; Xu, Y; Zheng, L, 2022
)
2.89
"The arachidonic acid (AA) cascade is an important immune response system responsible for both pro- and anti-inflammatory processes."( Arachidonic Acid Cascade and Eicosanoid Production Are Elevated While LTC4 Synthase Modulates the Lipidomics Profile in the Brain of the HIVgp120-Transgenic Mouse Model of NeuroHIV.
Han, X; Kaul, M; Maung, R; Xu, Z; Yuan, NY, 2022
)
2.64
"The arachidonic acid cascade is a major inflammatory pathway that produces prostaglandin E"( Tumor microenvironmental 15-PGDH depletion promotes fibrotic tumor formation and angiogenesis in pancreatic cancer.
Akiyama, T; Arima, K; Arima, Y; Baba, H; Bu, L; Fu, L; Hu, X; Ishimoto, T; Ismagulov, G; Itoyama, R; Kitamura, F; Moroishi, T; Mukunoki, T; Nishiyama, K; Okamoto, Y; Otani, J; Sheng, G; Takasugi, S; Uchihara, T; Wei, F; Yasuda, T; Yasuda-Yoshihara, N; Yonemura, A; Zhang, J, 2022
)
1.28
"Arachidonic acid is an essential ω-6 polyunsaturated fatty acid, which plays a significant role in cardiovascular health and neurological development, leading to its wide use in the food and pharmaceutical industries. "( Recent Development of Advanced Biotechnology in the Oleaginous Fungi for Arachidonic Acid Production.
Guo, Q; Li, YW; Nie, ZK; Peng, QQ; Shen, Q; Shi, TQ; Ye, C, 2022
)
2.4
"Arachidonic acid (AA) is a polyunsaturated fatty acid with a structure of 20:4(ω-6). "( The enantioselective separation and quantitation of the hydroxy-metabolites of arachidonic acid by liquid chromatography - tandem mass spectrometry.
Alammari, AH; Brocks, DR; El-Kadi, AOS; El-Sherbeni, AA; Isse, FA, 2023
)
2.58
"Arachidonic acid (AA) is an oomycete-derived microbe-associated molecular pattern (MAMP) capable of eliciting robust defense responses and inducing resistance in plants. "( The Oomycete Microbe-Associated Molecular Pattern, Arachidonic Acid, and an
Bostock, RM; Coaker, GL; Lewis, DC; Little, H; Richards, A; van der Zwan, T, 2023
)
2.6
"Arachidonic acid (AA) is a polyunsaturated fatty acid that is involved in male fertility. "( Arachidonic Acid Pathways and Male Fertility: A Systematic Review.
Barbonetti, A; Hoxha, M; Zappacosta, B, 2023
)
3.8
"Arachidonic acid (AA) is an omega-6 long-chain polyunsaturated fatty acid and is important for human health. "( Evaluation and Transcriptome Analysis of the Novel Oleaginous Microalga
Gao, B; Huang, L; Lei, X; Liu, J; Meng, G; Zhang, C, 2020
)
2
"Arachidonic acid (AA) is a phospholipase A2 metabolite that has been reported to mediate a plethora of cellular mechanisms involved in healthy and pathological states such as platelet aggregation, lymphocyte activation, and tissue inflammation. "( Arachidonic Acid Attenuates Cell Proliferation, Migration and Viability by a Mechanism Independent on Calcium Entry.
Cantonero, C; Lopez, JJ; Redondo, PC; Rosado, JA; Salido, GM; Sánchez-Collado, J, 2020
)
3.44
"Arachidonic acid is a precursor of PGE2 synthesis."( The opposite effects of Antarctic krill oil and arachidonic acid-rich oil on bone resorption in ovariectomized mice.
Han, L; Tian, Y; Wang, J; Wang, K; Xue, C; Zhan, Q, 2020
)
1.54
"Arachidonic acid (AA) is a precursor of enzymatic and non-enzymatic oxidized products such as prostaglandins, thromboxanes, leukotrienes, lipoxins, and isoprostanes. "( Regulation of arachidonic acid oxidation and metabolism by lipid electrophiles.
Rubbo, H; Trostchansky, A; Wood, I, 2021
)
2.42
"Arachidonic acid (ARA) is an integral constituent of the biological cell membrane, conferring it with fluidity and flexibility, which are necessary for the function of all cells, especially nervous system, skeletal muscle, and immune system. "( Immune-enhancing effects of anionic macromolecules extracted from Codium fragile coupled with arachidonic acid in RAW264.7 cells.
Jang, AY; Jung, SK; Lee, SM; Monmai, C; Park, WJ; Rod-In, W; You, S, 2020
)
2.22
"Arachidonic acid (AA) is a fatty acid involved in the modulation of several ion channels. "( Arachidonic acid effect on the allosteric gating mechanism of BK (Slo1) channels associated with the β1 subunit.
Castillo, K; Ducca, G; Fernández-Fernández, JM; González, C; Martín, P; Milesi, V; Moncada, M; Orsi, F, 2021
)
3.51
"Arachidonic acid (AA) is an ω-6 polyunsaturated fatty acid, which mainly exists in the cell membrane in the form of phospholipid. "( [Arachidonic acid metabolism in liver glucose and lipid homeostasis].
Guan, YF; Li, S; Su, W; Zhang, XY, 2021
)
2.97
"Free arachidonic acid (AA) is an important precursor of lipid mediators such as leukotrienes and prostaglandins that induces inflammation and is associated with atherosclerosis progression. "( Lysophosphatidylcholine Acyltransferase-3 Expression Is Associated with Atherosclerosis Progression.
Inuzuka, K; Iwaki, T; Sano, H; Sasaki, T; Setou, M; Suzuki, Y; Tanaka, H; Umemura, K; Unno, N; Urano, T; Yamamoto, N; Yata, T; Zaima, N, 2017
)
0.97
"Arachidonic acid (AA, 20:4) is an omega-6 polyunsaturated fatty acid (PUFA) and the main precursor to the class of lipid mediators known as eicosanoids. "( Lipidomics Reveals Dramatic Physiological Kinetic Isotope Effects during the Enzymatic Oxygenation of Polyunsaturated Fatty Acids Ex Vivo.
Dennis, EA; Navratil, AR; Shchepinov, MS, 2018
)
1.92
"Arachidonic acid (ARA) is a valuable polyunsaturated fatty acid produced by Mortierella alpina. "( How nitrogen sources influence Mortierella alpina aging: From the lipid droplet proteome to the whole-cell proteome and metabolome.
Huang, H; Ji, X; Jiang, L; Li, T; Wu, N; Yu, Y; Zhang, L, 2018
)
1.92
"Arachidonic acid (ARA), which is a ω-6 polyunsaturated fatty acid, has a wide range of biological activities and is an essential component of cellular membranes in some human tissues. "( Heavy ion mutagenesis combined with triclosan screening provides a new strategy for improving the arachidonic acid yield in Mortierella alpina.
Cui, Q; Feng, Y; Li, X; Lu, D; Song, X; Zhang, H, 2018
)
2.14
"Arachidonic acid is an essential fatty acid in cells, acting as a key inflammatory intermediate in inflammatory reactions. "( Structural basis for the mutation-induced dysfunction of human CYP2J2: a computational study.
Cong, S; Li, YX; Ma, XT; Wang, JF, 2013
)
1.83
"Arachidonic acid (AA) is a polyunsaturated fatty acid involved in a complex network of cell signaling. "( Arachidonic acid activation of BKCa (Slo1) channels associated to the β1-subunit in human vascular smooth muscle cells.
Asuaje, A; Enrique, N; Gonzalez, C; Martín, P; Milesi, V; Moncada, M; Valdez Capuccino, JM, 2014
)
3.29
"Arachidonic acid (ARA) is an essential fatty acid and a major constituent of biomembranes. "( Dietary supplementation of arachidonic acid increases arachidonic acid and lipoxin A₄ contents in colon, but does not affect severity or prostaglandin E₂ content in murine colitis model.
Kakutani, S; Kawashima, H; Morita, I; Shibata, H; Tateishi, N, 2014
)
2.14
"Arachidonic acid (ARA) is an n-6 PUFA and is thought to have an important role in various physiological and psychological functions. "( Arachidonic acid-enriched triacylglycerol improves cognitive function in elderly with low serum levels of arachidonic acid.
Akimoto, K; Kawashima, H; Kiso, Y; Koga, Y; Kontani, M; Kusumoto, A; Shibata, H; Tokuda, H, 2014
)
3.29
"Arachidonic acid (AA) is a common dietary n-6 cis polyunsaturated fatty acid that under physiological conditions is present in an esterified form in cell membrane phospholipids, however it might be present in the extracellular microenvironment. "( Arachidonic acid promotes migration and invasion through a PI3K/Akt-dependent pathway in MDA-MB-231 breast cancer cells.
Castillo-Sanchez, R; Cortes-Reynosa, P; Salazar, EP; Serna-Marquez, N; Villegas-Comonfort, S, 2014
)
3.29
"Arachidonic acid (ARA) is a polyunsaturated fatty acid (PUFA) and an essential component of membrane lipids. "( Identification of a novel type of polyunsaturated fatty acid synthase involved in arachidonic acid biosynthesis.
Mitsuhashi, S; Nagano, M; Ujihara, T; Wada, H, 2014
)
2.07
"Arachidonic acid (AA) is a major PUFA that has been implicated in the regulation of adipogenesis. "( Arachidonic acid-dependent gene regulation during preadipocyte differentiation controls adipocyte potential.
Christian, M; Grimaldi, G; Hanyaloglu, AC; Jean-Alphonse, F; Nikolopoulou, E; Papacleovoulou, G; Parker, MG, 2014
)
3.29
"Arachidonic acid (ARA) is an essential fatty acid and a major constituent of biomembranes. "( Dietary supplementation with arachidonic acid increases arachidonic acid content in paw, but does not affect arthritis severity or prostaglandin E2 content in rat adjuvant-induced arthritis model.
Kakutani, S; Kaneda, Y; Kawashima, H; Morita, I; Shibata, H; Tateishi, N, 2015
)
2.15
"Arachidonic acid (AA) is an unsaturated fatty acid known to modulate the activities of various ion channels, including the voltage-gated proton (Hv) channel, which supports the rapid production of reactive oxygen species (ROS) in phagocytes through regulation of pH and membrane potential."( Effects of unsaturated fatty acids on the kinetics of voltage-gated proton channels heterologously expressed in cultured cells.
Kawanabe, A; Okamura, Y, 2016
)
1.16
"Arachidonic acid (AA) is a polyunsaturated fatty acid that is present in the phospholipids of the cell membranes of the body and is abundant in the brain. "( The effects of centrally injected arachidonic acid on respiratory system: Involvement of cyclooxygenase to thromboxane signaling pathway.
Altinbas, B; Erkan, LG; Guvenc, G; Niaz, N; Yalcin, M, 2016
)
2.16
"Arachidonic acid (ARA) is an important polyunsaturated fatty acid having various beneficial physiological effects on the human body. "( Mechanism of Arachidonic Acid Accumulation during Aging in Mortierella alpina: A Large-Scale Label-Free Comparative Proteomics Study.
Huang, H; Ji, X; Jiang, L; Li, T; Ren, L; Wu, N; Yu, Y, 2016
)
2.25
"Arachidonic acid (AA) is an n-6 PUFA, as well as a potent TREK-1 activator."( Arachidonic acid has protective effects on oxygen-glucose deprived astrocytes mediated through enhancement of potassium channel TREK-1 activity.
Gong, S; Liu, Y; Lu, L; Qian, W; Song, C; Wang, X; Wang, Z; Zhang, G; Zhou, S, 2017
)
2.62
"The arachidonic acid cascade is a key player in inflammation, and numerous well-established drugs interfere with this pathway. "( Design, Synthesis and Cellular Characterization of a Dual Inhibitor of 5-Lipoxygenase and Soluble Epoxide Hydrolase.
Angioni, C; Blöcher, R; Fürst, R; Geisslinger, G; Glatzel, D; Hartmann, M; Hofmann, B; Kretschmer, S; Meirer, K; Proschak, E; Steinhilber, D; Wittmann, SK, 2016
)
0.99
"Arachidonic acid is an essential constituent of cell membranes that is esterified to the sn-2-position of glycerophospholipids and is released from selected lipid pools by phospholipase cleavage. "( Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors.
Capdevila, JH; Chen, J; Chen, JK; Falck, JR; Guthi, JS; Hachey, DL; Harris, RC; Imig, JD; Wei, S, 2008
)
1.79
"Arachidonic acid (AA) is a common dietary n-6 polyunsaturated fatty acid that is present in an esterified form in cell membrane phospholipids, and it might be present in the extracellular microenvironment. "( Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells.
Navarro-Tito, N; Robledo, T; Salazar, EP, 2008
)
3.23
"Arachidonic acid metabolism is a potential source for reactive oxygen species (ROS) generation during ischemia and reperfusion."( Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes.
Li, J; Rosenberg, PA; Wang, H, 2009
)
1.07
"Arachidonic acid (AA) is a free fatty acid membrane-permeable second messenger that is liberated from cell membranes via receptor- and Ca(2+)-dependent events. "( Arachidonic acid potently inhibits both postsynaptic-type Kv4.2 and presynaptic-type Kv1.4 IA potassium channels.
Angelova, PR; Müller, WS, 2009
)
3.24
"Arachidonic acid is a substrate for the synthesis of eicosanoids, potent regulators of immune function."( Arachidonic and docosahexaenoic acid deficits in preterm neonatal mononuclear cell membranes. Implications for the immune response at birth.
Branford-White, CJ; Crawford, MA; Djahanbakhch, O; Moodley, T; Vella, C, 2009
)
1.07
"Arachidonic acid (AA) is a fatty acid that mediates cellular processes, such as cell survival, angiogenesis, chemotaxis, mitogenesis, migration and apoptosis."( Arachidonic acid promotes epithelial-to-mesenchymal-like transition in mammary epithelial cells MCF10A.
Castro-Sanchez, L; Martinez-Orozco, R; Navarro-Tito, N; Perez Salazar, E; Soto-Guzman, A, 2010
)
2.52
"Arachidonic acid (AA) release is a central message in cell signaling. "( Filtration assay for arachidonic acid release.
Kukkonen, JP; Putula, J; Turunen, PM, 2010
)
2.12
"Arachidonic acid (AA) is a second messenger released from the neuronal membrane phospholipids following the stimulation of the receptors coupled with G-proteins to the cytosolic phospholipase A (cPLA(2)) signalling pathway."( Upregulated arachidonic acid signalling in the olfactory bulbectomized rat model of depression.
Diksic, M; Kovačević, T; Sato, H; Skelin, I, 2011
)
1.47
"Arachidonic acid (AA) is a long-chain omega-6 polyunsaturated fatty acid (PUFA) synthesized from the precursor dihomo-gamma-linolenic acid (DGLA) that plays a vital role in immunity and inflammation. "( The impact of FADS genetic variants on ω6 polyunsaturated fatty acid metabolism in African Americans.
Barnes, KC; Becker, DM; Becker, LC; Bowden, DW; Case, D; Chilton, FH; Freedman, BI; Hugenschmidt, CE; Ivester, P; Kubala, M; Langefeld, CD; Mathias, RA; Ruczinski, I; Rudock, ME; Sergeant, S; Suktitipat, B; Torgerson, DG; Vaidya, D; Yanek, LR; Ziegler, JT, 2011
)
1.81
"High arachidonic acid (AA) content is a characteristic feature of Hinai-jidori chicken meat."( Supplemental arachidonic acid-enriched oil improves the taste of thigh meat of Hinai-jidori chickens.
Kiyohara, R; Rikimaru, K; Takahashi, H; Yamaguchi, S, 2011
)
1.19
"Arachidonic acid (AA) is a common dietary n-6 cis polyunsaturated fatty acid that under physiological conditions is present in an esterified form in cell membrane phospholipids, and it might be present in the extracellular microenvironment. "( Arachidonic acid induces an increase of β-1,4-galactosyltransferase I expression in MDA-MB-231 breast cancer cells.
Galindo-Hernandez, O; Navarro-Tito, N; Salazar, EP; Serna-Marquez, N; Villegas-Comonfort, S, 2012
)
3.26
"Arachidonic acid (AA) is a polyunsaturated fatty acid that stimulates the proliferation of many cellular types. "( Arachidonic acid stimulates DNA synthesis in brown preadipocytes through the activation of protein kinase C and MAPK.
Garcia, B; Martinez-de-Mena, R; Obregon, MJ, 2012
)
3.26
"Arachidonic acid (AA) is an important second messenger involved in signal transduction mediated by phospholipase A2. "( Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography.
Bokde, AL; Carson, RE; Chang, MC; Channing, MA; Connolly, C; Der, MG; Doudet, DJ; Eckelman, WC; Giovacchini, G; Herscovitch, P; Ma, Y; Mason, A; Rapoport, SI; Toczek, M; Vuong, BK, 2002
)
2.05
"Arachidonic acid is a polyunsaturated fatty acid that mediates inflammation and the functioning of several organs and systems either directly or upon its conversion into eicosanoids. "( Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death?
Curi, R; Lima, T; Pompeia, C, 2003
)
3.2
"Arachidonic acid is a dietary fatty acid known to affect cell metabolism."( Effects of arachidonic acid on leptin secretion and expression in primary cultured rat adipocytes.
Marti, A; Martínez, JA; Moreno-Aliaga, MJ; Pérez-Matute, P, 2003
)
1.43
"Arachidonic acid (AA) is a precursor of important vasoactive metabolites, but the role of AA-mediated vasodilation in Type 2 diabetes is not known. "( Impaired arachidonic acid-mediated dilation of small mesenteric arteries in Zucker diabetic fatty rats.
Kaduce, TL; Lee, HC; Spector, AA; Wang, XL; Zhou, W, 2005
)
2.19
"Arachidonic acid is an essential fatty acid in human nutrition and a biogenetic precursor of the biologically active prostaglandins and leukotrienes. "( [Isolation and functional identification of delta 5 desaturase gene from Mortierella alpina].
Cheng, H; Liu, Z; Yu, LJ; Zhu, L; Zhu, M, 2005
)
1.77
"Arachidonic acid (AA) is an essential fatty acid that is metabolized by cyclooxygenase (COX), lipoxygenase (LOX) or cytochrome P450 (CYP) enzymes to generate eicosanoids which in turn mediate a number of biological activities including regulation of angiogenesis. "( Emerging mechanisms for growth and protection of the vasculature by cytochrome P450-derived products of arachidonic acid and other eicosanoids.
Dhanasekaran, A; Dunn, LK; Falck, JR; Gabrilovich, M; Gruenloh, SK; Harder, DR; Jacobs, ER; Medhora, M; Pratt, PF, 2007
)
2
"Arachidonic acid is an essential constituent of cell membranes that is esterified to the sn-2 position of glycerophospholipids and is released from selected phospholipid pools by tightly regulated phospholipase cleavage. "( Mitogenic activity and signaling mechanism of 2-(14,15- epoxyeicosatrienoyl)glycerol, a novel cytochrome p450 arachidonate metabolite.
Anjaiah, S; Capdevila, JH; Chen, J; Chen, JK; Falck, JR; Guthi, JS; Harris, RC, 2007
)
1.78
"Arachidonic acid is a potential paracrine agent released by the uterine endometrial epithelium to induce PTGS2 [PG (prostaglandin)-endoperoxide synthase 2] in the stroma. "( Peroxisome-proliferator-activated receptors and the control of levels of prostaglandin-endoperoxide synthase 2 by arachidonic acid in the bovine uterus.
Abayasekara, DR; Chin, EC; Derecka, K; Flint, AP; Hodges, L; Marshall, E; Sheldrick, EL; Wathes, DC, 2007
)
1.99
"Arachidonic acid, which is a by-product of the luteolytic cascade in ruminants, is a potential paracrine signal from the epithelium to the stroma."( Control of cyclic AMP concentration in bovine endometrial stromal cells by arachidonic acid.
Abayasekara, DR; Cheng, Z; Flint, AP; Marshall, E; Sheldrick, EL; Wathes, DC, 2007
)
1.29
"Arachidonic acid is a polyunsaturated fatty acid covalently bound in esterified form in the cell membranes of most body cells. "( The acute inflammatory process, arachidonic acid metabolism and the mode of action of anti-inflammatory drugs.
Higgins, AJ; Lees, P, 1984
)
1.99
"Arachidonic acid is a membrane-permeant second messenger that can be released from membrane phospholipids by phospholipases in a calcium-dependent manner."( Arachidonic acid as a possible negative feedback inhibitor of nicotinic acetylcholine receptors on neurons.
Berg, DK; Blumenthal, EM; Huang, B; Vijayaraghavan, S, 1995
)
2.46
"Arachidonic acid (20:4) is a component of membrane lipids that has been implicated as a messenger both in physiological and pathophysiological processes, including ischemic injury and synaptic plasticity. "( Arachidonic acid: toxic and trophic effects on cultured hippocampal neurons.
Katsuki, H; Okuda, S; Saito, H, 1994
)
3.17
"Arachidonic acid is believed to be an important and necessary mediator of insulin secretion by beta-cells of islets of Langerhans, and it may regulate intracellular Ca2+ homeostasis. "( Transient activation of calcium-dependent phospholipase A2 by insulin secretagogues in isolated pancreatic islets.
Jolly, YC; Major, C; Wolf, BA, 1993
)
1.73
"Arachidonic acid (AA) is a polyunsaturated fatty acid (PUFA) found exclusively in animal products and is one of the most important fatty acids associated with membrane phospholipids. "( Antagonistic effects of dietary arachidonic acid and n-3 polyunsaturated fatty acids.
Whelan, J, 1996
)
2.02
"Arachidonic acid is an important regulator of cellular function via its effects on the physical properties of membranes, in its free form, or as a substrate for eicosanoids. "( Arachidonic acid maldistribution in obesity.
Phinney, SD, 1996
)
3.18
"Arachidonic acid is a polyunsaturated fatty acid precursor to prostaglandin formation in the stomach. "( Effects of polyunsaturated fatty acids on bile acid-induced gastric mucosal injury.
Dempsey, DT; Mercer, DW; Ritchie, WP, 1996
)
1.74
"Arachidonic acid (AA) functions as a structural component, eicosanoid precursor and surface material for chylomicron production in the gastrointestinal tract. "( Bile but not chyle lipoprotein is an important source of arachidonic acid for the rat small intestine.
Melin, T; Nilsson, A; Qi, C, 1996
)
1.98
"Arachidonic acid (AA) is a precursor of eicosanoids, which influence human health and the in vitro activity of immune cells. "( Effects of dietary arachidonic acid on human immune response.
Kelley, DS; Kyle, D; Mackey, BE; Nelson, GJ; Schmidt, PC; Taylor, PC, 1997
)
2.07
"Arachidonic acid (AA) is an extremely important fatty acid involved in cell regulation. "( Assessment of the arachidonic acid content in foods commonly consumed in the American diet.
Chiu, CH; Taber, L; Whelan, J, 1998
)
2.08
"Arachidonic acid metabolism is a particularly attractive and important target of chemopreventive measures."( Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism.
Fürstenberger, G; Marks, F; Müller-Decker, K, 1999
)
1.24
"Arachidonic acid (AA) is a critical second messenger in several cell types. "( Impaired activation of cytosolic phospolipase A(2) in inflamed canine colonic circular muscle.
Ali, I; Campbell, WB; Sarna, SK, 2000
)
1.75
"Arachidonic acid is an important modulator for the inflammatory process. "( [Modulation of potassium channel by arachidonic acid].
Cheng, GF; Guo, Y, 1997
)
2.01
"Arachidonic acid is a second messenger which activates protein kinase C (PKC) and is released from the heart during ischaemic preconditioning. "( Arachidonic acid protects neonatal rat cardiac myocytes from ischaemic injury through epsilon protein kinase C.
Mackay, K; Mochly-Rosen, D, 2001
)
3.2
"Arachidonic acid is a second messenger that has been implicated in several pathological conditions in nervous tissues. "( Arachidonic acid-induced inhibition of Ca2+ channel currents in retinal glial (Müller) cells.
Bringmann, A; Faude, F; Reichenbach, A; Schopf, S, 2001
)
3.2
"Arachidonic acid release is an important regulatory component of uterine contraction and parturition, and previous studies showed that lindane stimulates arachidonic acid release from myometrium. "( A calcium-independent phospholipase activity insensitive to bromoenol lactone mediates arachidonic acid release by lindane in rat myometrial cells.
Loch-Caruso, R; Peters-Golden, M; Wang, CT, 2001
)
1.98
"Arachidonic acid (AA) is a long-chain polyunsaturate (LCP) present in human breast milk as both triglyceride (TG) and as phospholipid (PL). "( Efficacy of dietary arachidonic acid provided as triglyceride or phospholipid as substrates for brain arachidonic acid accretion in baboon neonates.
Boehm, G; Brenna, JT; Diau, GY; Huang, MC; Nathanielsz, PW; Wijendran, V, 2002
)
2.08
"Arachidonic acid (AA) is a second messenger liberated via receptor activation of phospholipase A2 or diacylglycerol-lipase. "( Arachidonic acid modulates hippocampal calcium current via protein kinase C and oxygen radicals.
Alger, BE; Keyser, DO, 1990
)
3.16
"Arachidonic acid was found to be a competitive inhibitor of dipalmitoyl PC hydrolysis with a K1 of 5 microM."( Kinetic analysis of the Ca2+-dependent, membrane-bound, macrophage phospholipase A2 and the effects of arachidonic acid.
Deems, RA; Dennis, EA; Lister, MD; Ulevitch, RJ; Watanabe, Y, 1988
)
1.21

Effects

Arachidonic acid has been shown to release Ca2+ from isolated skeletal and cardiac sarcoplasmic reticulum (SR) vesicles. It has attracted attention because of its potential regulatory roles in the apoptosis of immature B cells.

ExcerptReferenceRelevance
"Arachidonic acid has a small but significant effect on chloride secretion when added alone to T84 cells and synergistically enhances, as does NECA, responses to calcium-dependent secretogogues."( Involvement of arachidonic acid in the chloride secretory response of intestinal epithelial cells.
Barrett, KE; Bigby, TD, 1993
)
1.36
"Arachidonic acid (AA) has potent anti-inflammatory actions and prevents the cytotoxic actions of alloxan and streptozotocin (STZ) against pancreatic β cells and thus, prevents the development of type 1 diabetes mellitus (induced by alloxan and STZ) and by virtue of its anti-inflammatory actions protects against the development of type 2 diabetes mellitus (DM) induced by STZ in experimental animals that are models of type 1 and type 2 DM in humans."( Syntaxin interacts with arachidonic acid to prevent diabetes mellitus.
Das, UN, 2022
)
1.75
"Arachidonic acid (AA) has potent pro-apoptotic effects on cancer cells at a low concentration and on macrophages at a very high concentration. "( Arachidonic acid induces macrophage cell cycle arrest through the JNK signaling pathway.
Hao, Y; Ji, Z; Ma, Y; Ren, W; Shen, Z; Tang, X; Yan, X; Zhong, Y, 2018
)
3.37
"Arachidonic acid (AA) pathway has been shown to play a role in the development and progression of prostate cancer (PCa). "( Serum levels of arachidonic acid metabolites change during prostate cancer progression.
Bangma, CH; Burgers, PC; Dekker, LJ; Ijzermans, JJ; Jenster, G; Luider, TM; Rodríguez-Blanco, G; Schenk-Braat, EA; Wildhagen, MF, 2014
)
2.19
"Arachidonic acid has been shown to mimic this effect, at least in part, by an undetermined mechanism."( Angiotensin II stimulates fibronectin protein synthesis via a Gβγ/arachidonic acid-dependent pathway.
Alagarsamy, S; Alexander, LD; Cui, X; Ding, Y, 2014
)
1.36
"Arachidonic acid has very different biological functions, for instance, in the vasculature and in specific aspects of immunity."( New European Food Safety Authority recommendation for infant formulae contradicts the physiology of human milk and infant development.
Brenna, JT; Crawford, MA; Forsyth, S; Wang, Y, 2013
)
1.11
"Arachidonic acid has very different biological functions compared to DHA, for example, arachidonic acid has unique functions in the vasculature and in specific aspects of immunity."( The European Food Safety Authority recommendation for polyunsaturated fatty acid composition of infant formula overrules breast milk, puts infants at risk, and should be revised.
Brenna, JT; Crawford, MA; Forsyth, S; Wang, Y, 2015
)
1.14
"Arachidonic acid metabolites have been implicated in development of periodontal disease, especially those derived from the cyclo-oxygenase (COX) pathway."( Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
Caliari, MV; Duarte, ID; Francischi, JN; Maltos, KL; Pacheco, CM; Queiroz-Junior, CM, 2009
)
1.07
"Arachidonic acid metabolites have been proposed as signaling molecules in hippocampal long-term potentiation (LTP) and long-term depression (LTD) for >15 years. "( 12-lipoxygenase metabolites of arachidonic acid mediate metabotropic glutamate receptor-dependent long-term depression at hippocampal CA3-CA1 synapses.
Begum, R; Bolshakov, VY; Feinmark, SJ; Funk, CD; Goussakov, I; Siegelbaum, SA; Tsvetkov, E, 2003
)
2.05
"Arachidonic acid (AA, 20:4) has been reported to modulate a variety of calcium-permeable ionic channels, both in the plasma membrane and in the endoplasmic reticulum. "( Calcium signals activated by arachidonic acid in embryonic chick ciliary ganglion neurons.
Ariano, P; Distasi, C; Erriquez, J; Gilardino, A; Lovisolo, D; Munaron, L, 2005
)
2.06
"Arachidonic acid metabolites have been considered as pivotal mediators in Helicobacter pylori-induced inflammatory response, which are mainly metabolized by two distinct enzymes: cyclooxygenase (COX) and lipoxygenase (LOX). "( 5-LOX inhibitor modulates the inflammatory responses provoked by Helicobacter pylori infection.
Cho, SW; Hahm, KB; Han, SU; Lee, KM; Park, KH; Park, S, 2007
)
1.78
"Arachidonic acid and heparin have been proposed to induce tau polymerization via a ligand dependent nucleation-elongation mechanism."( A complex mechanism for inducer mediated tau polymerization.
Branden, M; Carlson, SW; Gamblin, TC; Rankin, CA; Sun, Q; Voss, K, 2007
)
1.06
"Arachidonic acid (AA) has attracted attention because of its potential regulatory roles in the apoptosis of immature B cells."( Arachidonic acid-induced activation of large-conductance potassium channels and membrane hyperpolarization in mouse B cells.
Earm, YE; Kang, TM; Kim, SJ; Kim, TJ; Nam, JH; Nguen, YH; Zheng, H, 2008
)
2.51
"Arachidonic acid metabolism has been explored in preparations of purified human lung mast cells prelabeled with arachidonic acid (AA). "( Arachidonic acid metabolism in purified human lung mast cells.
Adkinson, NF; Hayes, EC; Lichtenstein, LM; MacGlashan, DW; Peters, SP; Rokach, J; Schleimer, RP; Schulman, ES, 1984
)
3.15
"Arachidonic acid has been proposed as an intercellular messenger in the nervous system. "( Arachidonic acid depresses non-NMDA receptor currents.
Attwell, D; Kovalchuk, Y; Miller, B; Sarantis, M, 1994
)
3.17
"Arachidonic acid metabolites have been implicated in the regulation of ACTH secretion. "( Role of lipoxygenase metabolites of arachidonic acid in the regulation of adrenocorticotropin secretion by perifused rat anterior pituitary cells.
Orth, DN; Won, JG, 1994
)
2.01
"Arachidonic acid has been shown to release Ca2+ from isolated skeletal and cardiac sarcoplasmic reticulum (SR) vesicles. "( Arachidonic acid-induced Ca2+ release from isolated sarcoplasmic reticulum.
Dettbarn, C; Palade, P, 1993
)
3.17
"Arachidonic acid (AA) has been shown to interact with transmembrane signaling pathways involved in T-cell activation. "( HIV-induced TNF-alpha regulates arachidonic acid and PGE2 release from HIV-infected mononuclear phagocytes.
Hassan, MI; Loesch, KA; Nokta, MA; Pollard, RB, 1995
)
2.02
"Arachidonic acid has been proposed to be a messenger molecule released following synaptic activation of glutamate receptors and during ischemia. "( Differential modulation of human glutamate transporter subtypes by arachidonic acid.
Amara, SG; Arriza, JL; Kavanaugh, MP; Zerangue, N, 1995
)
1.97
"Arachidonic acid has been implicated as a second messenger in insulin secretion on the basis of (1) mobilization of intracellular Ca2+ from the endoplasmic reticulum of islets and (2) amplification of voltage-dependent Ca2+ entry. "( Diacylglycerol hydrolysis to arachidonic acid is necessary for insulin secretion from isolated pancreatic islets: sequential actions of diacylglycerol and monoacylglycerol lipases.
Konrad, RJ; Major, CD; Wolf, BA, 1994
)
2.02
"Arachidonic acid has recently gained attention as a result of current evidence indicating that it may play the role of a 'second messenger' in signal transduction processes. "( Conformational analysis of arachidonic and related fatty acids using molecular dynamics simulations.
Rich, MR, 1993
)
1.73
"Arachidonic acid has a small but significant effect on chloride secretion when added alone to T84 cells and synergistically enhances, as does NECA, responses to calcium-dependent secretogogues."( Involvement of arachidonic acid in the chloride secretory response of intestinal epithelial cells.
Barrett, KE; Bigby, TD, 1993
)
1.36
"Arachidonic acid (AA) has recently been shown to influence various cellular functions in the central nervous system. "( Arachidonic acid stimulates glucose uptake in cerebral cortical astrocytes.
Magistretti, PJ; Martin, JL; Stella, N; Yu, N, 1993
)
3.17
"Arachidonic acid (AA) has been implicated in signaling actions in several cell types including endocrine cells. "( Arachidonic acid-induced hormone release in somatotropes: involvement of calcium.
Bacquart, T; Drouhault, R; Roudbaraki, MM; Vacher, P, 1996
)
3.18
"Arachidonic acid (AA) has been shown to inhibit the activity of the low-conductance ATP-sensitive K+ channel in the apical membrane of the cortical collecting duct [W. "( Arachidonic acid inhibits activity of cloned renal K+ channel, ROMK1.
Hebert, SC; Macica, CM; Wang, WH; Yang, Y, 1996
)
3.18
"Arachidonic acid (AA) has been implicated as an important amphiphilic co-factor in the activation of reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase in neutrophils and reconstituted cell-free systems. "( Arachidonic acid increases activation of NADPH oxidase in monocytic U937 cells by accelerated translocation of p47-phox and co-stimulation of protein kinase C.
Aepfelbacher, M; Danesch, U; Obermeier, H; Sellmayer, A; Weber, PC, 1996
)
3.18
"Arachidonic acid has been shown to affect the intracellular calcium concentration in many cell types (1-5), but the target of this regulation was unclear. "( Regulation of intracellular calcium release channel function by arachidonic acid and leukotriene B4.
Ehrlich, BE; Striggow, F, 1997
)
1.98
"Arachidonic acid has been implicated in the modulation of various transport processes, including conductive chloride transport in brush border membranes in the human placenta. "( Regulation of human placental chloride channel by arachidonic acid and other cis unsaturated fatty acids.
Parra, M; Riquelme, G, 1999
)
2
"Arachidonic acid has been shown to stimulate lung surfactant secretion from alveolar epithelial type II cells. "( Regulation of lung surfactant secretion by phospholipase A2.
Liu, L, 1999
)
1.75
"Arachidonic acid has been reported to modulate a variety of membrane proteins involved in cellular signaling."( Functional diversity of excitatory amino acid transporters: ion channel and transport modes.
Amara, SG; Fairman, WA, 1999
)
1.02
"Arachidonic acid (AA) has been related to both stimulation and inhibition of cellular proliferation. "( Is increased arachidonic acid release a cause or a consequence of replicative senescence?
Biagi, P; Bordoni, A; Cristofalo, VJ; Frisoni, L; Hrelia, S; Lorenzini, A; Marinucci, T, 2001
)
2.12
"Arachidonic acid has been implicated in normal synaptic transmission processes, including those related to the development of hippocampal long-term synaptic potentiation. "( Modulation of glutamate release from hippocampal mossy fiber nerve endings by arachidonic acid and eicosanoids.
Damron, DS; Dorman, RV; Freeman, EJ; Hamm, TF, 1992
)
1.95
"Arachidonic acid has been implicated as a second messenger in insulin secretion by islets of Langerhans. "( Carbachol stimulation of phospholipase A2 and insulin secretion in pancreatic islets.
Jolly, YC; Konrad, RJ; Major, C; Wolf, BA, 1992
)
1.73
"Arachidonic acid metabolites have been shown to modulate the secretion of various hormones, including luteinizing hormone, growth hormone and adrenocorticotropin. "( Arachidonic acid metabolites modulate rat hypothalamic corticotropin-releasing hormone secretion in vitro.
Bernardini, R; Calogero, AE; Chiarenza, A; Chrousos, GP; Gold, PW, 1989
)
3.16

Actions

Arachidonic acid reverses the increase in cyclic AMP levels of washed human platelets exposed to prostaglandin (PG)I2. The acid was lower in breast milk of atopic mothers compared with non-atopic mothers.

ExcerptReferenceRelevance
"Arachidonic acid (AA) plays a critical role in inflammatory regulation and secondary injury after spinal cord injury (SCI). "( LC-MS/MS-based arachidonic acid metabolomics in acute spinal cord injury reveals the upregulation of 5-LOX and COX-2 products.
Feng, S; Gao, X; Liu, X; Ning, G; Pang, Y; Shi, X; Xiong, H; Yang, X; Yao, X; Zhang, J; Zhang, X; Zhao, C; Zhao, X; Zhou, T, 2022
)
2.52
"The arachidonic acid (AA) pathway plays a crucial role in allergic inflammatory diseases; however, the functional roles of allergy-associated single nucleotide polymorphisms (SNPs) in this pathway remain incompletely illustrated."( Functional Polymorphisms of the Arachidonic Acid Pathway Associate with Risks and Clinical Outcomes of Allergic Diseases.
Chew, FT; Chiang, WC; Fok, YTR; Matta, SA; Say, YH; Shi, P; Sio, YY, 2023
)
1.75
"Arachidonic acid itself plays a role as an intracellular signaling molecule."( Membrane Lipid Derivatives: Roles of Arachidonic Acid and Its Metabolites in Pancreatic Physiology and Pathophysiology.
Castillejo-Rufo, A; Estarás, M; González, A; Ortiz-Placín, C, 2023
)
1.9
"Arachidonic acid levels were lower in the IR group, but dramatically increased in response to GEB."( Exploring the effects of Gastrodia elata Blume on the treatment of cerebral ischemia-reperfusion injury using UPLC-Q/TOF-MS-based plasma metabolomics.
Chen, R; Feng, Y; Li, Z; Wang, D; Wang, Q; Yang, S, 2019
)
1.24
"Arachidonic acid (AA) plays a fundamental role in the function of all cells. "( Arachidonic acid inhibits inflammatory responses by binding to myeloid differentiation factor-2 (MD2) and preventing MD2/toll-like receptor 4 signaling activation.
Cai, Y; Chen, H; Khan, ZA; Liang, G; Liu, H; Shan, P; Wu, D; Zhang, B; Zhang, W; Zhang, Y, 2020
)
3.44
"Arachidonic acid can inhibit TNF-α induced endothelial cell apoptosis by upregulating autophagy."( Effects and mechanism of arachidonic acid against TNF-α induced apoptosis of endothelial cells.
Chen, JX; Huang, XY; Lin, WT; Wang, P; Xu, WX; Zeng, M, 2021
)
1.65
"The arachidonic acid (AA) cascade plays a significant role in platelet aggregation. "( ALOX12 mutation in a family with dominantly inherited bleeding diathesis.
Hayasaka, K; Ishii, K; Izumino, H; Kawakami, Y; Makino, S; Meguro, T; Mitsui, T; Norota, I; Sato, H; Sudo, Y; Takahashi, Y; Tamiya, G, 2021
)
1.18
"Arachidonic acid causes an increase in free cytoplasmic calcium concentration ([Ca2+]i) in differentiated skeletal multinucleated myotubes C2C12 and does not induce calcium response in C2C12 myoblasts. "( Arachidonic acid activates release of calcium ions from reticulum via ryanodine receptor channels in C2C12 skeletal myotubes.
Avdonin, PV; Muslikhov, ER; Sukhanova, IF, 2014
)
3.29
"Arachidonic acid was 24.5% lower in erythrocytes (P < 0.0005), but did not differ in plasma."( Relationships between intestinal polyp formation and fatty acid levels in plasma, erythrocytes, and intestinal polyps in Min mice.
Kuriki, K; Mutoh, M; Tajima, K; Tatematsu, M; Wakabayashi, K, 2008
)
1.07
"Arachidonic acid (AA, 20:4n-6) plays a critical role in brain signaling and an up-regulated AA metabolic cascade was reported in postmortem brains from bipolar disorder patients."( Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain.
Chang, L; Cheon, Y; Kim, HW; Lee, HJ; Modi, HR; Park, JY; Rao, JS; Rapoport, SI, 2011
)
1.36
"Arachidonic acid may enhance the rate of infection via calcium transduction pathway."( [Signaling role of exogenous arachidonic acid in the invasion of macrophages by Toxoplasma gondii].
Huang, QL; Jiang, MS; Lin, JY; Peng, BW, 2003
)
2.05
"Arachidonic acid (AA) plays an important role as a signaling factor in the CNS. "( Arachidonic acid increases choline acetyltransferase activity in spinal cord neurons through a protein kinase C-mediated mechanism.
Chalimoniuk, M; Hennig, B; King-Pospisil, K; Malecki, A; Mattson, MP; Pedersen, WA; Toborek, M; Wylegala, E, 2004
)
3.21
"Arachidonic acid (AA) plays important physiological or pathophysiological roles. "( Arachidonic acid inhibits capacitative Ca2+ entry and activates non-capacitative Ca2+ entry in cultured astrocytes.
Chang, WL; Chen, WP; Su, MJ; Tsai, KL; Yang, KT, 2005
)
3.21
"Arachidonic acid, which plays a pivotal role in inflammatory reactions, amplifies the gH."( Potential, pH, and arachidonate gate hydrogen ion currents in human neutrophils.
Cherny, VV; DeCoursey, TE, 1993
)
1.01
"Arachidonic acid was used to increase the formation of endogenous PGI2."( Evidence that prostaglandins I2, E2, and D2 may activate ATP sensitive potassium channels in the isolated rat heart.
Bouchard, JF; Dumont, E; Lamontagne, D, 1994
)
1.01
"Arachidonic acid does not inhibit the acrosome reaction under similar conditions."( Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction.
Goldstein, E; Mechoulam, R; Schuel, H; Zimmerman, AM; Zimmerman, S, 1994
)
1.01
"Arachidonic acid reverses the increase in cyclic AMP levels of washed human platelets exposed to prostaglandin (PG)I2, under conditions where the PGH2 analogue U46619 is ineffective. "( Reduction by arachidonic acid of prostaglandin I2-induced cyclic AMP formation. Involvement of prostaglandins E2 and F2 alpha.
Faili, A; Hatmi, M; Randon, J; Vargaftig, BB, 1993
)
2.1
"Arachidonic acid caused an increase in [Ca2+]i which was dependent upon extracellular Ca2+."( Calcium oscillations in single cultured Chinese hamster ovary cells stably transfected with a cloned human cholecystokinin (CCK)B receptor.
Akagi, K; Nagao, T; Urushidani, T, 1997
)
1.02
"Arachidonic acid (AA) plays a signaling role in the induction of several genes. "( Arachidonic acid induces mobilization of calcium stores and c-jun gene expression: evidence that intracellular calcium release is associated with c-jun activation.
Kovacs, RJ; Leaver, AH; Rizzo, MT; Yu, WM, 1999
)
3.19
"Arachidonic acid (20:4n-6) was lower in breast milk of atopic mothers compared with non-atopic mothers (0.39 wt% vs 0.46 wt%, difference -0.07% wt% (95% confidence limits -0.13, -0.01 wt%; P<0. "( Essential fatty acids in breast milk of atopic mothers: comparison with non-atopic mothers, and effect of borage oil supplementation.
Houwelingen, A; Mordant, A; Poorterman, I; Thijs, C; van den Brandt, P, 2000
)
1.75
"Arachidonic acid caused an increase in the percentage of null sweeps and in the number of null sweeps that clustered together."( Effects of arachidonic acid on unitary calcium currents in rat sympathetic neurons.
Liu, L; Rittenhouse, AR, 2000
)
1.42
"Arachidonic acid did not cause an increase in cellular cyclic GMP level."( The upstream regulation of p38 mitogen-activated protein kinase phosphorylation by arachidonic acid in rat neutrophils.
Chang, LC; Wang, JP, 2000
)
1.25
"Arachidonic acid could in turn inhibit glutamate uptake into astrocytes, and the resulting external accumulation of glutamate could account for the somatostatin-evoked amplification of the alpha 1-adrenergic-agonist-stimulated hydrolysis of inositol-phospholipids."( Somatostatin potentiates the alpha 1-adrenergic activation of phospholipase C in striatal astrocytes through a mechanism involving arachidonic acid and glutamate.
Cordier, J; Delumeau, JC; Glowinski, J; Marin, P; Premont, J; Tence, M, 1991
)
1.21
"Free arachidonic acid alone could activate the enzyme to some extent."( Protein kinase C in Saccharomyces cerevisiae: comparison with the mammalian enzyme.
Ando, K; Fukami, Y; Ikeda, K; Iwai, T; Kishimoto, A; Koide, H; Miyamoto, S; Nishizuka, Y; Ogita, K; Oka, M, 1990
)
0.73
"Arachidonic acid stimulated an increase in transmural electrical potential difference (p.d.) in guinea-pig seminal vesicle tissue in vitro. "( Effect of castration on prostaglandin-mediated changes in membrane potential and prostaglandin synthesis in guinea-pig seminal vesicle tissue.
Carbonaro, C; Gerritsen, ME; Levine, N; Tarlin, N, 1985
)
1.71

Treatment

Arachidonic acid treatment led to a prolonged activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) by the addition of U0126 rescued differentiation. Treatment also significantly increased the production of immunoreactive prostaglandin E2 by LPS-treated and untreated macrophages.

ExcerptReferenceRelevance
"Arachidonic acid treatment at 25, 50, and 100 μM increased IL6 secretion in subcutaneous (P = 0.045, P = 0.002, and P < 0.001, respectively) and visceral (P = 0.034, P = 0.001, and P < 0.001, respectively) stromovascular cells."( Adipokines secretion in feline primary adipose tissue culture in response to dietary fatty acids.
Bolin, SR; Mazaki-Tovi, M; Schenck, PA, 2019
)
1.24
"Arachidonic acid-treated cells showed increased attachment and spreading on collagen type IV, as measured by electric cell-substrate impedance sensing."( p38 mitogen-activated protein kinase interacts with vinculin at focal adhesions during fatty acid-stimulated cell adhesion.
Akiyama, SK; George, MD; Kissling, GE; Lackford, B; Olden, K; Roberts, JD; Wine, RN, 2013
)
1.11
"Arachidonic acid treatment increased NADPH oxidase activity."( Arachidonic acid stimulates TNFα production in Kupffer cells via a reactive oxygen species-pERK1/2-Egr1-dependent mechanism.
Cubero, FJ; Nieto, N, 2012
)
2.54
"Arachidonic acid treatment led to a prolonged activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), and suppression of ERK1/2 activity by the addition of U0126 rescued differentiation."( Arachidonic acid-dependent inhibition of adipocyte differentiation requires PKA activity and is associated with sustained expression of cyclooxygenases.
Berge, RK; Frøyland, L; Furstenberger, G; Jørgensen, C; Kristiansen, K; Madsen, L; Muller-Decker, K; Petersen, RK; Rustan, AC, 2003
)
2.48
"Arachidonic acid treatment also significantly increased the production of immunoreactive prostaglandin E2 (PGE2) by LPS-treated and untreated macrophages."( Effects of in vitro exposure to arachidonic acid on TNF-alpha production by murine peritoneal macrophages.
Erickson, KL; Hubbard, NE; Lim, D; Somers, SD, 1993
)
1.29
"Arachidonic acid treatment in isolated liver nuclei resulted in a rapid and transient increase of Ca2+ concentration in the nucleoplasm which was monitored with the Ca(2+)-sensitive dye fura-2 dextran. "( Mechanism of arachidonic acid-induced Ca2+ mobilization in liver nuclei.
Calcerrada, MC; Catalán, RE; Martínez, AM; Miguel, BG, 1997
)
2.11
"Arachidonic acid rescued cells treated with antibodies to the FGF receptor or the PLC inhibitor, but not cells in which the activity of PKC, p59(fyn), FAK, Ras, or MEK was inhibited."( Neural cell adhesion molecule-stimulated neurite outgrowth depends on activation of protein kinase C and the Ras-mitogen-activated protein kinase pathway.
Berezin, V; Bock, E; Kolkova, K; Novitskaya, V; Pedersen, N, 2000
)
1.03
"Arachidonic acid treatment was accompanied by increased formation of the lipid peroxidation end products malondialdehyde and 4-hydroxy-2-nonenal, lowering in reduced glutathione content and in mitochondrial membrane potential."( Induction of apoptosis by arachidonic acid in human retinoblastoma Y79 cells: involvement of oxidative stress.
Carabillò, M; D'Alessandro, N; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R, 2000
)
1.33
"Arachidonic acid levels in the treated group increased significantly (P less than 0.005) in the first phase and also in the second phase (P less than 0.05)."( Double blind, placebo-controlled, crossover study of evening primrose oil in the treatment of canine atopy.
Lloyd, DH; Scarff, DH, 1992
)
1
"Arachidonic acid treatment did not contract the guinea-pig uterus."( Effect of trifluoperazine, a calmodulin antagonist, on prostaglandin output from the guinea-pig uterus.
Poyser, NL, 1985
)
0.99
"Treatment with arachidonic acid in epithelial cells increased VIM and TWIST1 expressions without decrease of CDH1 expression, while TGFβ1 decreased CDH1 and increased VIM and TWIST1; more importantly, TGFβ1 induced the expression of PLCG2, but arachidonic acid did not induce the expression of TGFB1."( Decrease of lactogenic hormones induce epithelial-mesenchymal transition via TGFβ1 and arachidonic acid during mammary gland involution.
Fujii, K; Liu, Y; Nagaoka, K; Usuda, K; Watanabe, G; Weng, J; Zhang, H, 2017
)
1.02
"Treatment with arachidonic acid increases the levels of a number of free fatty acids [including myristic (C14:0), linoleic (C18:2), linolenic (C18:3) and eicosapentaeneoic (C20:5) acids] and hydroxylated derivatives [such as 15-hydroxyeicosatetraenoic acid (15-HETE), 13-hydroxyoctadecatrienoic acid (13-HOTE) and 15-hydroxyeicosapentaenoic acid (15-HEPE)]."( Free Fatty Acids and Methyl Jasmonate Trigger Defense Reactions in Laminaria digitata.
Adas, F; Cosse, A; Gaquerel, E; Kloareg, B; Küpper, FC; Müller, DG; Peters, AF; Potin, P; Salaün, JP, 2009
)
0.69
"Treatment with arachidonic acid (an important messenger in NCAM-dependent signaling) restored NCAM-induced neurite outgrowth inhibited by HES-1."( Neural cell adhesion molecule-mediated neurite outgrowth is repressed by overexpression of HES-1.
Berezin, V; Bock, E; Jessen, U; Novitskaya, V; Walmod, PS, 2003
)
0.66
"Treatment with arachidonic acid led to sustained expression of COX-1 and COX-2."( Arachidonic acid-dependent inhibition of adipocyte differentiation requires PKA activity and is associated with sustained expression of cyclooxygenases.
Berge, RK; Frøyland, L; Furstenberger, G; Jørgensen, C; Kristiansen, K; Madsen, L; Muller-Decker, K; Petersen, RK; Rustan, AC, 2003
)
2.1
"Pretreatment of arachidonic acid increased the skin prostaglandins (prostaglandin D2, prostaglandin E2, prostaglandin F2alpha and 6-keto-prostaglandin F1alpha) contents, but indomethacin decreased the prostaglandin D2 and prostaglandin E2 contents."( Prostanoid DP1 receptor agonist inhibits the pruritic activity in NC/Nga mice with atopic dermatitis.
Arai, I; Futaki, N; Hashimoto, Y; Inoue, T; Nakaike, S; Sugimoto, M; Takahashi, N; Takano, N, 2004
)
0.66
"Pretreatment with arachidonic acid (AA) caused a decrease in the response to NA which was accompanied by a rise in the PGE level."( Relationship between endogenous prostaglandin E and the vasoconstrictor response to noradrenaline in a perfused arterial segment.
Michibayashi, T, 1984
)
0.59
"Pretreatment of arachidonic acid or albumin showed no effect on stretch-induced channel activation, excluding the possibility of fatty acids mediated channel activation during membrane stretch."( Membrane stretch increases the activity of Ca(2+)-activated K+ channels in rabbit coronary vascular smooth muscles.
Ahn, DS; Kang, BS; Kwon, S; Lee, CJ; Lee, YH, 2000
)
0.64
"Treatment with arachidonic acid or induces PTP opening in situ with similar kinetics, as assessed by the calcein loading-Co(2+) quenching technique (Petronilli, V., Miotto, G., Canton, M., Colonna, R., Bernardi, P., and Di Lisa, F."( The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ.
Bernardi, P; Di Lisa, F; Penzo, D; Petronilli, V; Scorrano, L, 2001
)
0.65
"Pretreatment with arachidonic acid partially protected cardiac myocytes against ischaemia."( Arachidonic acid protects neonatal rat cardiac myocytes from ischaemic injury through epsilon protein kinase C.
Mackay, K; Mochly-Rosen, D, 2001
)
2.08
"Treatment with arachidonic acid was initiated two weeks after his admission."( Treatment of hemorrhagic stroke with arachidonic acid.
Campo, R; Golfetto, I, 2001
)
0.92
"Treatment with arachidonic acid after ischemia restored pial arteriolar dilation to hypercapnia."( Topical arachidonic acid restores pial arteriolar dilation to hypercapnia of postischemic newborn pig brain.
Armstead, WM; Leffler, CW; Mirro, R; Shibata, M, 1992
)
1.06
"Pretreatment with arachidonic acid, or addition of exogenous PGE2, inhibits the angiotensin-mediated glomerular contraction."( The role of arachidonic acid metabolites in renal homeostasis. Non-steroidal anti-inflammatory drugs renal function and biochemical, histological and clinical effects and drug interactions.
Dunn, M, 1987
)
0.98

Toxicity

Arachidonic acid (ARA), an omega-6 fatty acid, is a potent schistosomicide that displayed significant and safe therapeutic effects in Schistosoma mansoni-infected schoolchildren in S.Ara. HepG2 cells overexpressing CYP2E1 (E47cells) were treated with 60 microM arachidonics acid (AA), which is known to be toxic to these cells. Phosphatidylcholine with a linoleic acid hydroperoxide residue had no effect.

ExcerptReferenceRelevance
" In workers exposed to Cd, however, it has been shown that a persistent low Mr proteinuria is predictive of an exacerbation of the age-related decline of the GFR; this biological change should be considered as an adverse effect."( Monitoring of early nephrotoxic effects of industrial chemicals.
Bernard, A; Cardenas, A; Lauwerys, R, 1992
)
0.28
" The toxic process is mediated either by specific antibodies or directly by the parasite itself."( Platelet cytotoxicity against parasites.
Auriault, C; Peyron, F; Polack, B, 1991
)
0.28
" gondii ratios as low as 1:3 were toxic to the organisms with direct cell-cell contact essential for platelet-mediated cytotoxicity."( Human platelet-mediated cytotoxicity against Toxoplasma gondii: role of thromboxane.
Chi, EY; Fritsche, TR; Henderson, WR; Yong, EC, 1991
)
0.28
" In this study, we tested inhibitors of arachidonate metabolism for possible protection against the toxic effects of the cytokine combination of tumor necrosis factor (TNF, 100 U/ml) and interferon-gamma (IFN-gamma, 100 U/ml) in rat islet cell monolayer cultures, using a 51Cr release cytotoxicity assay to measure islet cell lysis (% 51Cr release)."( Cytotoxic effects of cytokines on islet beta-cells: evidence for involvement of eicosanoids.
Baquerizo, H; Rabinovitch, A; Sumoski, W, 1990
)
0.28
" Thus, TCDD treatment increased by six to ten fold the P-450 mediated hepatic microsomal metabolism of AA to epoxides and monohydroxyeicosatetraenoic acids, products whose diverse biological activities suggest links to TCDD's toxic effects."( Arachidonic acid metabolism by dioxin-induced cytochrome P-450: a new hypothesis on the role of P-450 in dioxin toxicity.
Gannon, M; Gross, SS; Rifkind, AB, 1990
)
1.72
" 7,12-Dimethylbenz(a)anthracene (DMBA) and 7-hydroxymethyl-12-methylbenz(a)anthracene (7-OHM-12-MBA), but not benzo(a)pyrene (BP), selectively produce necrosis in the two inner zones of the rat adrenal cortex and are toxic to cultured rat adrenocortical cells."( Influence of effectors of prostaglandin metabolism on the toxicity induced by 7-hydroxymethyl-12-methylbenz(a)anthracene in cultured rat adrenal cells.
Hallberg, E; Rydström, J, 1990
)
0.28
" Experiments with scavengers of toxic oxygen radicals gave ambiguous results."( Reduced tumour necrosis factor-induced cytotoxicity by inhibitors of the arachidonic acid metabolism.
Beyaert, R; Fiers, W; Suffys, P; Van Roy, F, 1987
)
0.5
" Phosphatidylcholine with an arachidonic acid hydroperoxide residue was toxic to cells, while phosphatidylcholine with a linoleic acid hydroperoxide residue had no effect."( Cytotoxicity of phosphatidylcholine hydroperoxides is exerted through decomposition of fatty acid hydroperoxide moiety.
Baba, N; Kaneko, T; Matsuo, M, 1996
)
0.59
"The association of small quantities of ferric oxide with Benzo[a]Pyrene (BaP) appears to increase in vivo the toxic effect of BaP."( Toxicity of ferric oxide and benzo[a]pyrene alone or in combination in respiratory tract of Sprague Dawley rats.
Balduyck, M; Boutin, AC; Gosset, P; Haguenoer, JM; Huet, G; Marez, T; Shirali, P; Venembre, P, 1996
)
0.29
" Further, the oil did not show mutagenic or clastogenic activity and the acute oral toxicity, expressed as the LD50 value, exceeded 20 ml/kg body weight, that is, 18."( Preliminary safety assessment of an arachidonic acid-enriched oil derived from Mortierella alpina: summary of toxicological data.
Hempenius, RA; Lina, BA; Prinsen, M; Van Delft, JM, 1997
)
0.57
"95 in particular, should be considered safe for the submerged production of food ingredients."( On the safety of Mortierella alpina for the production of food ingredients, such as arachidonic acid.
Streekstra, H, 1997
)
0.52
" Thus, this study indicates that a blend of algal and fungal oils is a safe source of DHA and ARA as it produced no adverse effects in rats when administered for 4 wk at levels up to 22 times the expected infant exposure."( Evaluation of single cell sources of docosahexaenoic acid and arachidonic acid: a 4-week oral safety study in rats.
Burns, RA; Diersen-Schade, DA; Kelly, CM; Wibert, GJ,
)
0.37
" Here we report that Delta9-tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is toxic for hippocampal neurons."( Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol.
Chan, GC; Hinds, TR; Impey, S; Storm, DR, 1998
)
0.3
" In contrast to arachidonic acid, oleic acid was not toxic to the HepG2-MV2E1-9 cells."( Cytotoxicity and apoptosis produced by arachidonic acid in HepG2 cells overexpressing human cytochrome P-4502E1.
Cederbaum, AI; Chen, Q; Galleano, M, 1998
)
0.92
" No statistically significant, dose-dependent adverse effects were seen in reproductive performance or fertility, nor in the neonates from birth to weaning."( Evaluation of single-cell sources of docosahexaenoic acid and arachidonic acid: 3-month rat oral safety study with an in utero phase.
Burns, RA; Diersen-Schade, DA; Kelly, CM; Wibert, GJ, 1999
)
0.54
"We tested whether addition of n-3 and n-6 long-chain polyunsaturated fatty acids (LCPUFA) to infant-formula milk during the first 6 months promotes long-term cognitive and motor development, without adverse consequences."( Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomised trial.
Abbott, R; Clements, H; Elias-Jones, A; Lucas, A; MacFadyen, U; Morley, R; Stafford, M; Stephenson, T, 1999
)
0.3
"There was no evidence of a beneficial or adverse effect on cognitive and motor development or growth up to 18 months."( Efficacy and safety of long-chain polyunsaturated fatty acid supplementation of infant-formula milk: a randomised trial.
Abbott, R; Clements, H; Elias-Jones, A; Lucas, A; MacFadyen, U; Morley, R; Stafford, M; Stephenson, T, 1999
)
0.3
"Ethanol and polyunsaturated fatty acids such as arachidonic acid were shown to be toxic and cause apoptosis in HepG2 cells which express CYP2E1 but not in control HepG2 cell lines."( Ethanol and arachidonic acid produce toxicity in hepatocytes from pyrazole-treated rats with high levels of CYP2E1.
Cederbaum, AI; Wu, D, 2000
)
0.94
" DHASCO(R) and ARASCO(R) oils, concentrated sources of docosahexaenoic and arachidonic acids, respectively, have been tested in acute and subchronic studies without toxic effects."( A developmental safety study in rats using DHA- and ARA-rich single-cell oils.
Arterburn, LM; Boswell, KD; Henwood, SM; Kyle, DJ, 2000
)
0.54
" The types and incidences of adverse events were similar among the feeding groups."( A multicenter long-term safety and efficacy trial of preterm formula supplemented with long-chain polyunsaturated fatty acids.
Gross, S; Hegyi, T; Vanderhoof, J, 2000
)
0.31
"Polyunsaturated fatty acids such as arachidonic acid were previously shown to be toxic to HepG2 cells expressing CYP2E1 by a mechanism involving oxidative stress and lipid peroxidation."( Spin trapping agents (Tempol and POBN) protect HepG2 cells overexpressing CYP2E1 against arachidonic acid toxicity.
Cederbaum, AI; Pérez, MJ, 2001
)
0.81
" The better GI tolerability of meloxicam was also suggested by fewer adverse GI events and no withdrawals due to adverse events compared with piroxicam."( Endoscopic comparison of the gastroduodenal safety and the effects on arachidonic acid products between meloxicam and piroxicam in the treatment of osteoarthritis.
Chang, DM; Hsieh, TC; Hsu, CT; Kuo, SY; Young, TH, 2001
)
0.54
" Previous studies have shown that N-methyl-D-aspartate (NMDA) receptor antagonists can inhibit glutathione depletion and neurotoxicity induced by PrP(TSE) and a toxic prion protein peptide, PrP106-126, in vitro."( Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126.
Beyreuther, K; Cappai, R; Collins, SJ; Jobling, MF; Maher, F; Masters, CL; Needham, BE; Stewart, LR; Thyer, J; White, AR, 2001
)
0.31
" Providing DHA or DHA+ARA during the preterm period had no effect on subsequent visual acuity or incidence of adverse events."( Docosahexaenoic acid and arachidonic acid enhance growth with no adverse effects in preterm infants fed formula.
Adamkin, DH; Diersen-Schade, DA; Hall, RT; Hansen, JW; Harris, CL; Innis, SM; Kalhan, SC; Lair, C; Lim, M; Merkel, KL; Stevens, DC; Twist, PF, 2002
)
0.62
"Feeding DHA+ARA from single-cell triglycerides enhances weight gain in formula-fed premature infants with no evidence of adverse effects."( Docosahexaenoic acid and arachidonic acid enhance growth with no adverse effects in preterm infants fed formula.
Adamkin, DH; Diersen-Schade, DA; Hall, RT; Hansen, JW; Harris, CL; Innis, SM; Kalhan, SC; Lair, C; Lim, M; Merkel, KL; Stevens, DC; Twist, PF, 2002
)
0.62
" Concentrations of AA above 10 microM were toxic to RGCs."( Protective effect of arachidonic acid on glutamate neurotoxicity in rat retinal ganglion cells.
Barnstable, CJ; Han, MH; Hirata, K; Kawasaki, A; Otori, Y; Wei, JY, 2002
)
0.63
" The intracellular calcium chelator EGTA-AM protected CHP100 cells almost completely against the toxic effects of gp120."( Cholesterol-dependent modulation of the toxicity of HIV-1 coat protein gp120 in human neuroblastoma cells.
Bagetta, G; Catani, V; Corasaniti, MT; Finazzi-Agrò, A; Maccarrone, M; Navarra, M, 2002
)
0.31
" HepG2 cells overexpressing CYP2E1 (E47cells) were treated with 60 microM arachidonic acid (AA), which is known to be toxic to these cells by a mechanism dependent on CYP2E1, oxidative stress, and lipid peroxidation."( Metallothionein 2A induction by zinc protects HEPG2 cells against CYP2E1-dependent toxicity.
Cederbaum, AI; Pérez, MJ, 2003
)
0.55
"Arachidonic acid (AA) was shown to be toxic to HepG2 cells expressing cytochrome P4502E1 (CYP2E1) because of oxidative stress."( Lycopene attenuates arachidonic acid toxicity in HepG2 cells overexpressing CYP2E1.
Leo, MA; Lieber, CS; Xu, Y, 2003
)
2.09
" There were no test article related effects of DHA and/or ARA indicative of an adverse health consequence to the animals seen in the clinical signs, body weights, food consumption, clinical chemistry, hematology, organ weights or gross or histopathology."( Safety evaluation of sources of docosahexaenoic acid and arachidonic acid for use in infant formulas in newborn piglets.
Auestad, N; Buchanan, S; Kruger, C; Merritt, RJ, 2003
)
0.56
" HepG2 cells over-expressing CYP2E1 (E47 cells) were treated with arachidonic acid (AA) plus iron, agents important in development of alcoholic liver injury and which are toxic to E47 cells by a mechanism dependent on CYP2E1, oxidative stress, and lipid peroxidation."( Proteasome inhibition potentiates CYP2E1-mediated toxicity in HepG2 cells.
Cederbaum, AI; Pérez, MJ, 2003
)
0.56
" Exogenous AA is toxic to GSH-depleted cells."( Toxicity of glutathione depletion in mesencephalic cultures: a role for arachidonic acid and its lipoxygenase metabolites.
Cheong, J; Jnobaptiste, R; Kramer, BC; Mytilineou, C; Olanow, CW; Robakis, T; Yabut, JA, 2004
)
0.56
" We found that extracellular Ca2+ was not required for the toxic effect of AA."( Ca2+ influx is not involved in acute cytotoxicity of arachidonic acid.
Doroshenko, N; Doroshenko, P, 2004
)
0.57
" Lung function, anthropometrics, and adverse experiences were monitored throughout the study."( Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.
Arterburn, LM; Benisek, DC; Boyd-Trull, K; Hoffman, DR; Lester, LA; Lloyd-Still, JD; Powers, CA, 2006
)
0.33
" No adverse developments were associated with this large dose of DHA oil."( Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study.
Arterburn, LM; Benisek, DC; Boyd-Trull, K; Hoffman, DR; Lester, LA; Lloyd-Still, JD; Powers, CA, 2006
)
0.33
" Taken as whole, the toxic effect of the FA on insulin-producing RINm5F cells varied irrespective of the chain length and the degree of unsaturation."( Fatty acid-induced toxicity and neutral lipid accumulation in insulin-producing RINm5F cells.
Azevedo-Martins, AK; Curi, R; Lenzen, S; Lima, CL; Monteiro, AP, 2006
)
0.33
" Since the nineteenth century no NSAIDs have been developed that are devoid of renal adverse effects, including the COX-2 selective inhibitors."( Novel mechanisms of nonsteroidal anti-inflammatory drug-induced renal toxicity.
Knights, KM; Miners, JO; Tsoutsikos, P, 2005
)
0.33
" A preliminary acute toxicity study revealed that the biomass was safe at acute doses and that the LD50 exceeded 5000mg/kg BW, the highest dose used in the study."( Safety evaluation of arachidonic acid rich Mortierella alpina biomass in albino rats--a subchronic study.
Muthukumar, SP; Nisha, A; Venkateswaran, G, 2009
)
0.67
" Based on these findings, no adverse treatment-related effects for RAO were seen at up to 5% in the diet, equivalent to an overall average RAO intake of 3170 mg/kg bwt/day."( 90-Day feeding and genotoxicity studies on a refined arachidonic acid-rich oil.
Casterton, PL; Curry, LL; Kruger, CL; Lina, BA; Wolterbeek, AP, 2009
)
0.6
" This may offer a novel therapeutic target for management of the adverse effect of cisplatin chemotherapy."( Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis.
Aoyagi, T; Jia, Z; Liu, H; Wang, H; Wang, N; Yang, T, 2011
)
0.37
"Saturated fatty acids are toxic to pancreatic β-cells."( Arachidonic acid fights palmitate: new insights into fatty acid toxicity in β-cells.
Ortsäter, H, 2011
)
1.81
" Recent evidence also indicates a role for signaling molecules in the adverse effects associated with the exposure to environmental chemicals."( Cell signaling and neurotoxicity: ³H-arachidonic acid release (phospholipase A₂) in cerebellar granule neurons.
Kodavanti, PR, 2011
)
0.64
"An enteric-coated formulation of triflusal (triflusal EC), an antiplatelet agent, was developed to reduce the high incidence of gastrointestinal adverse events (AEs)."( A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY, 2011
)
0.37
"Doxorubicin [(DOX) Adriamycin] is an effective anticancer agent whose major limiting side effect is cardiotoxicity."( Chronic doxorubicin cardiotoxicity modulates cardiac cytochrome P450-mediated arachidonic acid metabolism in rats.
Alsaad, AM; El-Kadi, AO; El-Sherbeni, AA; Zordoky, BN, 2012
)
0.61
" Hence, there may be inherent risks and the kidneys may be especially vulnerable to toxic effects."( Mechanisms of herb-induced nephrotoxicity.
Allard, T; Efferth, T; Greten, HJ; Wenner, T, 2013
)
0.39
"Mercury is a potent environmental contaminant that exerts toxic effect on various vital organs in the human body."( Preventive effects of ZPDC glycoprotein (24 kDa) on hepatotoxicity induced by mercury chloride in vitro and in vivo.
Lee, J; Lee, SJ; Lim, KT, 2014
)
0.4
" In summary, no observable adverse effect level (NOAEL) in this study was placed at 5% RAO, the highest level tested."( A subchronic toxicity study, preceded by an in utero exposure phase, with refined arachidonic acid-rich oil (RAO) derived from Mortierella alpina XM027 in rats.
Cho, SS; Gao, Y; Hang, B; Jin, H; Kang, L; Lee, AW; Li, C; Li, S; Yan, M, 2014
)
0.63
" The NSAID-related adverse events are (1) gastroin- testinal toxicity (2) renal toxicity (3) cardiovascular risk."( [Management of Adverse Effects Associated with Nonsteroidal Anti-inflammatory Drugs and COX-2 Inhibitor].
Masuda, R, 2016
)
0.43
"Studies have shown that kresoxim-methyl (KM) and other strobilurin fungicides have toxic effects on aquatic organisms."( Histology and metabonomics reveal the toxic effects of kresoxim-methyl on adult zebrafish.
Fang, N; Hu, H; Jiang, J; Li, Y; Wang, X; Zhang, C; Zhao, X, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analyses indicated that fasting plasma GLA and EPA levels plateaued within 7 days' daily consumption at all levels of intake, whereas the time to maximum plasma concentration (Tmax) was shorter for GLA than for EPA."( Inhibition of leukotriene synthesis, pharmacokinetics, and tolerability of a novel dietary fatty acid formulation in healthy adult subjects.
Chilton, FH; Edens, MB; Koumenis, IL; Surette, ME; Tramposch, KM, 2003
)
0.32
"The objective of this study was to develop a mechanism-based pharmacodynamic model that characterizes the antiplatelet effects of aspirin (acetylsalicylic acid) and ibuprofen alone and in combination."( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008
)
0.35
" The final pharmacodynamic model was based on the turnover of cyclo-oxygenase-1 (COX-1) enzyme, and incorporated irreversible inhibition by aspirin and reversible binding and antiplatelet effects of ibuprofen."( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008
)
0.35
"A mechanism-based pharmacodynamic model has been developed that characterizes the antiplatelet effects of aspirin and ibuprofen, alone and concomitantly, and predicts a significant inhibition of aspirin antiplatelet effects in the presence of a typical ibuprofen dosing regimen."( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008
)
0.35
"The pharmacokinetic and pharmacodynamic profiles of the two triflusal formulations met the requirements for bioequivalence and non-inferiority, respectively."( A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
Baek, IH; Kwon, KI; Lee, HW; Lee, J; Lim, MS; Park, J; Seo, JJ; Seong, SJ; Yoon, YR; Yun, HY, 2011
)
0.37
"4-min radioactive half-life of (11)C-AA and challenges of routinely synthesizing (11)C fatty acids limit their translational utility as PET biomarkers."( The synthesis and in vivo pharmacokinetics of fluorinated arachidonic acid: implications for imaging neuroinflammation.
Chang, L; Cheon, Y; Eckelman, WC; Gao, F; Kiesewetter, D; Kotta, K; Pichika, R; Rapoport, SI; Taha, AY, 2012
)
0.62
"As a first step to develop a clinically useful (18)F-fluoroarachidonic acid ((18)F-FAA) with a long radioactive half-life of 109."( The synthesis and in vivo pharmacokinetics of fluorinated arachidonic acid: implications for imaging neuroinflammation.
Chang, L; Cheon, Y; Eckelman, WC; Gao, F; Kiesewetter, D; Kotta, K; Pichika, R; Rapoport, SI; Taha, AY, 2012
)
0.87
" The terminal half-life for CBD was 10."( Pharmacokinetics and effects on arachidonic acid metabolism of low doses of cannabidiol following oral administration to horses.
Kass, PH; Knych, HK; McKemie, DS; Puschner, B; Ryan, D, 2021
)
0.9

Compound-Compound Interactions

Omega-3 polyunsaturated fatty acids can enhance synaptic membrane levels in gerbils. It may do so in patients with neurodegenerative diseases, especially when given with a uridine source. omega-6 polyuns saturated fatty acid arachidonic acid is ineffective.

ExcerptReferenceRelevance
"We have investigated the effects of cyclosporin A (CsA, 3-50 ng/ml) in combination with the riminophenazine agents clofazimine and B669 (60-500 ng/ml) on the mitogen- and alloantigen-activated proliferative responses of human mononuclear leukocytes (MNL), as well as on the phospholipase A2 and Na+, K+- adenosine triphosphatase activities of these cells."( Augmentative inhibition of lymphocyte proliferation by cyclosporin A combined with the riminophenazine compounds clofazimine and B669.
Anderson, R; Prinsloo, Y; van der Walt, R; van Rensburg, CE, 1995
)
0.29
"The effects of gamma-linolenic acid-rich borage oil (BO), in combination with different marine oils, namely an eicosapentaenoic acid (EPA) rich oil (MO) or a DHA-rich oil (TO), on tissue fatty acid composition and prostaglandin production were investigated in turbot, a species which lacks appreciable delta5 fatty acyl desaturase activity."( Effects of dietary gamma-linolenic acid-rich borage oil combined with marine fish oils on tissue phospholipid fatty acid composition and production of prostaglandins E and F of the 1-, 2- and 3-series in a marine fish deficient in delta5 fatty acyl desatu
Bell, JG; Farndale, BM; Sargent, JR; Tocher, DR, 1997
)
0.3
" Hence administering omega-3 polyunsaturated fatty acids can enhance synaptic membrane levels in gerbils, and may do so in patients with neurodegenerative diseases, especially when given with a uridine source, while the omega-6 polyunsaturated fatty acid arachidonic acid is ineffective."( Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils.
Cansev, M; Wurtman, RJ, 2007
)
0.75
" Considerable knowledge has been recently gathered on the possible beneficial effects of n-3 PUFAs administered in combination with different antineoplastic drugs and radiotherapy against melanoma, leukemia, neuroblastoma, and colon, breast, prostate, and lung cancer."( Antineoplastic effects of n-3 polyunsaturated fatty acids in combination with drugs and radiotherapy: preventive and therapeutic strategies.
Calviello, G; Pessina, G; Piccioni, E; Serini, S, 2009
)
0.35
"We investigated the use of dietary omega-3 (ω-3) polyunsaturated fatty acids (PUFAs) in the treatment of neuroblastoma both as a sole agent and in combination with sunitinib, a broad-spectrum tyrosine kinase receptor inhibitor."( Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib.
Barnés, CM; Butterfield, C; Cassiola, F; Chaponis, D; Christison-Lagay, EA; Fallon, EM; Folkman, J; Kieran, M; Le, HD; Nehra, D; Panigrahy, D; Prox, D; Puder, M; Short, S, 2012
)
0.38
" This study assessed whether high-dose aspirin: a) provides additional anti-platelet efficacy, assessed in vivo and ex vivo, when combined with P2Y12 inhibition; and/or b) has a negative effect on vascular function."( High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H, 2013
)
0.39
" Additional diets included 10 g kg(-1) DHA in combination with 10 g kg(-1) of either eicosapentaenoic acid (EPA; 20:5n-3) or arachidonic acid (ARA; 20:4n-6), and a diet containing 5 g kg(-1) each of DHA and EPA."( Influence of dietary docosahexaenoic acid in combination with other long-chain polyunsaturated fatty acids on expression of biosynthesis genes and phospholipid fatty acid compositions in tissues of post-smolt Atlantic salmon (Salmo salar).
Betancor, MB; Glencross, BD; Howarth, FJ; Tocher, DR,
)
0.34
" In this study, the impact of sn2PA fat in combination with DHA or ARA in the diet on lipid metabolism in the liver and faecal microbiota composition were investigated in rats fed diets containing sn2PA fat, 90% sn2PA fat + 10% DHA oil (wt%), or 90% sn2PA fat + 10% ARA oil (wt%)."( The impact of dietary sn-2 palmitic triacylglycerols in combination with docosahexaenoic acid or arachidonic acid on lipid metabolism and host faecal microbiota composition in Sprague Dawley rats.
Hu, S; Jacoby, JJ; Liu, J; Wan, J; Yu, LL; Zhang, Y, 2017
)
0.67
" To increase its yield of arachidonic acid, heavy ion beam irradiation mutagenesis of Mortierella alpina was carried out in combination with triclosan and octyl gallate treatment."( Heavy ion mutagenesis combined with triclosan screening provides a new strategy for improving the arachidonic acid yield in Mortierella alpina.
Cui, Q; Feng, Y; Li, X; Lu, D; Song, X; Zhang, H, 2018
)
1
"The application of proton transfer ionization reaction mass spectrometry (PTR MS) combined with microscale supercritical fluid extraction (SFE) and supercritical fluid chromatography (SFC) aiming to quantitate single-cell fatty acid analysis levels was investigated."( Microscale supercritical fluid extraction combined with supercritical fluid chromatography and proton-transfer-reaction ionization time-of-flight mass spectrometry for a magnitude lower limit of quantitation of lipophilic compounds.
Furutani, H; Hondo, T; Miyake, Y; Ota, C; Toyoda, M, 2022
)
0.72

Bioavailability

UFAs were found to be well absorbed into tumor tissues after oral administration. Arachidonic acid (AA) content, in particular, was markedly decreased by treatment with DHA or EPA.

ExcerptReferenceRelevance
" The binding and bioavailability of vitamin D metabolites thus might be altered by mono- and polyunsaturated but not by saturated fatty acids."( Polyunsaturated fatty acids decrease the apparent affinity of vitamin D metabolites for human vitamin D-binding protein.
Bouillon, R; Convents, R; Van Baelen, H; Xiang, DZ, 1992
)
0.28
" The net zinc absorption rate (Jnet) of jejunal segments was decreased in diabetic rats compared to controls (13."( Intestinal zinc transport: influence of streptozotocin-induced diabetes, insulin and arachidonic acid.
Mooradian, AD; Song, MK, 1988
)
0.5
" Bioavailability and selectivity were assessed by ex vivo RIA of TXB2, LTB4, and 12-HETE from ionophore-challenged blood."( Simple procedure for measuring the pharmacodynamics and analgesic potential of lipoxygenase inhibitors.
Carey, F; Edmonds, AE; Forder, RA; Haworth, D, 1988
)
0.27
" In conclusion, A-127722 is ETA-selective, orally bioavailable and efficacious for inhibiting the effects of ET in the rat, and A-127722 is the most potent ET receptor antagonist yet reported."( Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist.
Adler, AL; Calzadilla, SV; Chiou, WJ; Dayton, BD; Dixon, DB; Gehrke, LJ; Hernandez, L; Magnuson, SR; Marsh, KC; Novosad, EI; Opgenorth, TJ; Von Geldern, TW; Wessale, JL; Winn, M; Wu-Wong, JR, 1996
)
0.29
" The bioavailability of ARASCO, DHASCO and Formulaid was verified by increases in DHA and ARA levels in heart and liver tissues in these animals."( Preclinical evaluation of single-cell oils that are highly enriched with arachidonic acid and docosahexaenoic acid.
Boswell, K; Carl, L; Glaza, S; Hensen, DJ; Koskelo, EK; Kyle, DJ; Williams, KD, 1996
)
0.53
" The consequent greater bioavailability of eicosanoid precursors, and in particular of arachidonic acid, could affect several vascular functions and have a bearing on the pathogenesis or complications of hypertension."( Increased membrane ratios of metabolite to precursor fatty acid in essential hypertension.
Azzini, M; Corrocher, R; Girelli, D; Guarini, P; Olivieri, O; Pasqualini, R; Russo, C, 1997
)
0.52
" Furthermore, the bioavailability of the mucoadhesive formulation in the aqueous humor against an aqueous-based solution was compared."( Pharmacological evaluation of anti-inflammatory pyrrole-acetic acid derivative eye drops.
Bucolo, C; Spadaro, A, 1997
)
0.3
" UFAs were found to be well absorbed into tumor tissues after oral administration, causing marked changes in relative levels, the arachidonic acid (AA) content, in particular, being markedly decreased by treatment with DHA or EPA, but not with DHA plus EPA or with DHA plus LA."( Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities.
Araki, E; Asamoto, M; Iigo, M; Ishikawa, C; Kuhara, T; Kunimoto, T; Moore, MA; Suzuki, I; Tsuda, H; Yazawa, K, 1997
)
0.5
" When using oral analgesics, factors that may interfere with effective analgesia include a child's refusal to take the medication, ineffective doses and dosing regimens, decreased bioavailability following PO administration, inability to tolerate PO medications because of nausea or vomiting, altered GI motility, and a delayed onset caused by slow absorption."( Weak analgesics and nonsteroidal anti-inflammatory agents in the management of children with acute pain.
Tobias, JD, 2000
)
0.31
", 1996), as well as on the basis of data from the literature, we now suggest a hypothesis that taurine promotes the bioavailability of the lipid soluble vitamins A, D, E, K, and F, probably by forming different types of water soluble, easily hydrolyzable complexes."( Taurine as a universal carrier of lipid soluble vitamins: a hypothesis.
Haroutounian, JE; Petrosian, AM, 2000
)
0.31
" The supplemented amounts of AA and DHA were less well absorbed and probably not impairing calcium absorption."( Fatty acid absorption in preterms on formulas with and without long-chain polyunsaturated fatty acids and in terms on formulas without these added.
Cortés, E; De Dios, JG; Juste, M; Moya, M; Vera, A, 2001
)
0.31
"Orally administered astemizole is well absorbed but undergoes an extensive first-pass metabolism to O-desmethylastemizole."( Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole.
Hirama, T; Matsubara, T; Matsumoto, S; Nagata, K; Yamazoe, Y, 2002
)
0.31
" The results demonstrated that the thienopyrimidine-2,4-dione core is an excellent surrogate for the thienopyridin-4-one and that thienopyrimidine-2,4-diones and thienopyridin-4-ones constitute a new class of potent and orally bioavailable LHRH receptor antagonists."( Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
Cho, N; Endo, S; Fujino, M; Furuya, S; Harada, M; Nara, Y; Sasaki, S; Suzuki, N, 2003
)
0.32
" These include inadequate production or reduction of bioavailability of nitric oxide, alterations in metabolism of arachidonic acid, resulting in an increase in vasoconstrictors and decrease in vasodilators, and upregulation of endothelin."( Role of oxidative stress in angiotensin-induced hypertension.
Reckelhoff, JF; Romero, JC, 2003
)
0.53
" The objective of this work was to determine whether the source of dietary LC-PUFA affects the bioavailability in full-term infants."( The source of long-chain PUFA in formula supplements does not affect the fatty acid composition of plasma lipids in full-term infants.
Campoy, C; Castellote, AI; López-Sabater, MC; Rivero, M; Rodriguez-Palmero, M; Sala-Vila, A, 2004
)
0.32
" Starting with the thienopyridin-4-one derivative 26d (T-98475) an optimization study was performed, which resulted in the identification of a highly potent and orally bioavailable LHRH receptor antagonist, 3-(N-benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-[4-(1-hydroxy-1-cyclopropanecarboxamido)phenyl]-5-isobutyryl-4-oxothieno[2,3-b]pyridine (33c)."( Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
Cho, N; Endo, S; Furuya, S; Harada, M; Hayase, Y; Imada, T; Imaeda, T; Kasai, S; Matsumoto, H; Sasaki, S; Suzuki, N, 2006
)
0.33
" Previously, we have reported the low bioavailability of EGCG in rats and mice."( Peracetylation as a means of enhancing in vitro bioactivity and bioavailability of epigallocatechin-3-gallate.
Ho, CT; Hong, J; Kwon, SJ; Lambert, JD; Lee, MJ; Sang, S; Yang, CS, 2006
)
0.33
" Our study was aimed at investigating the role of enhanced AA bioavailability modulating the hepatic vascular tone of cirrhotic livers and identifying which prostanoid is involved."( Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers.
Bosch, J; García-Calderó, H; García-Pagán, JC; Gracia-Sancho, J; Laviña, B; Rodríguez-Vilarrupla, A, 2007
)
0.34
" These include patients with poor bioavailability or noncompliance, an impaired platelet response to ASA in vitro and an increased, TX-independent hyperreactivity to collagen."( Variable platelet response to aspirin in patients with ischemic stroke.
Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007
)
0.34
" Unlike fish-sourced oils, the bioavailability of DHA from vegetarian-sourced (algal) oils has not been formally assessed."( Bioequivalence of Docosahexaenoic acid from different algal oils in capsules and in a DHA-fortified food.
Arterburn, LM; Bailey-Hall, E; Chung, G; Hamersley, J; Hoffman, JP; McCarthy, D; Oken, HA; Rom, D, 2007
)
0.34
" Long-lasting high sodium intake lowers NO bioavailability and promotes systemic and intrarenal vasoconstrictor activity of 20-HETE."( Cytochrome P-450 metabolites in renal circulation and excretion--interaction with the nitric oxide (NO) system.
Kompanowska-Jezierska, E; Kuczeriszka, M, 2008
)
0.35
" Likely arachidonic acid reducing NO bioavailability through all these mechanisms could potentiate its platelet aggregating power."( The arachidonic acid effect on platelet nitric oxide level.
Leoncini, G; Segantin, A; Signorello, MG, 2009
)
1.35
" Thus, Ang II-induced endothelial dysfunction cannot be explained by an acute formation of ROS reducing the bioavailability of nitric oxide but rather by COX-dependent formation of contracting factors acting on TP receptors."( Endothelium-derived contracting factors mediate the Ang II-induced endothelial dysfunction in the rat aorta: preventive effect of red wine polyphenols.
Chataigneau, T; Dal-Ros, S; Etienne-Selloum, N; Kane, MO; Madeira, SV; Sarr, M; Schini-Kerth, VB; Schott, C; Walter, A, 2010
)
0.36
" Taken together, these findings indicate that CYP-dependent signaling pathways are highly susceptible to changes in the relative bioavailability of the different PUFAs and may provide novel insight into the complex mechanisms that link essential dietary fatty acids to the development of cardiovascular disease."( Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids.
Konkel, A; Schunck, WH, 2011
)
0.37
" Overall the fundamental knowledge generated within the past decade indicates that orally bioavailable small molecule inhibitors of sEH may find a place in the treatment of a number of diverse painful conditions including inflammatory and neuropathic pain."( Soluble epoxide hydrolase inhibition, epoxygenated fatty acids and nociception.
Hammock, BD; Inceoglu, B; Wagner, K, 2011
)
0.37
" UVB is well absorbed in proteins and DNA leading to products such as cyclobutane pyrimidine dimers."( Fatty acids and vitamins generate singlet oxygen under UVB irradiation.
Bäumler, W; Knak, A; Landthaler, M; Maisch, T; Regensburger, J, 2012
)
0.38
" This review focuses on the consequences of dietary restriction in IEM on the bioavailability of long-chain polyunsaturated fatty acids (LCPUFAs) and on the attempts to ameliorate these consequences."( Long-chain polyunsaturated fatty acids in inborn errors of metabolism.
Decsi, T; Fekete, K, 2010
)
0.36
"Reduced intrahepatic nitric oxide (NO) bioavailability and increased cyclooxygenase-1 (COX-1)-derived vasoconstrictor prostanoids modulate the hepatic vascular tone in cirrhosis."( Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats.
Bosch, J; García-Pagán, JC; Gracia-Sancho, J; Monclús, M; Rodríguez-Vilarrupla, A; Rosado, E, 2012
)
0.38
" Further, relations between ALOX5 and disease outcomes may be enhanced or attenuated depending on the bioavailability of 5-lipoxygenase enzyme substrates."( 5-Lipoxygenase Gene Variants Are Not Associated With Atherosclerosis or Incident Coronary Heart Disease in the Multi-Ethnic Study of Atherosclerosis Cohort.
Cao, J; Guan, W; Liang, S; Rich, SS; Steffen, BT; Tsai, MY; Weir, NL, 2016
)
0.43
" Cocaine acts by altering DA bioavailability by targeting the DAT."( Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels.
Bering, T; Bluett, RJ; Erreger, K; Fink-Jensen, A; Galli, A; Graham, D; Hackett, TA; Osses, N; Patel, S; Pino, JA; Reddy, IA; Reyes, JG; Stanwood, GD; Sørensen, G; Torres, GE; Valle, C; Weikop, P; Wortwein, G, 2016
)
0.64
" This formulation could improve the bioavailability of macromolecule drugs without any serious local damage to the lungs."( Arachidonic acid with taurine enhances pulmonary absorption of macromolecules without any serious histopathological damages.
Emoto, C; Minami, T; Miyake, M; Mukai, T; Toguchi, H; Yamazaki, H, 2017
)
1.9
"Resveratrol (RVT) is a stilbene with a protective effect on the cardiovascular system; however, drawbacks including low bioavailability and fast metabolism limit its efficacy."( Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties.
Chin, CM; Dos Santos, JL; Dutra, LA; Guanaes, JFO; Johmann, N; Lopes Pires, ME; Marcondes, S, 2017
)
0.46
" Moreover, adding a substituent into the upper phenyl moiety further enhanced the intrinsic activity, which led to the discovery of 5-[(4S,5S)-5-(4fluorophenyl)-4-methyl-2-oxo-1,3-oxazolidin-3-yl]benzene-1,3-dicarbonitrile (4S,5S)-5n, endowed with excellent D5D binding affinity, cellular activity, and high oral bioavailability in a mouse."( Discovery of 3,5-Diphenyl-4-methyl-1,3-oxazolidin-2-ones as Novel, Potent, and Orally Available Δ-5 Desaturase (D5D) Inhibitors.
Andou, T; Fujimoto, J; Hara, R; Hayashi, R; Iida, K; Imanishi, M; Kawamoto, T; Kubo, K; Maekawa, T; Masada, S; Matsui, J; Matsunaga, N; Miyahisa, I; Nagase, H; Noguchi, N; Okamoto, R; Takagahara, S; Tamura, YO; Tohyama, K, 2017
)
0.46
" However, its bioavailability to the brain and potential central effects remain unexplored."( Neuropsychopharmacological profiling of scoparone in mice.
Budzyńska, B; El Sayed, NS; Gertsch, J; Kowalczyk, J; Kurach, Ł; Pellegata, D; Skalicka-Woźniak, K, 2022
)
0.72
" This study aimed to test the bioavailability of the oil derived from basil seeds and its effects on different physiological parameters using 7-15% dietary inclusion levels."( Bioavailability and biotransformation of linolenic acid from basil seed oil as a novel source of omega-3 fatty acids tested on a rat experimental model.
Bermúdez, F; Galisteo, M; Guzmán, A; López-Jurado, M; Martínez, R; Melguizo, C; Mesas, C; Porres, JM; Prados, J, 2022
)
0.72

Dosage Studied

Arachidonic acid-induced aggregation. DPDPE produced a significant reduction in allodynia that was antagonist reversible, peripherally restricted, and exhibited a typical dose-response relationship. PIF produced an increased release of [3H]arachidonics acid from prelabeled myoblasts with a dose- response curve parallel to tha

ExcerptRelevanceReference
", dose-response curves for U46619 and U44069 were shifted to the right in a parallel manner."( Blockade of thromboxane/endoperoxide receptor-mediated responses in the pulmonary vascular bed of the cat by sulotroban.
Babycos, CR; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD; Ragheb, MS, 1992
)
0.28
" Dose-response curves of epithelium-denuded tracheas were shifted to the left by approximately one order of magnitude."( Endothelins constrict guinea pig tracheas by multiple mechanisms.
Hasegawa, S; Hirata, F; Matsumoto, H; Ninomiya, H; Nomura, A; Ohse, H; Saotome, M; Uchida, Y, 1992
)
0.28
" Dose-response curves for U-46619 and U-44069 were shifted to the right in a parallel manner, and daltroban had no significant effect on responses to norepinephrine, serotonin, angiotensin II, BAY K 8644, endothelin-(ET) 1, ET-2, or platelet-activating factor (PAF)."( Daltroban blocks thromboxane responses in the pulmonary vascular bed of the cat.
Babycos, CR; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD, 1992
)
0.28
" Pretreatment of the cells with an inhibitor of the 5-lipoxygenase pathway, U-70344A, shifted the dose-response curve to the right; pretreatment with indomethacin, an inhibitor of the cyclooxygenase pathway, had no effect."( Arachidonic acid and lipoxygenase metabolites uncouple neonatal rat cardiac myocyte pairs.
Burt, JM; Massey, KD; Minnich, BN, 1992
)
1.73
" Bradykinin increased the two second messengers via independent mechanisms: (a) dose-response curves with different incubation media demonstrated that each second messenger could be generated independently of the other; (b) phorbol ester inhibited InsP production but stimulated arachidonic acid release; (c) for polarized cultures, submucosal bradykinin stimulated production of both second messengers but mucosal bradykinin stimulated only arachidonic acid release."( Polarized distribution of bradykinin receptors on airway epithelial cells and independent coupling to second messenger pathways.
Denning, GM; Welsh, MJ, 1991
)
0.46
"Arachidonic acid (AA)- or thromboxane A2/prostaglandin H2 (TXA2/PGH2) analog (STA2 and U-46619)-induced aggregations yielded a bell-shaped dose-response curve."( Elevation of platelet cyclic AMP level by thromboxane A2/prostaglandin H2 receptor agonists.
Ishikawa, Y; Ogawa, A, 1991
)
1.72
" In seven conscious sheep, specific lung resistance (SRL) was measured before and after x-xo challenge; approximately 30 min later when SRL had returned to baseline, airway responsiveness to carbachol was determined from dose-response curves by calculating the cumulative provocating dose of carbachol in breath units (BU, defined as one breath of a 1% wt/vol carbachol solution) that increased SRL 400% over baseline (PD400)."( Lipid mediators contribute to oxygen-radical-induced airway responses in sheep.
Abraham, WM; Ahmed, A; Cortes, A; Garcia, L; Lansing, MW; Lauredo, IT; Mansour, E; Wanner, A, 1991
)
0.28
"7 mmol/l) led to a potentiation of both phase 1 and phase 2 of glucose-induced insulin secretion, and caused a shift in the dose-response curve with 10 mmol/l and 16."( Role of protein kinase C and Ca2+ in glucose-induced sensitization/desensitization of insulin secretion.
Thams, P, 1991
)
0.28
" BN 50739 caused a right shift in PAF dose-response curves of platelet aggregation both in vitro and ex vivo."( Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
Farhat, M; Feuerstein, G; Rabinovici, R; Yue, TL,
)
0.13
" In contrast to previous studies examining birds and viviparous lizards, no dosage induced oviposition in any of the treated females."( Effects of prostaglandin F2 alpha prostaglandin E2 and arachidonic acid on the induction of oviposition in vivo and in vitro in oviparous lizards.
DeMarco, V; Guillette, LJ; Masson, GR, 1991
)
0.53
" SQ 30741 had no significant effect on mean vascular pressures in the cat, and the dose-response curve for U-46619 was shifted to the right in a parallel manner with a similar apparent maximal response."( Influence of SQ 30741 on thromboxane receptor-mediated responses in the feline pulmonary vascular bed.
Feng, CJ; Hood, JS; Ibrahim, IN; Kadowitz, PJ; McMahon, TJ; Nossaman, BD, 1991
)
0.28
" An intradermal dose-response study showed that rIL-8 is an extremely potent inducer of selective neutrophil infiltration in canine skin."( Recombinant human interleukin-8 is a potent activator of canine neutrophil aggregation, migration, and leukotriene B4 biosynthesis.
Ahnfelt-Rønne, I; Kirstein, D; Larsen, CG; Skak-Nielsen, T; Thestrup-Pedersen, K; Thomsen, HK; Thomsen, MK, 1991
)
0.28
" TNF alpha potentiated the release of [3H]arachidonate and PRL promoted by phospholipase-A2 and melittin, and markedly shifted the dose-response curve to the left."( Tumor necrosis factor-alpha increases release of arachidonate and prolactin from rat anterior pituitary cells.
Hirota, K; Ikegami, H; Kadowaki, K; Koike, K; Miyake, A; Ohmichi, M; Tanizawa, O; Yamaguchi, M, 1991
)
0.28
" The potentiating effect of 20-HETE resulted in a shifting to the left of the dose-response curve to Epo."( Modulation of erythropoiesis by novel human bone marrow cytochrome P450-dependent metabolites of arachidonic acid.
Abraham, NG; Falck, JR; Feldman, E; Lutton, JD; Schwartzman, ML, 1991
)
0.5
" Indomethacin inhibited PGI2 synthesis in a dose-response manner; at 7 x 10(-5) M, prostanoid synthesis was inhibited by greater than 80 per cent."( Synthesis of prostaglandins I2 and E2 by the canine gallbladder in vitro: studies using a new incubation chamber.
England, DW; Hoover, EL; Jaffe, BM; Webb, H, 1990
)
0.28
"Bilateral ovariectomy carried out in Java macaques with simultaneous dosed ligation of common bile duct distally to duodenum in order to induce acalculous hepato-cholecystitis, does not alter the lithogenic index of the bile."( [Effects of ovariectomy on the composition of fatty acids of phospholipids in Java macaques with cholestasis].
Bogdarin, IuA; Goncharov, NP, 1990
)
0.28
" The half-maximal inhibition (IC50) values obtained from the dose-response data for the inhibition of arachidonic acid release by steroids were comparable with normal cortisol levels in humans."( Inhibition of microcystin-induced release of cyclooxygenase products from rat hepatocytes by anti-inflammatory steroids.
Creasia, DA; Hines, HB; Naseem, SM, 1990
)
0.49
" In contrast, nerve growth factor-stimulated accumulation of [3H]inositol monophosphate exhibited a sigmoidal dose-response curve with an apparent maximum at 8 nM."( Nerve growth factor stimulation of arachidonic acid release from PC12 cells: independence from phosphoinositide turnover.
Fink, DW; Guroff, G, 1990
)
0.56
" The dose-response curve for vasopressin-sensitive Pf showed the Km to be 1 microU ml-1."( Modulation of vasopressin-induced water permeability of the cortical collecting tubule by endogenous and exogenous prostaglandins.
Stokes, JB, 1985
)
0.27
" Cumulative dose-response studies with capsaicin revealed an enhanced contractile response after P-3 infection."( Enhancement by parainfluenza 3 infection of contractile responses to substance P and capsaicin in airway smooth muscle from the guinea pig.
Buckner, CK; Dick, EC; Fishleder, RI; Saban, R, 1987
)
0.27
" In a similar dosing protocol, SK&F 86002 also protected mice in a second endotoxin shock model in which mice sensitized with Proprionibacterium acnes received LPS 10 days later."( Protective effect of SK&F 86002, a novel dual inhibitor of arachidonic acid metabolism, in murine models of endotoxin shock: inhibition of tumor necrosis factor as a possible mechanism of action.
Badger, AM; Hanna, N; Olivera, D; Talmadge, JE, 1989
)
0.52
" Dose-response curves with either arecoline or histamine on isolated tracheae from these animals display increased maximal contractions, and decreased EC50 values."( Endotoxin-induced hyperreactivity of the guinea-pig isolated trachea coincides with decreased prostaglandin E2 production by the epithelial layer.
Engels, F; Folkerts, G; Nijkamp, FP, 1989
)
0.28
" Garlic extracts (MEE and material extracted in chloroform, MEC) at higher dosage inhibited the degradation of platelet phospholipids and reduced the formation of thromboxane (TxB2) and lipoxygenase-derived products from labelled platelets."( Isolation and effects of some garlic components on platelet aggregation and metabolism of arachidonic acid in human blood platelets.
Justesen, U; Srivastava, KC, 1989
)
0.5
"The effects on platelet function of a four-week administration of aspirin at a low dosage (100 mg daily) were compared in two groups, 14 healthy young volunteers and 14 patients with coronary heart disease."( [Effects of low-dose acetylsalicylic acid on thrombocytes in health subjects and in patients with coronary heart disease].
Bleifeld, W; Kupper, W; Schuster, O; Terres, W, 1989
)
0.28
" In explanted rat hypothalami maintained viable in vitro, PAF stimulated immunoreactive CRH secretion in a bell-shaped dose-response fashion."( The alkyl-ether phospholipid platelet-activating factor is a stimulator of the hypothalamic-pituitary-adrenal axis in the rat.
Bernardini, R; Brucke, T; Calogero, AE; Chrousos, GP; Ehrlich, YH; Gold, PW, 1989
)
0.28
" A dose-response curve was constructed and revealed that the above changes became evident when the platelet number exceeded 10(7)."( Transcellular lipoxygenase metabolism between monocytes and platelets.
Bigby, TD; Meslier, N, 1989
)
0.28
", 3-fold rightward shift of the dose-response curve)."( Defective modulation of noradrenergic neurotransmission by exogenous prostaglandins in aging spontaneously hypertensive rats.
Herzer, WA; Jackson, EK; Lawson, JA, 1989
)
0.28
" At concentrations lacking agonist activity U-75302 was an effective antagonist, displacing the LTB4 dose-response curve."( Receptor antagonism of leukotriene B4 myotropic activity by the 2,6 disubstituted pyridine analog U-75302: characterization on lung parenchyma strips.
Fitzpatrick, FA; Lawson, CF; Morris, J; Wishka, DG,
)
0.13
" Chronic (4-6 days) dosing of mice or rats with high doses of U74006F (30-200 mg/kg/day) has indicated that the compound is devoid of both glucocorticoid and mineralocorticoid activity."( A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells.
Braughler, JM; Chase, RL; Day, JS; Hall, ED; Lahti, RA; Neff, GL; Sethy, VH; Yonkers, PA, 1988
)
0.48
" Des-Arg9-bradykinin-mediated relaxation was inhibited by the specific B1 receptor antagonist [Leu8]des-Arg9-bradykinin which produced parallel shifts in the dose-response curve."( Relaxation of isolated mesenteric arteries by des-Arg9-bradykinin stimulation of B1 receptors.
Churchill, L; Ward, PE, 1986
)
0.27
" Mastoparan, a known facilitator of phospholipase A2 enzymatic activity, shifted the bee venom phospholipase A2 dose-response curve to the left."( Inhibition of [3H]nitrendipine binding by phospholipase A2.
Goldman, ME; Pisano, JJ, 1985
)
0.27
" In vitro perfusion of rat lungs with AA (3 X 10(-5)M for 20 min) reduced the relaxant effect of isoproterenol (ISO) on lung parenchymal strips, shown by a shift to the right of ISO dose-response curve, similar to that obtained using desensitizing concentration of specific beta-agonist."( Arachidonic acid metabolites induce beta-adrenoceptor desensitization in rat lung in vitro.
Abbracchio, MP; Cattabeni, F; Daffonchio, L; Giani, E; Hernandez, A; Omini, C, 1985
)
1.71
" The dose-response effect of all of these drugs on Ig production was similar to the dose response of inhibition of 5-lipoxygenase."( Mechanism of action of glucocorticoid-induced immunoglobulin production: role of lipoxygenase metabolites of arachidonic acid.
Atluru, D; Goodwin, JS, 1986
)
0.48
" L-Serine borate complex, 45 mM, used as an inhibitor of the degradation of LTC4 to LTD4 by the enzyme gamma-glutamyl transpeptidase, in paired airway segments (adjacent segments from the same branch), produced a small degree (about 3-fold) of shift to the right of the dose-response curve and reduction of the maximum response to LTC4."( Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4.
Bernstein, PR; Buckner, CK; Coursin, DB; Krell, RD; Laravuso, RB; Will, JA, 1986
)
0.27
" Leukotriene B4 release approached a maximum around 30 min, and C6 dose-response studies performed at 1 h showed that maximal levels of leukotriene B4 were detected over a range of sublytic C5b-9 attack."( Release of leukotriene B4 from sublethally injured oligodendrocytes by terminal complement complexes.
Imagawa, DK; Shin, ML; Shirazi, Y, 1987
)
0.27
"12 to 80 microM) for 1 to 60 min at 37 degrees C to construct dose-response and time-dependence curves of lipoxygenase product generation."( Enhanced 5-lipoxygenase activity in lung macrophages compared to monocytes from normal subjects.
Bigby, TD; Holtzman, MJ, 1987
)
0.27
" Aspirin, at a dosage that almost completely inhibits both circulating cell and renal arachidonate metabolites, worsens the morphologic expression of rabbit nephrotoxic nephritis and negatively influences the clinical course of the disease."( Effect of aspirin and sulindac in rabbit nephrotoxic nephritis.
Benigni, A; Bertani, T; Carminati, C; Cutillo, F; Morelli, C; Remuzzi, G; Rocchi, G; Verroust, P, 1986
)
0.27
" Dosage reduction of the antibiotic in advanced renal failure and repeated control of prothrombin time is advised."( Alteration of hemostasis associated with cefoperazone treatment.
Andrassy, K; Bechtold, H; Fritz, S; Koderisch, J; Sonntag, H,
)
0.13
" No rebound phenomenon in inhibition of TXA2 synthetase was observed after the dosing was stopped."( CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
Imura, Y; Kato, K; Kawazoe, K; Nishikawa, K; Tanabe, M; Terao, S; Terashita, Z, 1986
)
0.27
" A dose-response curve was achieved for all three cyclooxygenase products with the calcium ionophore A23187."( Human peritoneal eosinophils and formation of arachidonate cyclooxygenase products.
Foegh, ML; Maddox, YT; Ramwell, PW, 1986
)
0.27
" The dose-response and kinetics of inhibition by calmodulin antagonists of acidic phospholipid-activated phospholipase A2 activity in purified preparations were similar to those of Ca2+-induced arachidonic acid release from membrane fractions."( Calmodulin-independent inhibition of platelet phospholipase A2 by calmodulin antagonists.
Hashimoto, Y; Kume, S; Naito, C; Oka, H; Teramoto, T; Watanabe, T, 1986
)
0.46
" The C6 dose-response curve for release of C20:4 plus its metabolites was monotonic, which indicates dependence on channel formation, whereas the dose-response curve for lysis displayed multi-hit behavior."( Release of arachidonic acid and formation of oxygenated derivatives after complement attack on macrophages: role of channel formation.
Hammer, CH; Imagawa, DK; Koga, PG; Mayer, MM; Osifchin, NE; Ramm, LE; Shin, HS, 1986
)
0.66
" IC50 was calculated from dose-response curves of ADP-, adrenaline-, collagen- and arachidonic acid-induced aggregation."( Effects of acetylsalicylic acid on platelet aggregation in male and female whole blood: an in vitro study.
Bellido, I; Camara, S; de la Cruz, JP; Martos, F; Sanchez de la Cuesta, F, 1986
)
0.5
"OH) radical was observed to affect cyclooxygenase metabolism in a dose-response manner."( Gender-related variations and interaction of human neutrophil cyclooxygenase and oxidative burst metabolites.
Bellanti, JA; Mallery, SR; Ramwell, PW; Zeligs, BJ, 1986
)
0.27
" Ulcerogenic effects of PGM on the gastric mucosa were approximately 1/7 and 1/10 times as potent as those of IND on a molar ratio 4 hr after single oral dosing to fasting and feeding rats, respectively."( [Pharmacological studies on proglumetacin maleate, a new non-steroidal anti-inflammatory drug. (3) Damaging effects on the gastrointestinal tract].
Miyake, H; Ono, N; Sunami, A; Yamamoto, N; Yamasaki, Y, 1986
)
0.27
" Cyclooxygenase inhibition with indomethacin displaced the dose-response curve to AA to the right but did not prevent the relaxant effects of the fatty acid."( Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway.
Abraham, NG; Mullane, KM; Pinto, A, 1987
)
1.72
"In normocapnic and deeply hypocapnic guinea-pig heart-lung-preparations (HLPs), dose-response relationships were estimated for the bronchoconstrictor and pulmonary hypertensive responses to histamine (H), 5 hydroxytryptamine (5HT), arachidonic acid (AA) and U-46619, a prostaglandin endoperoxide analogue acting on thromboxane (TXA2) receptors."( Arachidonic acid and pulmonary function in heart-lung-preparation of guinea-pig: modulation by PCO2.
Argiolas, L; Bedetti, C; Carpi, A; Del Basso, P, 1987
)
1.9
" In dose-response studies using TRH concentrations of 10(-6) M to 10(-12) M, the highest level of 9 HETE release was obtained at 10(-11) M TRH and the highest release of 15 HETE was at 10(-9) M TRH."( Arachidonic acid metabolism in a cloned strain of rat pituitary tumor cells: correlation between 15 hydroxyeicosatetraenoic acid release and the prolactin secretory process.
Chavis, C; Crastes de Paulet, A; Damon, M; Rabier, M, 1987
)
1.72
" The plasma concentration of fenflumizole reached a peak 2-3 hr after the dosing in non-fasted as well as fasted rats."( Antithrombotic and ulcerogenic effects of fenflumizole, a new anti-inflammatory imidazole derivative, in rats.
Nabata, H; Okazaki, A; Sakai, K; Uchino, M; Yamazaki, T, 1987
)
0.27
" The results showed that dexamethasone treatment did not diminish lung 6-keto-prostaglandin F1 alpha level even at the highest dosage used (12 mg/kg)."( Glucocorticoid and prostaglandin: lack of an inhibitory effect by dexamethasone on the synthesis of 6-ketoprostaglandin F1 alpha in rat lung.
Tsai, MY, 1987
)
0.27
" Moreover, the dose-response effects of NaF on arachidonate release and DG formation were different."( Differential sensitivity of arachidonic acid release and 1,2-diacylglycerol formation to pertussis toxin, GDP beta S and NaF in saponin-permeabilized human platelets: possible evidence for distinct GTP-binding proteins involving phospholipase C and A2 act
Hattori, H; Nakashima, S; Nozawa, Y; Shirato, L; Takenaka, A, 1987
)
0.57
" Isolated rings (circular preparations) obtained from rat thoracic aortae responded to increasing concentrations of NE with dose-dependent tonic enhancement, not significantly affected by the presence of indomethacin (10(-6)M); whereas, preincubation with phentolamine (10(-6)M), yohimbine (10(-7)M) or prazosin (10(-8)M), shifted significantly to the right points of the positive inotropic dose-response curve for NE."( Possible prostacyclin involvement on disparate tonic responses to "in vitro" norepinephrine in circular and in longitudinal preparations from rat thoracic aorta.
Chaud, M; Franchi, AM; Gimeno, AL; Gimeno, MA, 1987
)
0.27
" The N2O dosage affected on the migration of PMNs to the cornea."( Suppression of chemotaxis to corneal inflammation by nitrous oxide.
Kripke, BJ; Kupferman, A; Luu, KC, 1987
)
0.27
" An ischemia control group received NS, whereas experimental groups were given Nx, SOD, APL, or DEF with the same previous dosage schedule."( Experimental pharmacologic cerebroprotection.
Donovan, DL; Fink, JA; Pigott, JP; Sharp, WV, 1988
)
0.27
" Rabbits were fed a diet supplemented with 2% cholesterol and 8% peanut oil for 12 weeks with or without UK-38485 at a dosage that maintained 80% to 90% inhibition of TXA2 formation in serum."( Suppression of foam cell lesions in hypercholesterolemic rabbits by inhibition of thromboxane A2 synthesis.
Galang, CF; Gerrity, RG; Konieczkowski, M; Rebec, MV; Skrinska, VA,
)
0.13
" Dose-response curves comparing 45Ca efflux and insulin secretion suggested that AA also stimulates hormone release by at least one other mechanism in addition to Ca2+ mobilization."( Exogenous arachidonic acid promotes insulin release from intact or permeabilized rat islets by dual mechanisms. Putative activation of Ca2+ mobilization and protein kinase C.
Metz, SA, 1988
)
0.68
" This was associated with increasing inhibition of ex vivo platelet aggregation induced by platelet-activating factor during the dosing period, but inhibition of arachidonic acid-induced aggregation did not increase cumulatively during dosing and collagen-induced aggregation was not inhibited."( Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing.
FitzGerald, GA; Pedersen, AK, 1985
)
0.47
" When cells were pretreated with ibuprofen, aspirin, or indomethacin to block prostaglandin synthesis and then exposed to 20:4, the dose-response effect was shifted to the left."( Morphological alterations in cultured endothelial cells induced by arachidonic acid.
Bar, RS; Dolash, S; Kaduce, TL; Marshall, SJ; Sandra, A; Spector, AA, 1985
)
0.51
" Dose-response curves performed with thrombin and collagen revealed that increased stimulation resulted in higher ratios of 12-HETE/HHT."( Differential effect of external calcium on the oxygenated metabolism of endogenous and exogenous arachidonic acid in platelets.
Lagarde, M; Velardo, B, 1985
)
0.49
" The six dogs were then given phenylbutazone orally according to four different dosage levels and durations of treatment."( The effect of oral phenylbutazone on whole blood platelet aggregation in the dog.
Jackson, ML; Olexson, DW; Searcy, GP, 1985
)
0.27
" In subsequent time-course and dose-response experiments, a significant effect on [3H]arachidonic acid release could be observed as early as 15 min after LHRH addition, and the lowest effective dose was 10(-8) M LHRH."( Luteinizing hormone-releasing hormone stimulates arachidonic acid release in rat granulosa cells.
Leung, PC; Minegishi, T, 1985
)
0.75
" The dosage of 25 mg/kg (single and repeated) consistently inhibited platelet function, and the effects lasted 3 to 5 days."( Effects of aspirin and propranolol on feline platelet aggregation.
Greene, CE, 1985
)
0.27
" These results suggest that modulation of leukotaxis by NSAIDs may reflect a differential dose-response sensitivity of lipoxygenase and cycloxygenase pathways."( In vivo modulation of leukotaxis by non-steroidal anti-inflammatory drugs.
diZerega, GS; Nakamura, RM; Shimanuki, T, 1985
)
0.27
" Furthermore, the dose-response curve of the generation of phosphatidic acid by fMet-Leu-Phe is shifted to the right when compared with that for calcium mobilization."( Leukotriene B4 mobilizes calcium without the breakdown of polyphosphoinositides and the production of phosphatidic acid in rabbit neutrophils.
Molski, TF; Naccache, PH; Sha'afi, RI; Tao, W; Volpi, M; Yassin, R, 1984
)
0.27
" PGF-A enhanced both mucous glycoprotein release and the 5- and 15-lipoxygenation of arachidonic acid as well as the formation of leukotriene B4 (LTB4) with similar dose-response relationships."( Prostaglandin-generating factor of anaphylaxis induces mucous glycoprotein release and the formation of lipoxygenase products of arachidonate from human airways.
Goetzl, EJ; Kaliner, M; Marom, Z; Shelhamer, JH; Steel, L, 1984
)
0.49
" Inhibition of aggregation by the beta-adrenoceptor antagonists was manifested as a parallel shift to the right in the dose-response curve."( Beta-adrenoceptor antagonists and human platelets: relationship of effects to lipid solubility.
Kerry, R; Scrutton, MC; Wallis, RB, 1984
)
0.27
" In the presence of L (8 X 10(5) ml-1) the dose-response curve to Me shifted to the left and the efficacy of Me was enhanced."( alpha-Adrenoceptor stimulated lymphocytes trigger the mechanical response of vas deferens: participation of arachidonic acid metabolites.
Borda, ES; Cangiani, S; de Bracco, MM; Finiasz, M; Sterin-Borda, L, 1984
)
0.48
" The dose-response curves of bradykinin for the increase in the above changes were similar."( Bradykinin stimulates phospholipid methylation, calcium influx, prostaglandin formation, and cAMP accumulation in human fibroblasts.
Axelrod, J; Bareis, DL; Hirata, F; Manganiello, VC; Vaughan, M, 1983
)
0.27
" This action carried over to ex vivo situation following intraduodenal dosing as demonstrated in rabbits."( Inhibition of platelet aggregation by a new agent, 2,2'-dithiobis-(N-2-hydroxypropyl benzamide) (KF4939).
Nakamizo, N; Shuto, K; Yamada, K, 1983
)
0.27
" The dose-response curve of release of [3H]C20:4 from Ehrlich ascites tumor cells, with respect to C, was approximately in the same range as the cytolytic response."( Consequences of cell membrane attack by complement: release of arachidonate and formation of inflammatory derivatives.
Imagawa, DK; Mayer, MM; Osifchin, NE; Paznekas, WA; Shin, ML, 1983
)
0.27
" Lengthening the duration of HF diet treatment (0, 3, 6, 16 wk) increased mammary tumor development, suggesting a time dose-response relationship."( Promotion of 7,12-dimethylbenz[a]anthracene-induced mammary tumorigenesis by high dietary fat in the rat: possible role of intercellular communication.
Aylsworth, CF; Jone, C; Meites, J; Trosko, JE; Welsch, CW, 1984
)
0.27
" The time-course of [14C]LA and [3H]AA incorporation into human leucocyte total lipids was maximal at 80-90% of the initial dose within 20-30 min of dosing the cells."( Linoleic acid and arachidonic acid metabolism in human peripheral blood leucocytes: comparison with the rat.
Crawford, MA; Cunnane, SC; Keeling, PW; Thompson, RP, 1984
)
0.6
" In the presence of L (4 X 10(5) ml-1) the dose-response curve to NaA shifted to the left, the potency and the efficiency of NaA were enhanced and the chronotropic action was triggered."( Lymphocytes sensitize rat isolated atria to the inotropic and chronotropic effects of sodium arachidonate.
Borda, ES; de Bracco, MM; Finiasz, M; Sterin-Borda, L, 1984
)
0.27
" Under phase-contrast microscopy, PAF caused contraction of mesangial cells with a dose-response and time-course parallel to that for PGE2 synthesis."( Effect of platelet-activating factor and serum-treated zymosan on prostaglandin E2 synthesis, arachidonic acid release, and contraction of cultured rat mesangial cells.
Baud, L; Hagege, J; Perez, J; Satriano, JA; Schlondorff, D, 1984
)
0.49
" Dose-response curves gave the following rank order of potency: fluocinolone greater than dexamethasone greater than hydrocortisone."( Glucocorticoid inhibition of zymosan-induced arachidonic acid release by rat alveolar macrophages.
Bathon, J; Flores, R; Hirata, F; Newcombe, DS; Peters-Golden, M, 1984
)
0.53
"5 weeks, mean +/- SD) fortified with protein and minerals (FM-85, Nestle Ag, Munchen, Germany; dosage 5 g/100 ml milk) or were randomly assigned to blinded batches of an LBWI formula (Prematil, Milupa AG, Friedrichsdorf, Germany) without LCP (n = 10, 1280 +/- 229 g, 31."( Effects of a low birthweight infant formula containing human milk levels of docosahexaenoic and arachidonic acids.
Edenhofer, S; Koletzko, B; Lipowsky, G; Reinhardt, D, 1995
)
0.51
" Indomethacin shifted the G-CSF dose-response curve of cells treated with 10 nM RA to lower G-CSF concentrations."( Indomethacin potentiates the induction of HL60 differentiation to neutrophils, by retinoic acid and granulocyte colony-stimulating factor, and to monocytes, by vitamin D3.
Brown, G; Bunce, CM; Durham, J; French, PJ; Michell, RH; Stockley, RA, 1994
)
0.29
" Dose-response curves to PGE2, PGD2, and iloprost, a PGI2 analogue, were performed before and during KATP channel blockade with glibenclamide."( Evidence that prostaglandins I2, E2, and D2 may activate ATP sensitive potassium channels in the isolated rat heart.
Bouchard, JF; Dumont, E; Lamontagne, D, 1994
)
0.29
" The aim of this study was to investigate the rate of eicosanoid biosynthesis after oral dosing with nabumetone in nine healthy subjects."( Effects of nabumetone on prostanoid biosynthesis in humans.
Cipollone, F; Cuccurullo, F; Ganci, A; Greco, A; Panara, MR; Patrignani, P; Patrono, C, 1995
)
0.29
" Dose-response curve of PLA2-I-induced AA release was saturable with an EC50 of 14."( Arachidonic acid release from NIH 3T3 cells by group-I phospholipase A2: involvement of a receptor-mediated mechanism.
Miele, L; Mukherjee, AB; Xing, M, 1995
)
1.73
" The peptides produced dose-related increases in perfusion pressure, and dose-response curves to all six peptides were parallel."( Analysis of responses to angiotensin peptides in the hindquarters vascular bed of the cat.
Garrison, EA; Kadowitz, PJ; Osei, SY; Santiago, JA, 1995
)
0.29
" Dose-response data of AA-stimulated zinc uptake gives an apparent K0."( Characterization of zinc uptake and its regulation by arachidonic acid in fetal type II pneumocytes.
Kemp, PJ; McArdle, HJ; Oliver, RE; Ong, TJ, 1995
)
0.54
" A bell-shaped dose-response curve with maximal stimulation at picomolar concentrations was found."( Substance P: a competence factor for human fibroblast proliferation that induces the release of growth-regulatory arachidonic acid metabolites.
Herold, M; Kähler, CM; Wiedermann, CJ, 1993
)
0.5
" With this dosage the victim suffered from nausea, vomiting, and hypotension, and died of hypotensive shock."( Poisoning by the red alga 'ogonori' (Gracilaria verrucosa) on the Nojima Coast, Yokohama, Kanagawa Prefecture, Japan.
Asakawa, M; Fuse, M; Hosaka, Y; Iijima, N; Kirigaya, C; Matsui, T; Miyazawa, K; Noguchi, T; Shida, Y; Watabe, K, 1994
)
0.29
" For each aggregating agent, ED50 value (agonist concentration necessary to induce a maximal aggregation of 50%) was determined in control samples and following addition of different picotamide concentrations on the basis of dose-response curves."( Studies on in vitro effect of picotamide on human platelet aggregation in platelet-rich plasma and whole blood.
Anfossi, G; Cavalot, F; Massucco, P; Mattiello, L; Mularoni, EM; Parisi, S; Russo, I; Trovati, M, 1995
)
0.29
" Dose-response curves for the effect of arachidonic acid were established in each type of rat, then the effects of different doses of four NSAID (indomethacin, piroxicam, naproxen and sulindac) on these responses were measured."( The response to arachidonic acid before and after non-steroidal anti-inflammatory drugs in normotensive and hypertensive rats.
Hill, SR; Smith, AJ, 1994
)
0.9
" Increases in perfusion pressure in response to bolus injections of U46619 were used to construct dose-response curves."( Reduced thromboxane receptor affinity and vasoconstrictor responses in placentae from diabetic pregnancies.
Hollander, AM; Mento, PF; Wilkes, BM, 1994
)
0.29
" Clonogenic cell survival after irradiation showed a typical exponential radiation dose-response curve with a fairly broad initial shoulder."( Radiation reduces cyclooxygenase activity in cultured human endothelial cells at low doses.
Dewit, L; Koomen, GC; van Mourik, JA; Verheij, M, 1994
)
0.29
" Initial doses were randomly assigned and dosing intervals were separated by 2 weeks."( Effects of low-dose aspirin on in vitro platelet aggregation in the early minutes after ingestion in normal subjects.
Dabaghi, SF; Kamat, SG; Kleiman, NS; Marks, GF; Payne, J; Roberts, R; Schafer, AI, 1994
)
0.29
"It has been reported that the dose-response curves for exogenous arachidonic acid (AA)-induced human platelet aggregation and secretion are biphasic."( [The studies on the mechanism of platelet activation induced by exogenous arachidonic acid with special reference to intraplatelet Ca2+ mobilization].
Koyama, M, 1994
)
0.76
" Of the 52 with partial inhibition at initial testing, 35 achieved complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or fluctuation of response at the same dosage, but 8 of those 35 (22."( Development of aspirin resistance in persons with previous ischemic stroke.
Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994
)
0.29
" The mechanisms by which increased dosage requirement or ASA resistance develops and the clinical significance of this development are currently undefined."( Development of aspirin resistance in persons with previous ischemic stroke.
Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994
)
0.29
" In animal experiments the compound has antiphlogistic, analgesic, antipyretic, antiasthmatic and antiaggregative activity at a dosage that causes no gastrointestinal damage."( Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase.
Augustin, J; Dannhardt, G; Laufer, S; Tries, S, 1994
)
0.29
" Time- and dose-response studies were used to establish half-maximal stimulatory (SC50) and inhibitory (IC50) as well as 10-fold stimulatory (ED10) concentrations for arachidonic acid release, cytotoxicity, and IL-1 alpha release, respectively."( Keratinocyte-derived proinflammatory key mediators and cell viability as in vitro parameters of irritancy: a possible alternative to the Draize skin irritation test.
Fürstenberger, G; Marks, F; Müller-Decker, K, 1994
)
0.48
"The phenomenon of supercooperativity in platelet aggregation is manifested by the occurrence of clear-cut thresholds in dose-response relationships; in such cases the Hill coefficient has unusually high values."( Supercooperativity in platelet aggregation: substituted pyridyl isoxazoles, a new class of supercooperative platelet aggregation inhibitors.
Demina, OV; Shram, SI; Varfolomeev, SD; Vrzheshch, PV, 1994
)
0.29
" The kinetics of neutrophil respiratory burst priming by IL-8 were the same when measured in whole blood samples and in purified cell suspensions, and IL-8 dose-response curves were similar, showing that the low affinity IL-8 receptors on erythrocytes do not rapidly sequester circulating IL-8."( The effects of interleukin-8 on neutrophil fMetLeuPhe receptors, CD11b expression and metabolic activity, in comparison and combination with other cytokines.
Carver, JE; Khwaja, A; Linch, DC; Mire-Sluis, AR; Pizzey, AR; Roberts, PJ, 1993
)
0.29
" The dose-response for calcium release induced by sphingosine-1-phosphate correlated closely with the concentration required for stimulation of DNA synthesis."( Sphingosine-1-phosphate, a putative second messenger, mobilizes calcium from internal stores via an inositol trisphosphate-independent pathway.
Brooker, G; Mattie, M; Spiegel, S, 1994
)
0.29
" The dose-response and temporal analysis of CGRP effect show that the maximal activity is present at the dose of 30 pmol/ear and when administered 30 min after the irritating agent."( Effects of CGRP in different models of mouse ear inflammation.
Amico-Roxas, M; Caruso, A; Catena Cutuli, VM; Clementi, G; de Bernardis, E; Maugeri, S; Prato, A; Scapagnini, U, 1994
)
0.29
" Cytotoxic dose-response curves have been generated resulting in CD50 (cytotoxic dose 50%) in the range of 1-50 micrograms toxin/culture."( Cytolysins increase intracellular calcium and induce eicosanoids release by pheochromocytoma PC12 cell cultures.
Lazarovici, P; Raya, SA; Shohami, E; Trembovler, V, 1993
)
0.29
" Stimulation of DNA synthesis and inhibition of cAMP accumulation by LPA were inhibited by pertussis toxin, but with different dose-response characteristics."( A novel synergistic stimulation of Swiss 3T3 cells by extracellular ATP and mitogens with opposite effects on cAMP levels.
Heller, EJ; Heppel, LA; Huang, NN; Wang, DJ, 1994
)
0.29
" Indomethacin did not affect the ET-1-induced pallor but significantly shifted to the right the flare dose-response curve to ET-1."( Cyclooxygenase products mediate the cutaneous vasodilation induced by endothelin-1 in humans.
Bellofiore, S; Di Maria, GU; Mistretta, A; Novo, S; Puglisi, S; Ricciardolo, FL, 1993
)
0.29
" Such a complex dose-response effect may have significant impact in explaining the pathologic effects of NO2."( Dual effect of nitrogen dioxide on rat alveolar macrophage arachidonate metabolism.
Forman, HJ; Robison, TW,
)
0.13
" EC50s of the dose-response curves for adrenaline, AII and PDBU were also markedly increased in aortae from DM rats compared to controls."( Differential changes of adrenoceptor- and muscarinic receptor-linked prostacyclin synthesis by the aorta and urinary bladder of the diabetic rat.
Jeremy, JY; Mikhailidis, DP; Thompson, CS, 1993
)
0.29
" Dose-response studies demonstrate a higher potency and intrinsic activity of phenethylamines for polyphosphoinositide turnover but not for arachidonic acid release."( Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor.
Brown, F; Gaivin, R; Graham, RM; Hwa, J; Mathur, M; Perez, DM, 1996
)
0.5
" Dose-response studies with esculetin and BW 755C demonstrated that the concentrations for 50% inhibition of reepithelialization (65."( Effect of inhibitors of arachidonic acid metabolism on corneal reepithelialization in the rat.
Gupta, AG; Hirakata, A; Proia, AD, 1993
)
0.59
" In clones that were sensitive to growth inhibition by GRP by virtue of their expression of relatively high levels of the GRP receptor, the dose-response curve of GRP-stimulated DNA synthesis was bell shaped."( Gastrin-releasing peptide receptor signaling resulting in growth inhibition.
Feldman, RI; Fried, S; Liang, M; Mann, E; Wu, JM, 1996
)
0.29
" The Khalf values of the dose-response curve were 12 and 97 microM in the JSR membrane vesicles and the solubilized proteins, respectively."( Modulation of ryanodine binding to the cardiac Ca2+ release channel by arachidonic acid.
Imanaga, I; Uehara, A; Yasukochi, M, 1996
)
0.53
" Bradykinin elicited a biphasic dose-response curve in the formation of the vasoconstrictor and platelet aggregating thromboxane A2 (TxA2)."( The effect of bradykinin and substance P on the arachidonate cascade of platelets.
Gecse, A; Kis, B; Mezei, Z; Telegdy, G, 1996
)
0.29
" Dose-response curves to bradykinin (a stimulator of nitric oxide synthesis), arachidonic acid (the precursor of prostanoid production) and GTN (a nitric oxide donor) were constructed before and 1 h after endotoxin."( Endothelial "stunning" following a brief exposure to endotoxin: a mechanism to link infection and infarction?
Bhagat, K; Collier, J; Moss, R; Vallance, P, 1996
)
0.52
"21 g/d (LO20:4 diet) of arachidonic acid for 50 d and then dosed with a mixture containing ethyl esters of 20:3n-6[d4] and 18:1n-9[d2]."( Influence of dietary arachidonic acid on metabolism in vivo of 8cis,11cis,14-eicosatrienoic acid in humans.
Adlof, RO; Duval, SM; Emken, EA; Nelson, GJ, 1997
)
0.92
" Experimental dose-response curve characterized by additivity of some enzyme intermediates (absorption spectra, fluorescence, EPR, etc."( [Integral kinetics of multisubstrate enzyme reactions. Criteria of kinetic behavior and characteristic coordinates for solution of direct and reverse problems].
Vrzheshch, PV, 1996
)
0.29
" Although its ability to inhibit the cyclooxygenase pathway was readily observed in whole blood and in vivo, tenidap's 5-LO blockade could not be demonstrated by ionophore stimulated human blood, nor after oral dosing in rat models in which peritoneal leukotriene products were measured after challenge with three different stimuli."( Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models.
Carty, TJ; Cheng, JD; Ernest, MJ; Eskra, JD; Griffiths, RJ; Joseph, PA; Kadin, SB; Loose, LD; Moore, PF; Murase, S; Nagahisa, A; Pazoles, PP; Pillar, JS; Sweeney, FJ, 1997
)
0.3
" These inhibitory effects were observed within 30 min and sustained for 24 h at a single dosage of 5 mg/kg of vapiprost."( The potent inhibition of vapiprost, a novel thromboxane A2 receptor antagonist, on the secondary aggregation and ATP release of human platelets.
Hiraishi, S; Horie, S; Ishii, H; Kazama, M; Kizaki, K; Kurusu, O; Nakahara, T; Noritake, S; Satoh, M; Yamada, M, 1997
)
0.3
" This explains the different dosage requirements of aspirin as an antithrombotic (COX-1) and an anti-inflammatory drug (COX-2), respectively."( Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
Schrör, K, 1997
)
0.3
" Subsequently, time-course, pulse-chase and dose-response studies of the effect of hCG on [14C]AA release were performed."( Arachidonic acid release from rat Leydig cells depends on the presence of luteinizing hormone/human chorionic gonadotrophin receptors.
Llanos, MN; Moraga, PF; Ronco, AM, 1997
)
1.74
" The decrease in edema in the footpads of EFAD rats was nearly identical to the decrease in edema in the footpads of Control rats dosed with indomethacin."( Modulation of adjuvant-induced arthritis by dietary arachidonic acid in essential fatty acid-deficient rats.
Chinn, KS; Mehta, A; Obukowicz, MG; Raz, A; Salsgiver, WJ; Welsch, DJ, 1997
)
0.55
" AA reduced the maximum amplitude of nIACh estimated from the dose-response relationship without causing an appreciable change in the apparent dissociation constant."( Inhibitory effects of arachidonic acid on nicotinic transmission in bullfrog sympathetic neurons.
Minota, S; Watanabe, S, 1997
)
0.61
" Female Sprague-Dawley rats were dosed with diethylnitrosamine (15 mg/kg) at 24 h of age."( Effect of dietary lipid on gamma-glutamyl transferase-positive foci during hepatocarcinogenesis in rats.
Chen, HW; Ko, JJ; Lii, CK, 1998
)
0.3
" Synergism might also lead to a reduction in dosage and a decreased risk of side-effects."( Rationale for the combination of anti-aggregating drugs.
Herman, AG, 1998
)
0.3
" It appears that 325 mg of aspirin is sufficient to affect PGE2 production and that increasing the dosage to 650 mg daily provides an additional decrease in PGE2 synthesis."( Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients.
Dyavanapalli, M; Frommel, TO; Kazi, N; Liao, Y; Lietz, H; Mobarhan, S; Oldham, T, 1997
)
0.3
" Only 12-HETE showed a dose-response effect on [3H]-thymidine incorporation."( Effects of lipoxygenase metabolites of arachidonic acid on the growth of human mononuclear marrow cells and marrow stromal cell cultures.
Denizot, Y; Desplat, V; Dulery, C; Dupuis, F; Praloran, V; Trimoreau, F, 1998
)
0.57
"To study the influence of meloxicam, a cyclooxygenase-2 (COX-2) preferential nonsteroidal anti-inflammatory drug, on serum thromboxane and platelet function in healthy volunteers with use of the maximum recommended daily dosage of 15 mg/day."( Meloxicam, 15 mg/day, spares platelet function in healthy volunteers.
de Meijer, A; de Metz, M; Novakova, I; Thomas, C; Verbruggen, B; Vollaard, H, 1999
)
0.3
" PIF produced an increased release of [3H]arachidonic acid from prelabeled myoblasts with a dose-response curve parallel to that of protein degradation and with a maximum at 4 nM PIF."( Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid.
Lorite, MJ; Smith, HJ; Tisdale, MJ, 1999
)
0.57
"The atopic mothers were randomly assigned to low (n=10) or high (n=10) dosage oral supplementation with oral borage oil for one week (230 or 460 mg gamma-linolenic acid (18:3n-6) per day)."( Essential fatty acids in breast milk of atopic mothers: comparison with non-atopic mothers, and effect of borage oil supplementation.
Houwelingen, A; Mordant, A; Poorterman, I; Thijs, C; van den Brandt, P, 2000
)
0.31
" The latter dosing scheme may provide a more consistent serum level, thereby improving analgesia."( Weak analgesics and nonsteroidal anti-inflammatory agents in the management of children with acute pain.
Tobias, JD, 2000
)
0.31
"05) in all prostanoids evaluated in a dose-response fashion."( Nitric oxide inhibits prostanoid synthesis in the rat oviduct.
Farina, M; Franchi, AM; Gimeno, M; Ogando, D; Perez Martinez, S; Ribeiro, ML, 2000
)
0.31
" A dose-response effect was demonstrated for LA, ALA, EPA and DHA in both J774A."( Effect of long-chain fatty acids in the culture medium on fatty acid composition of WEHI-3 and J774A.1 cells.
Babu, US; O'Donnell, MW; Wiesenfeld, PW, 2001
)
0.31
" Clofibrate at lower concentrations (10-200 microM) produced increases in the mRNA levels of cPLA(2) in a dose-response manner."( Modulation of cytosolic phospholipase A(2) by PPAR activators in human preadipocytes.
Choy, PC; Dembinski, T; Hatch, GM; Jiang, YJ; Kroeger, EA; Mymin, D, 2001
)
0.31
" The observed increase in time to occlusion was abolished when celecoxib was administered to animals dosed with HDA-ER (80."( Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.
Barrett, TD; Crofford, LJ; Driscoll, EM; Hennan, JK; Huang, J; Lucchesi, BR; Park, AM; Willens, DE, 2001
)
0.31
" Our studies with RIA showed that: at the dosage of inhibiting platelet aggregation, ASAA was found to inhibit the formation of cyclooxygenase pathway metabolites TXB2 in platelets."( [Effects of acetylsalvianolic acid A on arachidonic acid metabolism in platelets].
Xu, L; Yu, W, 1998
)
0.57
"The dose-response effect of dietary docosahexaenoic acid (DHA, 22:6 n-3) ethyl ester (EE) on maze-learning ability in mice was studied."( Dose-response effect of docosahexaenoic acid ethyl ester on maze behavior and brain fatty acid composition in adult mice.
Lim, SY; Suzuki, H, 2002
)
0.31
" Until more definitive data become available, when prescribing and dosing ASA for the prevention of MI or vascular ischemia, clinicians should identify possible risk factors for ASA resistance."( Possible mechanisms of aspirin resistance.
Cambria-Kiely, JA; Gandhi, PJ, 2002
)
0.31
" A portal perfusion pressure dose-response curve to methoxamine was performed in control and cirrhotic rat livers preincubated with vehicle, the nitric oxide synthase blocker N(G)-nitro-L-arginine (L-NNA), indomethacin cyclooxygenase (COX) inhibitor, L-NNA + indomethacin, or the thromboxane (TX) A(2) receptor blocker SQ 29,548."( Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers.
Abraldes, JG; Bosch, J; Bragulat, M; Corominola, H; García-Pagán, JC; Graupera, M; Peralta, C; Rodés, J, 2003
)
0.32
"The newly synthesized linoleic acid derivative, FR236924, induces a long-lasting facilitation of hippocampal neurotransmission based on a persistent enhancement in the activity of presynaptic nicotinic ACh receptors via a PKC pathway and the ensuing increase in glutamate release, not only in vitro but in vivo at a low dosage (2mg/kg, ip), which suggested the possibility of its use as a promising anti-dementia drug."( The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
Nishizaki, T; Tanaka, A, 2003
)
0.32
" The dose-response relationships for the above effects show that simvastatin, atorvastatin and fluvastatin affect linoleic acid conversion and the delta5 desaturase step more potently than the synthesis of cholesterol, simvastatin being the most effective in inhibiting sterol synthesis, whereas atorvastatin in stimulating the conversion of linoleic acid."( Relative potencies of statins in reducing cholesterol synthesis and enhancing linoleic acid metabolism.
Galli, C; Ghezzi, S; Risé, P, 2003
)
0.32
" Our data suggested that PMA stimulated the production of superoxide anion in a dose-response manner, as compared with A23187, which did not induce a significant release of superoxide anion in PMNs-RA."( Phospholipase A2 modulates respiratory burst developed by neutrophils in patients with rheumatoid arthritis.
Bostan, M; Brasoveanu, LI; Constantin, MC; Galatiuc, C; Hirt, M; Iordachescu, D,
)
0.13
" Pinane thromboxane, a selective thromboxane synthase inhibitor and receptor blocker, inhibited OxAA stimulation of TXB(2) and IL-8 in a dose-response manner."( Linoleic acid induces interleukin-8 production by Crohn's human intestinal smooth muscle cells via arachidonic acid metabolites.
Alzoghaibi, MA; Fowler, AA; Graham, MF; Walsh, SW; Willey, A; Yager, DR, 2004
)
0.54
" Some key representatives showed potent pharmacological in vivo activities after oral dosing in both a CB agonist-induced blood pressure model and a CB agonist-induced hypothermia model."( Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists.
Adolfs, TJ; Coolen, HK; de Jong, NM; den Hartog, AP; Dijksman, JA; Herremans, AH; Hoogendoorn, J; Keizer, HG; Kruse, CG; Lange, JH; McCreary, AC; Ronken, E; Stork, B; Tipker, K; van Stuivenberg, HH; Veerman, W; Verveer, PC; Wals, HC, 2004
)
0.32
" The dose-response curve of the AA effect on ENaC shows that 2 microM AA inhibited the ENaC activity by 50%."( Arachidonic acid inhibits epithelial Na channel via cytochrome P450 (CYP) epoxygenase-dependent metabolic pathways.
Falck, JR; Kemp, R; Lin, DH; Nasjletti, A; Wang, WH; Wei, Y; Yaddanapudi, GS, 2004
)
1.77
" Thus, on a per dosage basis, the total amounts of n-3 and n-6 end products accreted in plasma were considerably greater for C20 EFA precursors relative to C18."( In vivo conversion of 18- and 20-C essential fatty acids in rats using the multiple simultaneous stable isotope method.
Lin, YH; Salem, N, 2005
)
0.33
" The mPAP in rats of the double dosage and single dosage of CMOC groups were (26."( [The effect of compound macrostem onion capsule on metabolism of arachidonic acid in a rat model of monocrotaline-induced pulmonary artery hypertension].
Jiang, J; Shang, N; Sun, JG; Xi, ZQ; Zou, X, 2005
)
0.57
" The dose-response study of AA and IDM demonstrated that the concentration of intracellular AA accumulated by IDM is less than 100 nm."( Enhancement of Ca2+-regulated exocytosis by indomethacin in guinea-pig antral mucous cells: arachidonic acid accumulation.
Fujiwara, S; Kato, M; Katsu, K; Nakahari, T; Nakanishi, Y; Shimamoto, C, 2006
)
0.55
"Irinotecan hydrochloride (CPT-11), a topoisomerase I inhibitor highly effective for various cancers, has its dosage limited by diffuse mucosal damage with increased prostaglandin (PG) E(2)."( Phospholipid fatty acid composition and diamine oxidase activity of intestinal mucosa from rats treated with irinotecan hydrochloride (CPT-11) under vegetable oil-enriched diets: comparison between perilla oil and corn oil.
Aoyama, M; Fueda, Y; Kishimoto, K; Miyoshi, M; Ohata, A; Ohmae, K; Usami, M,
)
0.13
" We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37."( Dose- and time-dependent antiplatelet effects of aspirin.
Fitzgerald, D; Hjemdahl, P; Perneby, C; Rooney, C; Wallén, NH, 2006
)
0.33
" At a dosage of 20 or 40 mg/kg, PF preconditioning 48 h before MCAO followed by 24-h reperfusion significantly reduced the mortality and infarct volume and reversed the neurological deficits caused by ischemia."( Involvement of multitargets in paeoniflorin-induced preconditioning.
Cai, X; Chen, DM; Xiao, L; Zeng, R; Zhu, XZ, 2006
)
0.33
" A significant interpatient variation in response to the 4 dosing regimes was observed."( Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers.
Alberts, MJ; Coleman, JL, 2006
)
0.33
"We prospectively studied the effect of aspirin dosing on platelet function in 125 stable outpatients with coronary artery disease randomized in a double-blind, double-crossover investigation (81, 162, and 325 mg/d for 4 weeks each over a 12-week period)."( Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Bliden, KP; Chaganti, SK; DiChiara, J; Etherington, A; Gesheff, T; Gurbel, PA; Neerchal, NK; Newcomer, J; Tantry, US; Weng, W, 2007
)
0.34
" Plasma phospholipid levels of EPA, DHA, and EPA/AA ratios were significantly inversely correlated with increasing body weight and BMI in the Omacor 4-g dosage group but not in the Omacor 8-g dosage group."( Is body size a biomarker for optimizing dosing of omega-3 polyunsaturated fatty acids in the treatment of patients with IgA nephropathy?
Bergstralh, EJ; Bibus, DM; Donadio, JV; Grande, JP, 2006
)
0.33
"A mechanism-based pharmacodynamic model has been developed that characterizes the antiplatelet effects of aspirin and ibuprofen, alone and concomitantly, and predicts a significant inhibition of aspirin antiplatelet effects in the presence of a typical ibuprofen dosing regimen."( Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
Bates, VE; Gengo, FM; Hong, Y; Mager, DE; Rainka, MM, 2008
)
0.35
"AA at dosage of 30-90 microM proportionally induced luminescence in N/N 1003A cells."( [The role of NADPH oxidase in superoxide anion generation in rabbit lens epithelial cells].
An, Y; Lou, M; Qu, S; Song, X; Zhang, W, 2007
)
0.34
" Thus, a concentration of 1 mM of both indolamines was sufficient to inhibit in approximately 70% of the light emission in mitochondria, whereas a greater dosage of 10 times (10 mM) was necessary to produce the same effect in microsomes."( Relative efficacies of alpha-tocopherol, N-acetyl-serotonin, and melatonin in reducing non-enzymatic lipid peroxidation of rat testicular microsomes and mitochondria.
Catalá, A; Gavazza, M, 2009
)
0.35
" Based on these results, we suggest that increasing dietary supply of DHA above the larval requirement level results in its increased oxidation for energy purposes and we propose potential applications of the tube feeding methodology using radiolabelled EFA in conjunction with dose-response studies."( A new method for the study of essential fatty acid requirements in fish larvae.
Conceição, LE; Morais, S, 2009
)
0.35
" However, following priming (15 min) with bradykinin or arachidonic acid, DPDPE produced a significant reduction in allodynia that was antagonist reversible, peripherally restricted, and exhibited a typical dose-response relationship."( Peripheral delta opioid receptors require priming for functional competence in vivo.
Berg, KA; Clarke, WP; Hargreaves, KM; Patwardhan, AM; Rowan, MP; Ruparel, NB, 2009
)
0.6
" Cumulative dose-response curves were generated with concentrations of 10(-5) to 10(-3) M ropivacaine enantiomer in the presence or absence of quinacrine dihydrochloride, nordihydroguaiaretic acid, quinacrine dihydrochloride plus nordihydroguaiaretic acid, indomethacin, fluconazole, AA-861, and verapamil."( Direct effect of ropivacaine involves lipoxygenase pathway activation in rat aortic smooth muscle.
Baik, JS; Hwang, EM; Ogawa, K; Park, JY; Sohn, JT; Sung, HJ, 2009
)
0.35
"When dosed appropriately, fish oil-based lipid emulsions contain sufficient EFAs to prevent EFAD."( The essentiality of arachidonic acid and docosahexaenoic acid.
de Meijer, VE; Gura, KM; Le, HD; Meisel, JA; Puder, M,
)
0.45
" Oral diltiazem treatment in therapeutic dosage before and during the implantation period did not cause any change in normal uterine milieu during the window of implantation."( Role of the calcium channel in blastocyst implantation: a novel contraceptive target.
Banerjee, A; Nivsarkar, M; Padh, H, 2009
)
0.35
" Similar effects were observed in side-by-side dose-response comparisons with DOI; although at the highest dose tested (5."( The serotonin 5-HT(2A) receptor agonist TCB-2: a behavioral and neurophysiological analysis.
Blackler, AR; Fox, MA; French, HT; LaPorte, JL; Murphy, DL, 2010
)
0.36
" Although flax oil may decrease severity of illness in children and adolescents with bipolar disorder who have meaningful increases in serum EPA percent levels and/or decreased AA and DPA n-6 levels, individual variations in conversion of alpha-LNA to EPA and docosahexaenoic acid as well as dosing burden favor the use of fish oil both for clinical trials and clinical practice."( Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder.
Chirieac, MC; Costescu, S; Finucane, TL; Gracious, BL; Hibbeln, JR; Youngstrom, EA, 2010
)
0.36
" Our findings suggest that the imbalance between AA and PGE2, characterized by increased AA at a low dosage and decreased PGE2 at a high dosage of celecoxib, was an important indicator of cytotoxicity of celecoxib on H22 cells."( The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathway.
Chen, L; Lv, X; Xiang, D; Xu, Z; Zhang, M; Zhang, X, 2010
)
0.59
" Dose-response curves were created and half-maximal effective concentration values were calculated."( Platelet reactivity and pregnancy loss.
Dicker, P; Flood, K; Geary, M; Kenny, D; Kent, E; Malone, FD; Peace, A; Tedesco, T, 2010
)
0.36
" The dose-response curves were tightly matched for the other agonists."( Platelet reactivity and pregnancy loss.
Dicker, P; Flood, K; Geary, M; Kenny, D; Kent, E; Malone, FD; Peace, A; Tedesco, T, 2010
)
0.36
" During the dosing period EPA increased 460-480% from the baseline concentration, while DHA increased 150-160%."( Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.
Kostner, K; Salm, P; Taylor, PJ, 2011
)
0.59
" Once-daily dosing of aspirin might not suffice to adequately inhibit platelet aggregation in patients with an increased platelet turnover."( Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease.
Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Mortensen, SB, 2011
)
0.37
" Estrone and 2-hydroxy-estrone showed biphasic dose-response curves of PGE(2), whereas estriol and 16-α-hydroxy-estrone increased PGE(2) levels at high concentrations."( Estrogen metabolites in the release of inflammatory mediators from human amnion-derived cells.
Biondi, C; Dalpiaz, A; Lunghi, L; Paganetto, G; Pavan, B, 2011
)
0.37
"Twenty-four hours after the last dosing on day 6 in volunteers receiving aspirin alone or aspirin before naproxen, serum TXB(2) was almost completely inhibited (median [range] 99."( Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
Anzellotti, P; Bruno, A; Capone, ML; Di Francesco, L; Di Gregorio, P; Garcia Rodriguez, LA; Grossi, L; Jeyam, A; Merciaro, G; Patrignani, P; Price, TS; Renda, G; Tacconelli, S; Tontodonati, P, 2011
)
0.37
" Whether studies of the effect of supplementation will reveal an effect not only depends on the dosage and duration of supplementation but also on 1) the timing of supplementation, 2) the age at which the outcome is assessed, 3) the application of age-specific sensitive neurodevelopmental tools, and 4) the functional domain evaluated."( Prenatal and early postnatal supplementation with long-chain polyunsaturated fatty acids: neurodevelopmental considerations.
Hadders-Algra, M, 2011
)
0.37
"This study determined the sensitivity of heart and brain arachidonic acid (ARA) and docosahexaenoic acid (DHA) to the dietary ARA level in a dose-response design with constant, high DHA in neonatal piglets."( Heart arachidonic acid is uniquely sensitive to dietary arachidonic acid and docosahexaenoic acid content in domestic piglets.
Blank, BS; Bradford, KL; Brenna, JT; Butt, CM; Kothapalli, KS; Park, WJ; Salem, N; Tyburczy, C; Zimmer, JP, 2011
)
1.1
" In addition, the reproductive system may be more sensitive to exposure of CTD even earlier in development (prenatal and early postnatal), and therefore it could be expected that more severe effects could also be observed at the NOAEL dose levels, if dosing had occurred in utero or early postnatal."( Effects of clothianidin exposure on sperm quality, testicular apoptosis and fatty acid composition in developing male rats.
Bal, R; Baydaş, G; Etem, E; Kuloğlu, T; Naziroğlu, M; Türk, G; Yılmaz, Ö, 2012
)
0.38
" Information on the strength of the association between ARA exposure and cancer risk, the dose-response relationship, and methodological limitations was collected and evaluated with respect to consistency and study design."( Arachidonic acid and cancer risk: a systematic review of observational studies.
Horikawa, C; Kakutani, S; Kawashima, H; Okubo, H; Sakai, M; Sasaki, S; Shibata, H; Tokuda, H, 2012
)
1.82
" Conversely, there was no strong positive association or dose-response relationship for breast or prostate cancer."( Arachidonic acid and cancer risk: a systematic review of observational studies.
Horikawa, C; Kakutani, S; Kawashima, H; Okubo, H; Sakai, M; Sasaki, S; Shibata, H; Tokuda, H, 2012
)
1.82
" Additionally, we performed a dose-response meta-analysis of similar prospective studies on cholesteryl ester PUFA."( N-6 and N-3 fatty acid cholesteryl esters in relation to fatal CHD in a Dutch adult population: a nested case-control study and meta-analysis.
Boer, JM; de Goede, J; Geleijnse, JM; Kromhout, D; Verberne, LD; Verschuren, WM, 2013
)
0.39
" Supplementing DHA to the diet of PKU patients may improve their LCPUFA status; however, further research is needed to determine the optimal supplementation dosage and to establish beneficial functional outcomes."( Lower n-3 long-chain polyunsaturated fatty acid values in patients with phenylketonuria: a systematic review and meta-analysis.
Decsi, T; Fekete, K; Lohner, S, 2013
)
0.39
" Use of different NSAIDs with different pharmacological properties, differences in dosing regimens, and differences in study models and outcome measures have complicated comparisons between studies."( NSAID therapy effects on healing of bone, tendon, and the enthesis.
O'Connor, JP; Su, B, 2013
)
0.39
" Dose-response curves were plotted for each agonist for the nonpregnant cohort and in each trimester for the pregnant cohort."( Platelet reactivity changes significantly throughout all trimesters of pregnancy compared with the nonpregnant state: a prospective study.
Burke, N; Cotter, B; Dempsey, M; Dicker, P; Fay, L; Flood, K; Geary, MP; Kenny, D; Malone, FD; Murray, A, 2013
)
0.39
" Moreover, light transmission aggregometry may detect impaired ristocetin-induced platelet agglutination, enabling dosage of aspirin to be adjusted."( Assessment of platelet function with light transmission aggregometry in 24 patients supported with a continuous-flow left ventricular assist device: a single-center experience.
Barandon, L; Calderon, J; Fiore, M; James, C; Mouton, C; Ouattara, A; Picard, F, 2014
)
0.4
" The patients in the platelet function monitoring guided group received an antiplated therapy guided by a modified thromboelastography (TEG) platelet mapping: If inhibition of platelet aggregation (IPA) induced by arachidonic acid (AA) was less than 50% the aspirin dosage was raised to 200 mg/d; if IPA induced by adenosine diphosphate (ADP) was less than 30% the clopidogrel dosage was raised to 150 mg/d, for three months."( Platelet function monitoring guided antiplatelet therapy in patients receiving high-risk coronary interventions.
Li, K; Li, W; Liu, Y; Ni, Z; Sun, H; Wang, H; Wang, L; Xia, K; Xu, L; Yang, X; Zhang, D, 2014
)
0.59
" The objectivation of perioperative pain by scales of clinical evaluation does not offer a certain and objective quantification; so, the dosing of some hormonal and acute phase inflammation mediators could realize a more realistic projection."( Perioperatory pain in oncological patient - physiopathological and therapeutical implications.
Blidaru, A; Bordea, C; Cirimbei, C; Diaconu, C; Pantis, C, 2014
)
0.4
" Inflammatory bowel disease was induced by replacing drinking water with 3 % DSS solution during the last 7 d of the AA dosing period."( Effects of arachidonic acid intake on inflammatory reactions in dextran sodium sulphate-induced colitis in rats.
Aoki, S; Furuya, M; Harauma, A; Iwai, N; Ji, X; Miyazawa, D; Moriguchi, T; Nagata, T; Naito, Y; Ohara, N; Tachibana, S; Tazura, Y, 2015
)
0.81
"The percentages of EPA, DHA, and the omega-6 arachidonic acid (AA) were measured in RBCs at baseline and posttreatment in 122 participants with DSM-IV major depression who were randomly assigned between May 2005 and December 2008 to receive either 50 mg/d of sertraline and a daily dosage of 930 mg EPA/750 mg DHA or sertraline plus placebo."( Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements.
Carney, RM; Freedland, KE; Harris, WS; Rich, MW; Rubin, EH; Steinmeyer, BC, 2016
)
0.69
" Omega-3 supplementation may be an effective treatment for depression, but the requisite dosage and duration of treatment may depend on the patient's baseline level of omega-3 fatty acids."( Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements.
Carney, RM; Freedland, KE; Harris, WS; Rich, MW; Rubin, EH; Steinmeyer, BC, 2016
)
0.43
"Twenty-eight survivors with a median birth weight of 806 g completed dosing and sampling."( Early docosahexaenoic and arachidonic acid supplementation in extremely-low-birth-weight infants.
Caplan, M; Carlson, SE; Frost, B; Murthy, K; Robinson, DT; Yoder, R, 2016
)
0.73
"To assess the consequences of switching aspirin dosage from 100 mg/d to 40 mg/d on cardiovascular benefit, bleeding risk and platelet aggregation in very elderly patients."( [Dose-response of aspirin on platelet function in very elderly patients].
Fan, Y; Feng, XR; Liu, F; Liu, ML; Tian, QP, 2016
)
0.43
"Switching aspirin dosage from 100 mg/d to 40 mg/d reduces the bleeding events and improves upper gastrointestinal symptoms, thus inhibiting platelet aggregation effectively in very elderly patients."( [Dose-response of aspirin on platelet function in very elderly patients].
Fan, Y; Feng, XR; Liu, F; Liu, ML; Tian, QP, 2016
)
0.43
"The DHA Intake and Measurement of Neural Development (DIAMOND) trial represents one of only a few studies of the long-term dose-response effects of LCPUFA-supplemented formula feeding during infancy."( Docosahexaenoic acid (DHA) and arachidonic acid (ARA) balance in developmental outcomes.
Carlson, SE; Colombo, J; Gustafson, KM; Jill Shaddy, D; Kerling, EH, 2017
)
0.74
" Under the different PO2 levels, dose-response agonist induced endothelium-dependent vasodilation (acetylcholine, arachidonic acid), endothelium-independent vasodilation (s-nitroprusside), as well as vasoconstriction (norepinephrine, prostaglandin F2α) were examined."( Hyperoxia does not directly affect vascular tone in isolated arteries from mice.
de Waard, MC; Eringa, EC; Girbes, ARJ; Oudemans-van Straaten, HM; Smit, B; Smulders, YM; Spoelstra-de Man, AME, 2017
)
0.67
" Follow-up studies of infants given DHA-/ARA-supplemented versus control formula have shown better performance on tests of impulsivity and attention control in the supplemented children, with indications of a dose-response relationship for DHA."( Effects of Nutrition on the Development of Higher-Order Cognition.
Willatts, P, 2018
)
0.48
"5-15 mg/kg), the effective dosage range of diclofenac was identified (> 5 mg/kg/day)."( Dose-dependency of the cardiovascular risks of non-steroidal anti-inflammatory drugs.
Ahmed, SA; Al-Lawati, H; Jamali, F, 2019
)
0.51
" To surmount the reduced LC-MS based plasma stability, a novel dosage form in olive oil has been developed."( Development of a Novel Apigenin Dosage form as a Substitute for the Modern Triple Antithrombotic Regimen.
Chatzigiannis, CM; Gkalpinos, V; Kostagianni, AD; Kostomitsopoulos, N; Papakyriakopoulou, P; Tellis, CC; Tselepis, AD; Tsiailanis, AD; Tzakos, AG; Valsami, G, 2023
)
0.91
" Dose-response curves indicated a linear negative correlation between AA intake and the prevalence of ED."( Association between polyunsaturated fatty acid intake and the prevalence of erectile dysfunction: A cross-sectional analysis of the NHANES 2001-2004.
Huang, Y; Su, H; Wang, H; Wang, Y; Xu, C; Xu, H; Zhang, Y; Zhou, F, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (6 Items)

ItemProcessFrequency
First age baby milk powdercore-ingredient1
Baby milks in powdercore-ingredient1
Infant formulascore-ingredient1
Baby milkscore-ingredient1
Dried productscore-ingredient1
Baby foodscore-ingredient1

Roles (4)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
EC 3.1.1.1 (carboxylesterase) inhibitorAny EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of carboxylesterase (EC 3.1.1.1 ).
Daphnia galeata metaboliteA Daphnia metabolite produced by the species Daphnia galeata.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
icosa-5,8,11,14-tetraenoic acidAny icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.
omega-6 fatty acidA family of polyunsaturated fatty acids that have in common a final carbon-carbon double bond in the n-6 position, i.e., the sixth bond from the methyl end of the fatty acid.
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (86)

PathwayProteinsCompounds
Alpha Linolenic Acid and Linoleic Acid Metabolism517
Arachidonic Acid Metabolism2966
Leukotriene C4 Synthesis Deficiency2966
Piroxicam Action Pathway2967
Acetylsalicylic Acid Action Pathway2967
Etodolac Action Pathway2967
Ketoprofen Action Pathway2967
Ibuprofen Action Pathway5076
Rofecoxib Action Pathway2967
Diclofenac Action Pathway2967
Sulindac Action Pathway2967
Celecoxib Action Pathway3573
Ketorolac Action Pathway2967
Suprofen Action Pathway2967
Bromfenac Action Pathway2967
Indomethacin Action Pathway3067
Mefenamic Acid Action Pathway2967
Oxaprozin Action Pathway2967
Nabumetone Action Pathway2967
Naproxen Action Pathway2967
Diflunisal Action Pathway2967
Meloxicam Action Pathway2967
Valdecoxib Action Pathway2967
Fc Epsilon Receptor I Signaling in Mast Cells4211
Antipyrine Action Pathway2967
Antrafenine Action Pathway2967
Carprofen Action Pathway2967
Etoricoxib Action Pathway2967
Fenoprofen Action Pathway2967
Flurbiprofen Action Pathway2967
Magnesium Salicylate Action Pathway2967
Lumiracoxib Action Pathway2967
Lornoxicam Action Pathway2967
Phenylbutazone Action Pathway2967
Nepafenac Action Pathway2967
Trisalicylate-Choline Action Pathway2967
Tolmetin Action Pathway2967
Tiaprofenic Acid Action Pathway2967
Tenoxicam Action Pathway2967
Salsalate Action Pathway2967
Salicylate-Sodium Action Pathway2967
Salicylic Acid Action Pathway2967
Acetaminophen Action Pathway2967
GnRH Signaling Pathway474
Prostaglandin and Leukotriene metabolism ( Prostaglandin and Leukotriene metabolism )2223
Relationship between inflammation, COX-2 and EGFR02
Blood clotting and drug effects05
Metabolism of alpha-linolenic acid615
Eicosanoid metabolism via cyclooxygenases (COX)137
Eicosanoid metabolism via cytochrome P450 monooxygenases pathway113
Eicosanoid metabolism via lipooxygenases (LOX)040
Omega-3 / omega-6 fatty acid synthesis038
Linoleic acid metabolism affected by SARS-CoV-2513
RAS and bradykinin pathways in COVID-19113
Orexin receptor pathway2915
Prostaglandin and leukotriene metabolism in senescence619
Quercetin and Nf-kB / AP-1 induced apoptosis09
Leukotriene metabolic pathway219
Mitochondrial beta-oxidation064
Arachidonic acid (AA, ARA) oxylipin metabolism076
Elongation of (very) long chain fatty acids345
Folic acid network070
Relationship between glutathione and NADPH036
Angiotensin II signaling (acute) in thick ascending limbs08
Eicosanoid lipid synthesis map17
Eicosanoid metabolism via lipoxygenases (LOX)040
Eicosanoid metabolism via cytochrome P450 monooxygenases213
Vascular smooth muscle contraction013
Quercetin and Nf-kB / AP-1 induced cell apoptosis09
Selenium micronutrient network095
Eicosanoid synthesis026
Endothelin pathways013
TNF-alpha signaling pathway01
Spinal cord injury08
Nanoparticle triggered regulated necrosis26
PDGF pathway208
Cannabinoid receptor signaling020
Chromosomal and microsatellite instability in colorectal cancer02
Ferroptosis133
Non-genomic actions of 1,25 dihydroxyvitamin D364
Arachidonate epoxygenase / epoxide hydrolase09
Arachidonic acid metabolism pathway011
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway035
Arachidonic acid metabolism via CYP (Cytochromoe P450) pathway014
Arachidonic acid metabolism via LOX (Lipooxygenase) pathway033
Omega-3 and omega-6 unsaturated fatty acids biosynthesis pathway014

Protein Targets (77)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency12.58930.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency17.78280.004023.8416100.0000AID485290
Chain A, Beta-lactamaseEscherichia coli K-12Potency35.48130.044717.8581100.0000AID485341
Chain A, HADH2 proteinHomo sapiens (human)Potency2.98820.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency2.98820.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency26.65140.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency23.45350.125919.1169125.8920AID2549
Chain A, CruzipainTrypanosoma cruziPotency27.82980.002014.677939.8107AID1476
15-lipoxygenase, partialHomo sapiens (human)Potency0.19780.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency42.74140.141337.9142100.0000AID1490
USP1 protein, partialHomo sapiens (human)Potency53.17640.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency20.87720.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency21.63030.180013.557439.8107AID1460; AID1468
thioredoxin glutathione reductaseSchistosoma mansoniPotency17.78280.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency5.38080.011212.4002100.0000AID1030
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency15.84890.035520.977089.1251AID504332
heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa)Homo sapiens (human)Potency50.11870.016525.307841.3999AID602332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency25.11890.540617.639296.1227AID2528
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency31.62280.316212.443531.6228AID902
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency17.90080.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency6.78330.354828.065989.1251AID504847
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency3.16230.65619.452025.1189AID927
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency34.19510.00798.23321,122.0200AID2546; AID2551
lethal(3)malignant brain tumor-like protein 1 isoform IHomo sapiens (human)Potency39.81070.075215.225339.8107AID485360
DNA polymerase kappa isoform 1Homo sapiens (human)Potency14.21910.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency23.87700.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.09890.251215.843239.8107AID504327
DNA dC->dU-editing enzyme APOBEC-3G isoform 1Homo sapiens (human)Potency33.49830.058010.694926.6086AID588379
caspase-1 isoform alpha precursorHomo sapiens (human)Potency31.62280.000311.448431.6228AID900
lamin isoform A-delta10Homo sapiens (human)Potency15.84890.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency3.16231.584913.004325.1189AID927
GABA theta subunitRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency23.87701.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)IC50 (µMol)100.00000.00020.59827.0000AID346660
TrypsinSus scrofa (pig)IC50 (µMol)200.00000.50000.50000.5000AID402793
Coagulation factor VIIHomo sapiens (human)IC50 (µMol)105.00000.00020.83363.3000AID402795
60 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)4.50000.17004.559010.0000AID1594139
AromataseHomo sapiens (human)IC50 (µMol)28.20000.00001.290410.0000AID376617
Tissue factorHomo sapiens (human)IC50 (µMol)105.00000.00010.734410.0000AID402795
Fatty acid-binding protein, adipocyteHomo sapiens (human)IC50 (µMol)2.75000.22101.22532.7500AID1854431
10 kDa heat shock protein, mitochondrialHomo sapiens (human)IC50 (µMol)4.50000.17004.559010.0000AID1594139
Fatty acid-binding protein 5Homo sapiens (human)Ki5.65670.24802.77129.3700AID1802832
Thiosulfate sulfurtransferaseHomo sapiens (human)IC50 (µMol)100.00000.06003.96319.7000AID1594135
Lanosterol 14-alpha demethylaseHomo sapiens (human)IC50 (µMol)200.00000.05001.43904.0000AID322753
60 kDa chaperonin Escherichia coliIC50 (µMol)12.65000.03903.55529.8000AID1594140; AID1594141
10 kDa chaperonin Escherichia coliIC50 (µMol)12.65000.03903.55529.8000AID1594140; AID1594141
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)1.07150.10472.71957.0795AID977603
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki0.82000.08002.46889.8000AID977604
Cytosolic phospholipase A2 gammaHomo sapiens (human)IC50 (µMol)100.00000.42000.42000.4200AID55271
Transient receptor potential cation channel subfamily V member 2Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.03701.93458.6000AID1400243; AID1400244
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)0.60260.05002.37979.7000AID977600
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki0.33000.04401.36305.0000AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ADIPOCYTE LIPID-BINDING PROTEINMus musculus (house mouse)Kd4.40004.40004.40004.4000AID977611
Chain A, SERUM ALBUMINHomo sapiens (human)Kd0.09100.00850.04970.0910AID977611
Chain A, SERUM ALBUMINHomo sapiens (human)Kd0.09100.00850.04970.0910AID977611
Fatty acid-binding protein, adipocyteHomo sapiens (human)Kd0.18000.15000.65822.0500AID32788
Prostaglandin G/H synthase 2Homo sapiens (human)Kd8.07000.00901.87258.4000AID1802596
Fatty acid-binding protein 5Mus musculus (house mouse)Kd0.04210.04210.07080.1003AID1802827
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Prostaglandin G/H synthase 1 Bos taurus (cattle)Km8.80008.80008.80008.8000AID399408
Prostaglandin G/H synthase 2Homo sapiens (human)Km105.50001.00001.00001.0000AID1568943; AID336480
Calmodulin Bos taurus (cattle)Km9.70009.70009.70009.7000AID399409
Prostaglandin G/H synthase 2Ovis aries (sheep)Km9.70009.70009.70009.7000AID399409
Solute carrier organic anion transporter family member 2A1Rattus norvegicus (Norway rat)Km96.00000.07001.65207.5690AID681576
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (264)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
protein folding60 kDa chaperoninEscherichia coli K-12
response to radiation60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
virion assembly60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
protein refolding60 kDa chaperoninEscherichia coli K-12
chaperone cofactor-dependent protein refolding60 kDa chaperoninEscherichia coli K-12
response to heat60 kDa chaperoninEscherichia coli K-12
adhesion of symbiont to host60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell60 kDa heat shock protein, mitochondrialHomo sapiens (human)
'de novo' protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein60 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to cold60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interferon-alpha production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of type II interferon production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-10 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-12 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of interleukin-6 production60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein refolding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell proliferation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
B cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of macrophage activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of apoptotic process60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isotype switching to IgG isotypes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein stabilization60 kDa heat shock protein, mitochondrialHomo sapiens (human)
positive regulation of T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone-mediated protein complex assembly60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein maturation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
biological process involved in interaction with symbiont60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cellular response to interleukin-760 kDa heat shock protein, mitochondrialHomo sapiens (human)
T cell activation60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein import into mitochondrial intermembrane space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial unfolded protein response60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apoptotic mitochondrial changes60 kDa heat shock protein, mitochondrialHomo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
response to bacteriumFatty acid-binding protein, adipocyteHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, adipocyteHomo sapiens (human)
cholesterol homeostasisFatty acid-binding protein, adipocyteHomo sapiens (human)
negative regulation of DNA-templated transcriptionFatty acid-binding protein, adipocyteHomo sapiens (human)
positive regulation of inflammatory responseFatty acid-binding protein, adipocyteHomo sapiens (human)
white fat cell differentiationFatty acid-binding protein, adipocyteHomo sapiens (human)
brown fat cell differentiationFatty acid-binding protein, adipocyteHomo sapiens (human)
cellular response to lithium ionFatty acid-binding protein, adipocyteHomo sapiens (human)
cellular response to tumor necrosis factorFatty acid-binding protein, adipocyteHomo sapiens (human)
positive regulation of cold-induced thermogenesisFatty acid-binding protein, adipocyteHomo sapiens (human)
fatty acid transportFatty acid-binding protein, adipocyteHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 2Homo sapiens (human)
embryo implantationProstaglandin G/H synthase 2Homo sapiens (human)
learningProstaglandin G/H synthase 2Homo sapiens (human)
memoryProstaglandin G/H synthase 2Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell population proliferationProstaglandin G/H synthase 2Homo sapiens (human)
response to xenobiotic stimulusProstaglandin G/H synthase 2Homo sapiens (human)
response to nematodeProstaglandin G/H synthase 2Homo sapiens (human)
response to fructoseProstaglandin G/H synthase 2Homo sapiens (human)
response to manganese ionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vascular endothelial growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 2Homo sapiens (human)
bone mineralizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of prostaglandin biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fever generationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic plasticityProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of synaptic transmission, dopaminergicProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin secretionProstaglandin G/H synthase 2Homo sapiens (human)
response to estradiolProstaglandin G/H synthase 2Homo sapiens (human)
response to lipopolysaccharideProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationProstaglandin G/H synthase 2Homo sapiens (human)
response to vitamin DProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to heatProstaglandin G/H synthase 2Homo sapiens (human)
response to tumor necrosis factorProstaglandin G/H synthase 2Homo sapiens (human)
maintenance of blood-brain barrierProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of protein import into nucleusProstaglandin G/H synthase 2Homo sapiens (human)
hair cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of apoptotic processProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of cell cycleProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of vasoconstrictionProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle contractionProstaglandin G/H synthase 2Homo sapiens (human)
decidualizationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of smooth muscle cell proliferationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of inflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
response to glucocorticoidProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of calcium ion transportProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicProstaglandin G/H synthase 2Homo sapiens (human)
response to fatty acidProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to mechanical stimulusProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to lead ionProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to ATPProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to hypoxiaProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to non-ionic osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to fluid shear stressProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of transforming growth factor beta productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesisProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of fibroblast growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of brown fat cell differentiationProstaglandin G/H synthase 2Homo sapiens (human)
positive regulation of platelet-derived growth factor productionProstaglandin G/H synthase 2Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 2Homo sapiens (human)
regulation of neuroinflammatory responseProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stressProstaglandin G/H synthase 2Homo sapiens (human)
cellular response to homocysteineProstaglandin G/H synthase 2Homo sapiens (human)
response to angiotensinProstaglandin G/H synthase 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to hypoxiaNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron migrationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to amphetamineNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-templated transcriptionNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
adult locomotory behaviorNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
post-embryonic developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system projection neuron axonogenesisNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
habenula developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to oxidative stressNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of dopamine metabolic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopamine biosynthetic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron maturationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of respiratory gaseous exchangeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
fat cell differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
general adaptation syndromeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
canonical Wnt signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
midbrain dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
osteoblast differentiation10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process10 kDa heat shock protein, mitochondrialHomo sapiens (human)
response to unfolded protein10 kDa heat shock protein, mitochondrialHomo sapiens (human)
chaperone cofactor-dependent protein refolding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumCalmodulin Bos taurus (cattle)
negative regulation of ryanodine-sensitive calcium-release channel activityCalmodulin Bos taurus (cattle)
positive regulation of ryanodine-sensitive calcium-release channel activityCalmodulin Bos taurus (cattle)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
glucose metabolic processFatty acid-binding protein 5Homo sapiens (human)
lipid metabolic processFatty acid-binding protein 5Homo sapiens (human)
phosphatidylcholine biosynthetic processFatty acid-binding protein 5Homo sapiens (human)
epidermis developmentFatty acid-binding protein 5Homo sapiens (human)
negative regulation of glucose transmembrane transportFatty acid-binding protein 5Homo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein 5Homo sapiens (human)
regulation of prostaglandin biosynthetic processFatty acid-binding protein 5Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayFatty acid-binding protein 5Homo sapiens (human)
glucose homeostasisFatty acid-binding protein 5Homo sapiens (human)
regulation of sensory perception of painFatty acid-binding protein 5Homo sapiens (human)
regulation of retrograde trans-synaptic signaling by endocanabinoidFatty acid-binding protein 5Homo sapiens (human)
positive regulation of cold-induced thermogenesisFatty acid-binding protein 5Homo sapiens (human)
lipid transport across blood-brain barrierFatty acid-binding protein 5Homo sapiens (human)
fatty acid transportFatty acid-binding protein 5Homo sapiens (human)
sulfur amino acid catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
cyanate catabolic processThiosulfate sulfurtransferaseHomo sapiens (human)
epithelial cell differentiationThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA import into mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
rRNA transportThiosulfate sulfurtransferaseHomo sapiens (human)
steroid biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
cholesterol biosynthetic processLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol metabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein catabolic processLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of protein secretionLanosterol 14-alpha demethylaseHomo sapiens (human)
negative regulation of amyloid-beta clearanceLanosterol 14-alpha demethylaseHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
phospholipid metabolic processCytosolic phospholipase A2 gammaHomo sapiens (human)
platelet activating factor biosynthetic processCytosolic phospholipase A2 gammaHomo sapiens (human)
inflammatory responseCytosolic phospholipase A2 gammaHomo sapiens (human)
parturitionCytosolic phospholipase A2 gammaHomo sapiens (human)
arachidonic acid metabolic processCytosolic phospholipase A2 gammaHomo sapiens (human)
intracellular signal transductionCytosolic phospholipase A2 gammaHomo sapiens (human)
phosphatidylcholine acyl-chain remodelingCytosolic phospholipase A2 gammaHomo sapiens (human)
phosphatidylethanolamine acyl-chain remodelingCytosolic phospholipase A2 gammaHomo sapiens (human)
glycerophospholipid catabolic processCytosolic phospholipase A2 gammaHomo sapiens (human)
lipid droplet formationCytosolic phospholipase A2 gammaHomo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (95)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
magnesium ion binding60 kDa chaperoninEscherichia coli K-12
protein binding60 kDa chaperoninEscherichia coli K-12
ATP binding60 kDa chaperoninEscherichia coli K-12
isomerase activity60 kDa chaperoninEscherichia coli K-12
ATP hydrolysis activity60 kDa chaperoninEscherichia coli K-12
identical protein binding60 kDa chaperoninEscherichia coli K-12
unfolded protein binding60 kDa chaperoninEscherichia coli K-12
ATP-dependent protein folding chaperone60 kDa chaperoninEscherichia coli K-12
lipopolysaccharide binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
p53 binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
DNA replication origin binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
single-stranded DNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
double-stranded RNA binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
high-density lipoprotein particle binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
isomerase activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP hydrolysis activity60 kDa heat shock protein, mitochondrialHomo sapiens (human)
enzyme binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ubiquitin protein ligase binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
apolipoprotein A-I binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding60 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP-dependent protein folding chaperone60 kDa heat shock protein, mitochondrialHomo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, adipocyteHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, adipocyteHomo sapiens (human)
hormone receptor bindingFatty acid-binding protein, adipocyteHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, adipocyteHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 2Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 2Homo sapiens (human)
protein bindingProstaglandin G/H synthase 2Homo sapiens (human)
enzyme bindingProstaglandin G/H synthase 2Homo sapiens (human)
heme bindingProstaglandin G/H synthase 2Homo sapiens (human)
protein homodimerization activityProstaglandin G/H synthase 2Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 2Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 2Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
beta-catenin bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein heterodimerization activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
ATP binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein folding chaperone10 kDa heat shock protein, mitochondrialHomo sapiens (human)
unfolded protein binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-folding chaperone binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
metal ion binding10 kDa heat shock protein, mitochondrialHomo sapiens (human)
calcium ion bindingCalmodulin Bos taurus (cattle)
protein bindingCalmodulin Bos taurus (cattle)
protein domain specific bindingCalmodulin Bos taurus (cattle)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
retinoic acid bindingFatty acid-binding protein 5Homo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein 5Homo sapiens (human)
fatty acid bindingFatty acid-binding protein 5Homo sapiens (human)
protein bindingFatty acid-binding protein 5Homo sapiens (human)
lipid bindingFatty acid-binding protein 5Homo sapiens (human)
identical protein bindingFatty acid-binding protein 5Homo sapiens (human)
thiosulfate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
5S rRNA bindingThiosulfate sulfurtransferaseHomo sapiens (human)
3-mercaptopyruvate sulfurtransferase activityThiosulfate sulfurtransferaseHomo sapiens (human)
iron ion bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
sterol 14-demethylase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
heme bindingLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activityLanosterol 14-alpha demethylaseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenLanosterol 14-alpha demethylaseHomo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
lysophospholipase activityCytosolic phospholipase A2 gammaHomo sapiens (human)
protein bindingCytosolic phospholipase A2 gammaHomo sapiens (human)
phospholipid bindingCytosolic phospholipase A2 gammaHomo sapiens (human)
O-acyltransferase activityCytosolic phospholipase A2 gammaHomo sapiens (human)
phospholipase A1 activityCytosolic phospholipase A2 gammaHomo sapiens (human)
calcium-independent phospholipase A2 activityCytosolic phospholipase A2 gammaHomo sapiens (human)
phosphatidyl phospholipase B activityCytosolic phospholipase A2 gammaHomo sapiens (human)
calcium ion bindingCytosolic phospholipase A2 gammaHomo sapiens (human)
calcium-dependent phospholipid bindingCytosolic phospholipase A2 gammaHomo sapiens (human)
calcium-dependent phospholipase A2 activityCytosolic phospholipase A2 gammaHomo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (59)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
cytoplasm60 kDa chaperoninEscherichia coli K-12
cytosol60 kDa chaperoninEscherichia coli K-12
membrane60 kDa chaperoninEscherichia coli K-12
GroEL-GroES complex60 kDa chaperoninEscherichia coli K-12
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular space60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytoplasm60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrion60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix60 kDa heat shock protein, mitochondrialHomo sapiens (human)
early endosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosol60 kDa heat shock protein, mitochondrialHomo sapiens (human)
plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
clathrin-coated pit60 kDa heat shock protein, mitochondrialHomo sapiens (human)
cell surface60 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
coated vesicle60 kDa heat shock protein, mitochondrialHomo sapiens (human)
secretory granule60 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm midpiece60 kDa heat shock protein, mitochondrialHomo sapiens (human)
sperm plasma membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
migrasome60 kDa heat shock protein, mitochondrialHomo sapiens (human)
protein-containing complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
lipopolysaccharide receptor complex60 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial inner membrane60 kDa heat shock protein, mitochondrialHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
nucleusFatty acid-binding protein, adipocyteHomo sapiens (human)
cytoplasmFatty acid-binding protein, adipocyteHomo sapiens (human)
lipid dropletFatty acid-binding protein, adipocyteHomo sapiens (human)
cytosolFatty acid-binding protein, adipocyteHomo sapiens (human)
extracellular exosomeFatty acid-binding protein, adipocyteHomo sapiens (human)
cytosolFatty acid-binding protein, adipocyteHomo sapiens (human)
nucleusFatty acid-binding protein, adipocyteHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nuclear inner membraneProstaglandin G/H synthase 2Homo sapiens (human)
nuclear outer membraneProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulumProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum lumenProstaglandin G/H synthase 2Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 2Homo sapiens (human)
caveolaProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
protein-containing complexProstaglandin G/H synthase 2Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 2Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 2Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cytoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear speckNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein-containing complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
mitochondrion10 kDa heat shock protein, mitochondrialHomo sapiens (human)
membrane10 kDa heat shock protein, mitochondrialHomo sapiens (human)
extracellular exosome10 kDa heat shock protein, mitochondrialHomo sapiens (human)
mitochondrial matrix10 kDa heat shock protein, mitochondrialHomo sapiens (human)
cytosolCalmodulin Bos taurus (cattle)
spindle poleCalmodulin Bos taurus (cattle)
cytoplasmCalmodulin Bos taurus (cattle)
protein-containing complexCalmodulin Bos taurus (cattle)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
extracellular regionFatty acid-binding protein 5Homo sapiens (human)
nucleusFatty acid-binding protein 5Homo sapiens (human)
nucleoplasmFatty acid-binding protein 5Homo sapiens (human)
cytoplasmFatty acid-binding protein 5Homo sapiens (human)
cytosolFatty acid-binding protein 5Homo sapiens (human)
plasma membraneFatty acid-binding protein 5Homo sapiens (human)
postsynaptic densityFatty acid-binding protein 5Homo sapiens (human)
secretory granule membraneFatty acid-binding protein 5Homo sapiens (human)
azurophil granule lumenFatty acid-binding protein 5Homo sapiens (human)
synapseFatty acid-binding protein 5Homo sapiens (human)
extracellular exosomeFatty acid-binding protein 5Homo sapiens (human)
cytosolFatty acid-binding protein 5Homo sapiens (human)
nucleusFatty acid-binding protein 5Homo sapiens (human)
extracellular spaceThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrial matrixThiosulfate sulfurtransferaseHomo sapiens (human)
mitochondrionThiosulfate sulfurtransferaseHomo sapiens (human)
endoplasmic reticulum membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
membraneLanosterol 14-alpha demethylaseHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
endoplasmic reticulum membraneCytosolic phospholipase A2 gammaHomo sapiens (human)
lipid dropletCytosolic phospholipase A2 gammaHomo sapiens (human)
cytosolCytosolic phospholipase A2 gammaHomo sapiens (human)
plasma membraneCytosolic phospholipase A2 gammaHomo sapiens (human)
cell cortexCytosolic phospholipase A2 gammaHomo sapiens (human)
membraneCytosolic phospholipase A2 gammaHomo sapiens (human)
mitochondrial membraneCytosolic phospholipase A2 gammaHomo sapiens (human)
nuclear envelopeCytosolic phospholipase A2 gammaHomo sapiens (human)
cytosolCytosolic phospholipase A2 gammaHomo sapiens (human)
nucleoplasmCytosolic phospholipase A2 gammaHomo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (116)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID701911Proapoptotic activity in human MDA-MB-468 cells assessed as activation of caspase-3 by luminometry2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2.
AID701913Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by MTT assay2012Journal of medicinal chemistry, Aug-23, Volume: 55, Issue:16
Antiproliferative and antimigratory actions of synthetic long chain n-3 monounsaturated fatty acids in breast cancer cells that overexpress cyclooxygenase-2.
AID330322Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of fetal calf serum medium by RT-PCR2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID409936Ratio of kcat/km for soybean lipoxygenase 12008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Kinetic isotope effects in the oxidation of arachidonic acid by soybean lipoxygenase-1.
AID1616997Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 22019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID405533Inhibition of mPGES12008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID399408Activity of bovine seminal microsomal COX11998Journal of natural products, Jan, Volume: 61, Issue:1
Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
AID1744328Displacement of 6-(Ethyl-{5-isobutoxy-4-isopropyl-2-[(10-oxo-2,3,5,6-tetrahydro-1H,4H,10H-11-oxa-3a-aza-benzo[de]anthracene-9-carbonyl)-amino]-phenyl}-amino)-nicotinic acid from human RXRalpha-LBD by by fluorescence binding assay
AID32788Binding affinity against Adipocyte lipid binding protein2002Journal of medicinal chemistry, Jun-06, Volume: 45, Issue:12
Simple, intuitive calculations of free energy of binding for protein-ligand complexes. 1. Models without explicit constrained water.
AID1594139Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID977603pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID330321Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum assessed viral RNA level at 0.1 mM by RT-PCR relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1568944Substrate activity at COX-2 (unknown origin) in pH 7.5 HEPES buffer assessed as enzyme-mediated test compound metabolism by measuring Kcat by LC-MS analysis
AID376617Inhibition of aromatase in human placental microsomes by radiometric method2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID423131Binding affinity to Vibrio cholerae cholera toxin assessed as quenching of intrinsic fluorescence by two-state binding model assay2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Bile and unsaturated fatty acids inhibit the binding of cholera toxin and Escherichia coli heat-labile enterotoxin to GM1 receptor.
AID330317Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium assessed as increase of malondialdehyde at 0.1 mM relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID402794Octanol-water partition coefficient, log P of the compound1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID223074Concentration required to inhibit production of LDH from whole blood stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID330316Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of fetal calf serum medium assessed as increase of malondialdehyde at 0.1 mM relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1568945Substrate activity at COX-2 (unknown origin) in pH 7.5 HEPES buffer assessed as enzyme-mediated test compound metabolism by measuring Kcat/Km ratio by LC-MS analysis
AID423137Binding affinity to enterotoxigenic Escherichia coli 12566 heat-labile enterotoxin assessed as inhibition of heat-labile enterotoxin binding to ganglioside GM1 receptor2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Bile and unsaturated fatty acids inhibit the binding of cholera toxin and Escherichia coli heat-labile enterotoxin to GM1 receptor.
AID145834Effect on Torpedo nicotinic ACh receptor responses at 0 min determined by measuring percentage of original amplitude2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
AID977600pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID376618Inhibition of aromatase in human SKBR3 cells at 100 uM relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID1594137Inhibition of ATPase activity of Escherichia coli GroEL expressed in Escherichia coliDH5alpha incubated for 60 mins using ATP by spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID209198Concentration required to inhibit production of arachidonic acid from THP-1 cells stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID1350514Induction of apoptosis in human HOS cells at 12.5 by Annexin V-FITC/propidium iodide double staining based flow cytometry relative to control2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID409937Activity of soybean lipoxygenase 1 assessed as rate of oxidation under diffusion-controlled reaction at 20 deg C2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Kinetic isotope effects in the oxidation of arachidonic acid by soybean lipoxygenase-1.
AID322753Inhibition of human CYP51 expressed in Topp 3 cells by lanosterol demethylase assay2007Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 35, Issue:3
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
AID1594141Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID405528Inhibition of mPGES1 at 10 uM2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target.
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID223078Concentration required to inhibit production of arachidonic acid from whole blood stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID196758Tested for inhibition of rat glial cell gap junction at the concentration of 20 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID336480Activity of COX22002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID251876Inhibitory activity against PAF (8E-10M) induced aggregation of rabbit platelet at 2.1E-4 M concentration2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
AID323922Antiviral activity against HCV assessed as inhibition of HCV RNA replication in OR6 cells after 72 hrs by luciferase reporter assay2007Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6
Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID251873Inhibitory activity against PAF (4e-10 M) induced aggregation of rabbit platelet at 1.5E-6 M concentration2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
AID346660Inhibition of FAAH2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID209197Concentration required to inhibit production of PGE-2 from THP-1 cells stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID330333Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium assessed as increase of malonaldehyde at 0.1 mM after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID330332Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium assessed as reduction in viral RNA level at 0.1 mM after 12 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID251874Inhibitory activity against PAF (4e-10 M) induced aggregation of rabbit platelet at 2.1E-4 M concentration2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
AID330330Inhibition of hepatitis C virus replication in Huh7-K2040 in presence of delipidated fetal calf serum medium assessed as increase of malondialdehyde at 0.1 mM after 12 to 24 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID251872Inhibitory activity against PAF (4e-10 M) induced aggregation of rabbit platelet at 1.5E-5 M concentration2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
AID1350512Induction of apoptosis in human 143B cells at 12.5 by Annexin V-FITC/propidium iodide double staining based flow cytometry relative to control2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID223076Concentration required to inhibit production of PGE-2 from whole blood stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID402793Inhibition of pig pancreatic trypsin after 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID1594134Inhibition of native soluble pig heart MDH assessed as reduction in MDH enzyme activity using sodium mesoxalate as substrate and NADH by malachite green dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1854431Inhibition of FABP4 (unknown origin) incubated for 10 mins by fluorescence based analysis2022European journal of medicinal chemistry, Oct-05, Volume: 240Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. An update from 2017 to early 2022.
AID1350513Induction of apoptosis in human MG63 cells at 12.5 by Annexin V-FITC/propidium iodide double staining based flow cytometry relative to control2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID1207610Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID409939Activity of soybean lipoxygenase 1 assessed as rate of oxidation under diffusion-controlled reaction at 37 deg C2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Kinetic isotope effects in the oxidation of arachidonic acid by soybean lipoxygenase-1.
AID330335Cytotoxicity against human Huh7-K2040 cells in delipidated fetal calf serum medium2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1594140Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID1207609Inhibition of L-type calcium channel measured using whole-cell patch clamp in rat ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID196759Inhibition of rat glial cell gap junction at the concentration of 50 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID223077Concentration required to inhibit production of TXB2 from whole blood stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID402795Inhibition of amidolytic activity of human tissue factor/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID251852Inhibitory activity against PAF (4e-10 M) induced aggregation of rabbit platelet at 3E-5 M concentration2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
AID977604Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID399409Activity of sheep placental cotyledons COX21998Journal of natural products, Jan, Volume: 61, Issue:1
Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis.
AID55271Concentration required to inhibit human Cytosolic phospholipase A22001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID1177996Binding affinity to COX-2 (unknown origin) by ESI mass spectrometry2014European journal of medicinal chemistry, Apr-22, Volume: 77Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.
AID330334Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium assessed as reduction in viral RNA level at 0.1 mM after 72 hrs relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1885200Binding affinity towards Nurr1 ligand binding domain (unknown origin) measured by tryptophan fluorescence spectroscopy2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1594135Inhibition of native rhodanese (unknown origin) assessed as reduction in rhodanese enzyme activity after 45 mins by Fe(SCN)3 dye based spectrometric analysis2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID330323Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium by RT-PCR2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID223075Concentration required to inhibit production of LTB4 from whole blood stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID330331Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium assessed as increase of malondialdehyde at 0.1 mM after 48 hrs2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1338209Inhibition of Staphylococcus aureus FabI using t-o-NAC-thioester as substrate by spectrophometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Antitubercular activity of 1,2,3-triazolyl fatty acid derivatives.
AID251875Inhibitory activity against PAF (4e-10 M) induced aggregation of rabbit platelet at 7.5E-5 M concentration2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
AID409938Activity of soybean lipoxygenase 1 assessed as rate of oxidation under diffusion-controlled reaction at 5 deg C2008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Kinetic isotope effects in the oxidation of arachidonic acid by soybean lipoxygenase-1.
AID1400243Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of LPC-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID376615Inhibition of aromatase in human placental microsomes at 20 ug/ml by radiometric method relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID423126Binding affinity to Vibrio cholerae cholera toxin assessed as inhibition of cholera toxin binding to ganglioside GM1 receptor treated 15 mins before receptor addition by ELISA2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Bile and unsaturated fatty acids inhibit the binding of cholera toxin and Escherichia coli heat-labile enterotoxin to GM1 receptor.
AID1400244Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of CBD-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID681576TP_TRANSPORTER: uptake in PGT-expressing HeLa cells1995Science (New York, N.Y.), May-12, Volume: 268, Issue:5212
Identification and characterization of a prostaglandin transporter.
AID145835Effect on Torpedo nicotinic ACh receptor responses at 10 min determined by measuring percentage of original amplitude2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
AID977601Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID248458Inhibitory concentration against PAF (8E-10M) induced aggregation of rabbit platelet at 2.1E-4 M concentration2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
Synthesis of all-trans arachidonic acid and its effect on rabbit platelet aggregation.
AID330318Reversal of inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium assessed as malondialdehyde level at 0.1 mM in presence of vitamin E2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID209196Concentration required to inhibit production of LTC4 from THP-1 cells stimulated with A-231872001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Pyrrolidine inhibitors of human cytosolic phospholipase A2. Part 2: synthesis of potent and crystallized 4-triphenylmethylthio derivative 'pyrrophenone'.
AID1568943Substrate activity at COX-2 (unknown origin) in pH 7.5 HEPES buffer assessed as enzyme-mediated test compound metabolism by measuring Km by LC-MS analysis
AID409935Activity of soybean lipoxygenase 12008Bioorganic & medicinal chemistry letters, Nov-15, Volume: 18, Issue:22
Kinetic isotope effects in the oxidation of arachidonic acid by soybean lipoxygenase-1.
AID330320Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of fetal calf serum assessed viral RNA level at 0.1 mM by RT-PCR relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1177981Binding affinity to COX-1 (unknown origin) by ESI mass spectrometry2014European journal of medicinal chemistry, Apr-22, Volume: 77Rational design, synthesis and evaluation of chromone-indole and chromone-pyrazole based conjugates: identification of a lead for anti-inflammatory drug.
AID1346578Rat Kir3.4 (Inwardly rectifying potassium channels)1989Nature, Feb-09, Volume: 337, Issue:6207
G-protein beta gamma-subunits activate the cardiac muscarinic K+-channel via phospholipase A2.
AID1346477Human Kir2.3 (Inwardly rectifying potassium channels)2001Molecular pharmacology, May, Volume: 59, Issue:5
Direct activation of an inwardly rectifying potassium channel by arachidonic acid.
AID1346549Human K2P4.1 (Two P domain potassium channels)1998The EMBO journal, Jun-15, Volume: 17, Issue:12
A neuronal two P domain K+ channel stimulated by arachidonic acid and polyunsaturated fatty acids.
AID1346674Human K2P18.1 (Two P domain potassium channels)2003The Journal of biological chemistry, Jul-25, Volume: 278, Issue:30
A novel two-pore domain K+ channel, TRESK, is localized in the spinal cord.
AID1345398Human protein kinase C zeta (Iota subfamily)1995The EMBO journal, May-01, Volume: 14, Issue:9
PKC zeta is a molecular switch in signal transduction of TNF-alpha, bifunctionally regulated by ceramide and arachidonic acid.
AID1346602Human K2P3.1 (Two P domain potassium channels)2001The EMBO journal, Jan-15, Volume: 20, Issue:1-2
The endocannabinoid anandamide is a direct and selective blocker of the background K(+) channel TASK-1.
AID1346651Rat K2P4.1 (Two P domain potassium channels)1995The Journal of physiology, May-01, Volume: 484 ( Pt 3)Arachidonic acid activation of a new family of K+ channels in cultured rat neuronal cells.
AID1346679Human K2P10.1 (Two P domain potassium channels)2000The Journal of biological chemistry, Sep-15, Volume: 275, Issue:37
Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2002Molecular cell, Jan, Volume: 9, Issue:1
LTRPC2 Ca2+-permeable channel activated by changes in redox status confers susceptibility to cell death.
AID1346709Rat Kv4.2 (Voltage-gated potassium channels)1996The Journal of neuroscience : the official journal of the Society for Neuroscience, Apr-15, Volume: 16, Issue:8
Inhibition of the Kv4 (Shal) family of transient K+ currents by arachidonic acid.
AID1346604Human K2P2.1 (Two P domain potassium channels)1998The EMBO journal, Aug-03, Volume: 17, Issue:15
A mammalian two pore domain mechano-gated S-like K+ channel.
AID1346709Rat Kv4.2 (Voltage-gated potassium channels)1999Life sciences, , Volume: 65, Issue:12
Nicotine depresses the functions of multiple cardiac potassium channels.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1994The Journal of biological chemistry, Oct-14, Volume: 269, Issue:41
Adipocyte lipid-binding protein complexed with arachidonic acid. Titration calorimetry and X-ray crystallographic studies.
AID1811Experimentally measured binding affinity data derived from PDB1994The Journal of biological chemistry, Oct-14, Volume: 269, Issue:41
Adipocyte lipid-binding protein complexed with arachidonic acid. Titration calorimetry and X-ray crystallographic studies.
AID1802832Ligand Binding Assay from Article 10.1074/jbc.M113.514646: \\Structural basis for ligand regulation of the fatty acid-binding protein 5, peroxisome proliferator-activated receptor u00DF/d (FABP5-PPARu00DF/d) signaling pathway.\\2014The Journal of biological chemistry, May-23, Volume: 289, Issue:21
Structural basis for ligand regulation of the fatty acid-binding protein 5, peroxisome proliferator-activated receptor β/δ (FABP5-PPARβ/δ) signaling pathway.
AID1802827Fluorescence Competition Assay from Article 10.1074/jbc.M114.559062: \\Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor 2014The Journal of biological chemistry, May-02, Volume: 289, Issue:18
Fatty acid-binding protein 5 (FABP5) regulates cognitive function both by decreasing anandamide levels and by activating the nuclear receptor peroxisome proliferator-activated receptor β/δ (PPARβ/δ) in the brain.
AID1802596In Vitro COX Inhibition Assay from Article 10.1016/j.bioorg.2017.02.006: \\Synthesis, molecular docking and biological evaluation of some newer 2-substituted-4-(benzo[d][1,3]dioxol-5-yl)-6-phenylpyridazin-3(2H)-ones as potential anti-inflammatory and analg2017Bioorganic chemistry, 04, Volume: 71Synthesis, molecular docking and biological evaluation of some newer 2-substituted-4-(benzo[d][1,3]dioxol-5-yl)-6-phenylpyridazin-3(2H)-ones as potential anti-inflammatory and analgesic agents.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2001Journal of molecular biology, Dec-14, Volume: 314, Issue:5
Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001Journal of molecular biology, Dec-14, Volume: 314, Issue:5
Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18,621)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905283 (28.37)18.7374
1990's6022 (32.34)18.2507
2000's3965 (21.29)29.6817
2010's2650 (14.23)24.3611
2020's701 (3.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.52 (24.57)
Research Supply Index9.89 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index159.17 (26.88)
Search Engine Supply Index2.03 (0.95)

This Compound (83.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials486 (2.52%)5.53%
Reviews1,759 (9.12%)6.00%
Case Studies47 (0.24%)4.05%
Observational39 (0.20%)0.25%
Other16,964 (87.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]